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Abstract 
A significant characteristic of the herpesviruses is that they form latent infections in 
infected hosts, and can be reactivated to again induce lytic infections by stressors.  
This thesis deals with an epidemiological investigation of equine herpesvirus infection, 
particularly gammaherpesvirus infections, in foals and if there was evidence of 
reactivation of latent virus infections by stressors such as those associated with 
weaning.   
A longitudinal study of EHV infections in young foals and the effect of stressors such as 
weaning on the prevalence of virus infection was undertaken by the detection of DNA 
and mRNA of EHV2, EHV5, EHV1 and EHV4 in peripheral blood leukocyte (PBL) and 
nasal swabs (NS) from 13 mares and 46 foals in 4 stables.  EHV2 and EHV5 infections 
were detected commonly in the study population but infections with the 
alphaherpesviruses EHV1 and EHV4 were not detected, although lytic infections by the 
alphaherpesviruses may have been missed due to the frequency of sampling.  Age 
differences in the prevalence of EHV2 and EHV5 infection were detected: the 
prevalence of EHV2 was higher in young foals than in older foals and adult animals; the 
prevalence of EHV5 was higher in older foals and adults than in younger foals.  The 
prevalence of EHV2 and EHV5 infection increased in association with weaning, 
presumably in association with stressors associated with weaning, but was not clearly 
associated with disease in the weaned animals.  It was also observed that EHV5 
produced a transient lytic infection in PBL of young foals but tended to produce a 
persistent lytic infection of PBL in older foals and adults.  Persistent lytic EHV5 
infections of ≥37 weeks duration were also detected in 2 of 13 adult mares and this has 
not been reported previously.  The persistent lytic infection of PBL was not associated   v 
with the detection of virus in NS and the mares with persistent lytic infection of PBL with 
EHV5 did not transfer the infection to their foals.   
To determine if any of the animals examined were latently infected with the 
alphaherpesviruses, an examination for transcripts of genes 63 and 64 of EHV1 and 
EHV4, putative latency-associated transcripts (LAT) of EHV, was undertaken. Evidence 
of these transcripts was detected in PBL and bronchiolar lymph nodes in the absence 
of transcripts of the structural gB, supporting previous studies indicating that transcripts 
of genes 63 and 64 may represent LAT.  In PBL, EHV1 gene 64 RNA transcripts but 
not gene 63 transcripts were detected in PBL. In bronchiolar lymph nodes, EHV1 gene 
64 (but not gene 63) RNA transcripts were detected. In contrast, EHV4 infection was 
detected in the trigeminal ganglia only and there was no evidence of EHV4 infection in 
lymph nodes or PBL. In the trigeminal ganglion, EHV4 gB DNA and gene 63 RNA 
transcripts were detected. The presence of RNA transcripts of EHV1 gene 64 in PBL 
and lymph node in the absence of any evidence of the replication of structural proteins 
suggests PBL and lymph node are sites of EHV1 latent infections. The presence of 
EHV4 gene 63 transcripts in trigeminal ganglia in the absence of any evidence of 
replication of structural proteins suggests the trigeminal ganglion is the major site of 
latency of EHV4.  
As a potential means of detecting latency of the gammaherpesvirus EHV2, 4 EHV2 
genes ORF74, E4, E8 and E10 were selected as having possible roles during EHV2 
latency based on sequence analysis and comparison with gene products identified or 
postulated as having roles in latency in other gammaherpesviruses. Kinetic 
transcription of these genes was evaluated in an in vitro time course study using a non 
neuronal cell line (equine kidney [EK] cells). While the gB and gH genes encoding 
structural glycoproteins were abundantly transcribed in vitro, the 4 putative EHV2   vi 
latency-associated genes were minimally transcribed during lytic infection in EK cells, a 
result analogous to results obtained for the expression of LATs in other 
gammaherpesviruses. Attempts to demonstrate transcription products of these genes in 
PBL or other tissues of horsed presumed to be latently infected with EHV2 (in which gB 
transcripts had been detected previously) and actively infected with EHV2 (in which gB 
transcripts had been detected at the time of sampling), were unsuccessful.    vii 
Acknowledgments  
My special gratitude goes to my supervisor, Professor Graham Wilcox for his support, 
guidance, consistent advice and excellent supervision throughout the course of the 
study. 
My most sincere appreciation and gratitude goes to my co-supervisor Dr Sharanne 
Raidal for her great and excellent contribution in ensuring the completion of this study, 
particularly collection of samples for epidemiological study.  
My special thanks go to my working partner Dr Andrea Pizzirani for his contribution in 
helping me during the study. 
My gratitude also to the owners and trainers who contributed horses to this study.  
Without the cooperation of owners and trainers epidemiological investigations such as 
those included in this study would not be possible. Their willingness to give freely of 
their time and to bear the costs involved is very gratefully acknowledged. 
My sincere appreciation also goes to all the members in the animal virology group for 
their special assistance and friendship: Surachmi Setiyaningsih, Meredith Stewart, 
Judhi Rachmat, Bahman Khalesi, William Ditcham, Moira Desport, Jill Muhling, Warren 
Raye, Ingrid Nilsson, Carol Sheridan, Emilija Filipovska-Naumovska, Inna Narayani, 
Stephen Wareing, Melanie Crockford, Andrew Hughes, Mark O‟Dea, Josh Lewis and 
Martin Thompson.    
My warmest thanks also go to Ms Sandy MacPhail, Ms Jane MacKay, Ms Linda Davies 
and Mr David Lines for their technical assistance and support.  Many thanks also to Dr 
David Berryman and Ms Frances Brigg in the State Agricultural Biotechnology Centre 
(SABC), Western Australia and to the staff in the Division of Veterinary and Biomedical 
Sciences, Murdoch University for their great assistance.   viii 
Sincere thanks are conveyed to the Universiti Putra Malaysia (UPM) and the Public 
Service Department (JPA), Malaysia for the provision of the scholarship, the Rural 
Industries Research and Development Corporation (RIRDC), Australia Government for 
the provision of the research grant (Project No. UMU-28A), State Agricultural and 
Biotechnology Centre (SABC), Western Australia for provision of an excellent well-
equipped laboratory and also to Murdoch University for provision of an excellent 
environment for study.    
Last but not least, my gratitude goes to my beloved husband Dr Mohd Rosly Shaari 
who has consistently provided me with support, encouragement and valuable advice 
throughout the course of the study, my loving sons Muhammad Qurratul Aqyun and 
Muhammad Faris Akmal, my parents and family for their generous love and also not to 
forget all colleagues in the Faculty of Veterinary Medicine, UPM for their moral support. 
   1 
Chapter 1 
General introduction 
Respiratory disease is an important cause of wastage in the Australian horse racing 
industry (Bailey et al., 1997).  Respiratory tract disease in horse may be of complex 
aetiology and many agents or factors may be involved, including viral and bacterial 
infections, and various non-infectious causes (Mumford and Rossdale, 1980).  Viruses 
associated with respiratory disease include the alphaherpesviruses equine herpesvirus 
type 1 (EHV1) and type 4 (EHV4), the gammaherpesviruses equine herpesvirus type 2 
(EHV2) and type 5 (EHV5), equine rhinitis viruses, equine influenza virus, equine 
arteritis virus, parainfluenza-3 virus, equine adenovirus, and Hendra virus (McChesney, 
1975; Sherman et al., 1977; Coggins, 1979; Reif, 1979; McAllister, 1982; Colahan et 
al., 1992; Mumford et al., 1998).  Confirmation of the role of herpesviruses in 
respiratory disease can only be achieved with laboratory support and requires a good 
understanding of the epidemiology and pathogenesis of all 4 equine herpesviruses that 
have been associated with respiratory disease in the horse.   
A significant characteristic of the herpesviruses is that they form latent infections in 
infected hosts, and can be reactivated to again induce lytic infections by stressors.  
This thesis deals with an investigation of equine herpesvirus infection, particularly 
gammaherpesvirus infections, in foals and to determine if there was evidence of 
reactivation of latent virus infections by stressors such as those associated with 
weaning.  A critical analysis of the literature dealing with herpesvirus infections in 
horses and with a focus on the mechanisms of latency was undertaken initially, and is 
provided in Chapter 2.  An understanding of latency was considered critical to the 
interpretation of the results of this thesis as it is generally recognised that not all horses   2 
infected with the equine herpesviruses develop clinical disease, that not all virus 
detected by conventional PCR assays may represent actively replicating virus, and it 
was hypothesised that latency or reactivation of latent virus may be one explanation for 
the occurrence of equine herpesviral disease in some horses in association with 
stressors.  The need to be able to differentiate active (lytic) virus infection and latent 
virus infection is important for clarification of these issues. 
The development of rapid, sensitive and specific methods for detecting equine 
herpesvirus infection was considered critical for future epidemiological or pathogenesis 
studies.  Cell culture has been the gold standard technique for detection of equine 
herpesvirus infection, but is time consuming, expensive and not ideal for large scale 
epidemiological investigations.  Recent advances in molecular biology, enabling 
sequence analysis of most equine herpesvirus types, have led to the development of 
PCR based techniques for the detection and differentiation of the alphaherpesviruses 
EHV1 and EHV4 (Borchers and Slater,1993; Carvalho et al., 2000b), and the 
gammaherpesviruses EHV2 and EHV5 (Reubel et al., 1995).  It was hypothesised that 
detection of both viral DNA and RNA transcripts of the late structural genes (for 
example, those encoding glycoproteins B and H), would indicate that the virus detected 
was present as a lytic infection, while detection of viral DNA could also occur with latent 
infections.  Hence, a reverse transcriptase-PCR (RT-PCR) technique was developed to 
detect lytic herpesvirus infections.  The development of RT-PCR for the detection of 
equine herpesviruses and a comparison of the sensitivity of this technique with other 
PCR based techniques for the detection of the equine herpesviruses is reported in 
Chapter 3.  The developed techniques were then applied to an investigation of equine 
herpesviruses in foals from birth to postweaning in 4 stables to determine the   3 
prevalence of infections and the effect of stressors such as weaning on the prevalence 
of infection. These results are also reported in Chapter 3. 
To further our understanding of latency in equine herpesviruses, and especially to 
determine if it was possible to develop PCR-based assays that would specifically detect 
latent virus infections, the detection of latency-associated transcripts (LAT) of the 
equine herpesviruses was undertaken and is reported in Chapters 4 and 5.  The LAT of 
the equine alphaherpesviruses have been described previously (Edington et al., 1985, 
1994; Scott et al., 1983; Welch et al., 1992; Baxi et al., 1995, 1996; Chesters et al., 
1997; Marshall and Field, 1997; Smith et al., 1998; Borchers et al., 1999b,c) and in 
Chapter 4 the presence of equine alphaherpesvirus LATs in horses was investigated, 
examining their presence in different tissues of some of the horses examined during the 
investigations reported in Chapter 3 and in additional samples collected post-mortem 
from horses that had been euthanased for reasons unrelated to the studies reported in 
this thesis.  Latency-associated genes in equine gammaherpesviruses have not been 
documented, and in Chapter 5 an investigation was undertaken of possible genes of 
EHV2 that might be associated with latency.  Efforts to identify latent genes were 
focused on EHV2, as this virus genome has been completely sequenced (Telford et al., 
1995).  Four possible latency-associated EHV2 genes were identified and their 
transcription in virus infected cell cultures and in tissues of horses was examined.   
A general discussion of the results reported in the thesis and their significance are 
provided in Chapter 6.   4 
Chapter 2 
Review of the literature  
2.1 Introduction 
Equine respiratory disease is a common and important disease in many countries 
(Studdert et al., 1970; Allen and Bryans, 1986; Studdert, 1996; Fu et al., 1986; Murray 
et al., 1998; Sherman et al., 1977; Mumford et al., 1998, Mumford and Edington, 1980; 
de Boer et al., 1979; Schroer et al., 2000; Bryans, 1980; Ruiz et al., 1998; Carvalho 
et al., 2000a, b; Galosi et al., 2001; Borchers and Frolich, 1997, Adeyefa, 1992 and 
Singh et al., 1995) and has been identified as one of the leading causes of wastage in 
the Australasian racing industry (Bailey et al., 1997; Perkins, Reid and Morris, 2004). 
Costs accrue associated with diagnosis and treatment and, in the case of racing and 
performance horses, with loss of training days and decreased earnings.  
Equine respiratory disease may affect the upper and/or lower respiratory tract 
(Ainsworth and Biller, 1998). Infectious causes include viruses, bacteria, fungi and 
parasites. Non-infectious conditions include various inflammatory conditions and 
exercise-induced pulmonary haemorrhage. Clinical manifestations of these different 
conditions overlap considerably, making differentiation of the underlying aetiology 
difficult on the basis of clinical signs alone. Horses with respiratory disease may be 
febrile and/or demonstrate other clinical signs of systemic disease, such as 
inappetance and depression. They may demonstrate regional lymphadenopathy, an 
acute or chronic cough, abnormal respiratory noise with exercise, nasal discharge, 
decreased exercise tolerance, finishing a race in respiratory distress, and/or poor 
performance. Horses with viral respiratory tract infections are often pyrexic and 
inappetant in the early stages of infection, typically prior to the development of clinical   5 
signs which may be localised to the respiratory tract but are non-specific for viral 
illness, such as lymphadenopathy, nasal discharge and, less commonly, coughing. 
2.2 Herpesviruses as causes of equine respiratory disease  
Viruses associated with respiratory disease, or isolated from the respiratory tract in the 
horse, are presented in Table 2.1. The alphaherpesviruses EHV1 (equine abortion 
virus) and EHV4 (equine rhinopneumonitis virus) have been well characterised as 
pathogens and major causes of acute respiratory disease of horses, although not all 
horses infected with these 2 viruses necessarily develop overt clinical disease. EHV1 
has also been associated with viral abortion and neurological disease. The role of the 
gammaherpesviruses, EHV2 and EHV5 as causes of disease is less well documented. 
Although a number of reports (for example, Schlocker et al., 1995; Murray et al., 1996) 
have associated EHV2 with disease, primarily respiratory disease, the virus has also 
been detected (albeit at a lower incidence) in samples from clinically normal horses 
(Schlocker et al., 1995). Recent work in this laboratory has demonstrated that EHV2 
was more commonly identified in the respiratory tract of young horses with respiratory 
disease (Wang, 2003), although the virus was also isolated from clinically normal 
horses and experimental challenge with the virus did not induce disease (Wang, 2003). 
There is even less evidence to support a role for EHV5 in disease, with studies in this 
laboratory demonstrating that it is very commonly identified in respiratory and 
peripheral blood samples from healthy horses (Wang, 2003; Wang et al., 2007).    6 
Table 2.1. Identified viral pathogens of horses. 
Virus  Taxonomic group  Associated disease  Key reference(s) 
Equine  herpesvirus  1 
(equine abortion virus) 
Alphaherpesvirinae 
URT infection, abortion, 
neurological disease 
Allen and Bryans (1986) 
Crabb  and  Studdert 
(1995) 
Equine  herpesvirus  4 
(rhinopneumonitis) 
Alphaherpesvirinae  URT infection 
Matumoto et al. (1965) 
Bagust et al. (1968) 
Equine herpesvirus 2  Gammaherpesvirinae  Uncertain  Browning et al. (1988) 
Equine herpesvirus 5  Gammaherpesvirinae  Uncertain  Dunowska et al. (1999) 
Equine rhinitis B virus  Picornaviridae  URT infection  Hofer et al. (1973) 
Equine rhinitis A virus  Picornaviridae  URT infection 
Plummer  and  Kerry 
(1962) 
Equine influenza virus  Orthomyxoviridae 
Respiratory disease 
Exotic to Australia 
Sovinova et al. (1958) 
Waddell et al. (1963) 
Equine arteritis virus  Arteriviridae 
Abortion 
Exotic to Australia 
Doll et al. (1957) 
Equine  parainfluenza-3 
virus 
Paramyxoviridae  Respiratory disease  Jolly et al. (1986) 
Equine adenovirus  Adenoviridae 
Possible  cause  of 
respiratory disease 
Todd (1969) 
Hendra virus 
(equine morbillivirus) 
Paramyxoviridae 
Respiratory disease 
Neurological disease 
Selvey et al. (1995) 
Murray et al. (1995) 
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2.3 Characteristics of Herpesviridae 
The family Herpesviridae is divided into 4 subfamilies: Alphaherpesvirinae, 
Betaherpesvirinae, Gammaherpesvirinae and an un-named subfamily comprising the 
channel catfish herpesvirus-like viruses (van Regenmortel et al., 2000). Although there 
is considerable variation between the more than 100 species that have been identified, 
features common to all members of the Herpesviridae include aspects of their genome, 
structure and biological properties including replication and a propensity to form latent 
infections in infected animals.  
Alphaherpesviruses cause severe lytic infection of host cells and are rapidly cytopathic 
when cultured. Betaherpesviruses and gammaherpesviruses are not highly lytic for 
infected cells, replicate relatively slowly in vitro, and typically cause chronic infections 
lasting several months before clinical recovery. Some species of Gammaherpesvirinae, 
including Marek‟s disease virus (MDV) and Kaposi’s sarcoma-associated herpesvirus 
(KSHV), have been associated with tumour development. All herpesviruses produce 
life-long persistent infections of the natural host, with persistence of the virus in a latent 
form after recovery from the initial acute disease. Aspects of these features, relevant to 
equine herpesvirus infections, will be reviewed below.  
2.3.1 General features of the structure of herpesviruses 
The Herpesviridae have distinct virion architecture and all possess similar structural 
components. The DNA genome, and viral proteins, are located within a torus-shaped 
inner core, approximately 75 nm in diameter (Knopf, 2000). This is contained within an 
icosahedral capsid 100-125 nm in diameter, composed of 162 hollow capsomers, in 
turn surrounded by an amorphous tegument. An outer bilaminar membrane, or 
envelope, encloses the entire structure and is responsible for many of the   8 
characteristics which determine viral persistence outside the host (Knopf, 2000). The 
envelope contains glycoprotein spikes, which play an important part in the infection 
process, mediating both entry of the virion into the host cell and cell-to-cell spread of 
virus (Spear, 1985). 
2.3.2 The structure of the herpesvirus genome  
Herpesvirus DNA is linear and double-stranded, but circularises immediately upon 
release from capsids into the nuclei of infected cells. There is a large degree of 
variation in the composition, size and structure of herpesvirus DNA (White and Fenner, 
1994). The genome size ranges from 124-235 kbp (Roizman et al., 1992) and may also 
vary within independent isolates of the same virus species by up to 10 kbp (Roizman 
and Sears, 1996). The genomes of EHV1 and EHV4 have been completely sequenced 
(Telford et al., 1992; Telford et al., 1998, respectively), as has the genome of EHV2 
(Telford et al., 1995). To date, only the sequence of the gB gene of EHV5 has been 
published (Holloway et al., 1999). 
Characteristically the herpesvirus genome is composed of reiterated sequences which 
divide the genome into a unique long (UL) region and a unique short (US) region (van 
Regenmortel et al., 2000) (Figure 2.1). Intragenomic and intergenomic recombination 
events can alter the number of reiterated sequences, creating polymorphism; most of 
the variability in genome size is due to variation in the number of these internal and 
terminal indirect repeat sequences (IR and TR) (Roizman and Sears, 1996). Inversion 
of the reiterated sequences during replication can invert the UL and US sequences 
relative to one another, giving rise to 2 or 4 different isomers of the genome, present in 
equimolar proportions (van Regenmortel et al., 2000).    9 
 
Figure 2.1. Diagram illustrating the basic structure of herpesvirus genomes (from 
http://www.uct.ac.za/microbiology/cann/335/Herpesviruses.html; accessed 19
th September, 
2007). Each herpesvirus has a unique long (UL) and a unique short (US) region, bounded by 
inverted repeat sequences (IR) or terminal repeat sequences (TR). Genome size of various 
isolates of a particular virus can vary by up to 10 kbp, depending on the number of repeated 
sequence. Abbreviations: HSV, Herpes simplex virus; VZV, Varicella-zoster virus; CMV, 
cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, Human herpesvirus type 6. 
 
The percentage of guanine plus cytosine (G + C ratio) in herpesvirus DNA varies from 
31-75%, a range exceeding that found in DNA of eukaryotes (van Regenmortel et al., 
2000). The herpesvirus genome contains a large number of open reading frames 
(ORFs) which potentially encode proteins; the number of potential ORFs varies from an 
estimated 71 for Varicella-zoster virus (VZV) (Peters et al., 2008) to 206 for Human 
cytomegalovirus (HCMV) (Murphy and Shenk, 2008). In the case of HSV, at least 84 of 
the ORFs identified in the genome are expressed (Roizman, 1999). DNA replication 
occurs with sequential transcription and translation of immediate early (IE) or  , early 
(E) or  , and late (L) or   genes producing  ,   and   proteins respectively. 
   10 
2.3.3 Classification of the herpesviruses 
Classification of herpesviruses is based on the type of disease produced, their cellular 
tropism, the nature of the latent infection and nucleotide sequence (van Regenmortel 
et al., 2000).  
Alphaherpesvirinae exhibit a wide host cell range, have a relatively short reproductive 
cycle, spread rapidly from cell to cell in culture, cause widespread destruction of 
infected cells, and typically establish latent infections in sensory ganglia. This subfamily 
includes Human herpesvirus types 1 and 2 (herpes simplex virus 1 and 2; HSV1 and 
HSV2), EHV1 and EHV4, and VZV (Roizman and Sears, 1996).  
Betaherpesvirinae have a more restricted host range than the alphaherpesviruses, a 
longer reproductive cycle, and spread slowly from cell to cell in culture. Infected cells 
frequently become enlarged (cytomegalic) and carrier cultures are readily established. 
Betaherpesviruses are normally latent in secretory glands, lymphoreticular cells, 
kidneys and other tissues (Roizman and Sears, 1996). Included in the 
Betaherpesvirinae is the genus Cytomegalovirus (Human herpesvirus 5 or Human 
cytomegalovirus, and Cercopithecine herpesvirus 5), genus Muromegalovirus (Murid 
cytomegalovirus 1 or Mouse cytomegalovirus 1, and Murid herpesvirus 2 or Rat 
cytomegalovirus) and genus Roseolavirus (Human herpesvirus 6 or Roseola virus). 
Gammaherpesvirinae also have a restricted host range and are specific for either T or 
B-lymphocytes (Drummer et al., 1996). Gammaherpesvirinae comprises 2 genera, 
Lymphocryptovirus (the gamma-1 herpesviruses) including the Baboon herpesvirus, 
Cercopithecine herpesvirus 14 and Human herpesvirus 4 (Epstein-Barr virus [EBV]), 
and Rhadinovirus (the gamma-2 herpesviruses) including Alcelaphine herpesvirus 
(Wildebeest-associated malignant catarrhal fever virus), Bovine herpesvirus 4, the 2 
equine gammaherpesviruses EHV2 and EHV5, and Equid herpesvirus 7 (Asinine   11 
herpesvirus 2) isolated from a donkey (Browning et al., 1988), Human herpesvirus 8 
(KSHV), Ovine herpesvirus 2 (Sheep-associated malignant catarrhal fever virus) and 
Saimirine herpesvirus 2 (Herpesvirus saimiri [HVS]).  Gammaherpesviruses can 
establish latency in multiple cell types: Murine gammaherpesvirus 68, for example, will 
establish latency not only in B cells but also in macrophages, including alveolar 
macrophages (Weck et al., 1999), and lung epithelial cells (Stewart et al., 1998; Wu 
et al., 2000).  EBV will establish latency in both B cells and epithelial cells (Robertson 
et al., 1996). EHV2 is latent in B lymphocytes (Drummer et al., 1996). In some cases, 
infection is associated with transformation of host cells without the production of 
progeny virus.  
2.3.4 Herpesvirus replication 
Events associated with herpesvirus replication are depicted in Figure 2.2, and can be 
divided into the following stages (Knopf, 2000):  
(i)  attachment of the virus to the host cell, fusion of the virion envelope with the cell 
membrane and penetration of the virus into the host cell; 
(ii)  transport of the viral nucleocapsid to the nuclear pores; 
(iii) uncoating of the nucleocapsid and entry of the core into the nuclear compartment, 
where viral transcriptional events take place; 
(iv) viral DNA replication and recombination; 
(v)  assembly of capsids, cleavage and packaging of viral DNA into preformed capsids;  
(vi) envelopment of nucleocapsids by budding through the nuclear membrane, egress 
and release of mature infectious virions. 
   12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Schematic diagram illustrating the major features of the replication cycle of a typical 
herpesvirus (from http://www.stanford.edu/group/virus/1999/inesicle/replication.html; accessed 
19
th February 2007). (1) virion attaches to host cell via complexing of envelope glycoprotein (gC) 
with heparan sulphate moieties of cellular proteoglycans. Viral gD is believed to bind to a 
secondary cellular receptor. (2) The viral envelope fuses to the plasma membrane in a pH-
independent fashion such that the nucleocapsid enters the cytoplasm. Glycoproteins gB, gD, 
and gH are instrumental for this process. (3) The capsid travels along the cytoskeleton to a 
nuclear pore where the viral DNA is released. The linear genome enters the nucleus and 
circularises. (4) Once in the nucleus, the viral DNA is transcribed into mRNA by cellular RNA 
polymerase II. In herpesviruses, viral gene expression is tightly regulated and divided into 3 
kinetic classes of expression. First, a tegument protein associates with cellular proteins, and the 
complex transactivates transcription of immediate-early (IE or  ) genes. IE genes generally 
encode regulatory proteins. Second, an IE protein initiates transcription of the early (E or  ) 
genes. These gene products are enzymes needed to increase the pool of nucleotides and for 
viral replication. Lastly, late (L or  ) genes are activated for production of viral structural proteins. 
(5) After transcription in the nucleus, all mRNA transcripts are translated into protein in the 
cytoplasm. Subsequently, the proteins can go to the nucleus, stay in the cytoplasm, or become 
a part of the membrane bilayer. (6) Capsid proteins assemble in the nucleus to form empty 
capsids. (7) Full-length viral DNA is packaged to form nucleocapsids. (8) The nucleocapsids 
associate with segments of the nuclear membrane where tegument and glycosylated envelope 
proteins have bound. This association triggers envelopment by budding through the nuclear 
membrane. (9) Enveloped virions accumulate in the endoplasmic reticulum (ER). (10) Mature 
virions are released by exocytosis. (11) Virus-specific proteins are also found on the plasma 
membrane of infected cells.  
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2.3.5 Herpesvirus proteins and glycoproteins  
The IE ( ), E ( ) and L ( ) genes encode a number of proteins (Stokes et al., 1996), 
which have discrete roles in replication of virus. 
Immediate early (IE) genes 
Chen et al. (1996ab) identified 5 IE genes in HSV1 that express infected cell proteins 
(ICPs): ICP0, ICP4, ICP22, ICP27 and ICP47. Synthesis of these proteins peaks 2-4 h 
post-infection (p.i.), but production continues until late in infection. With the possible 
exception of ICP47 (York et al., 1994), all proteins encoded by IE genes appear to 
function as transacting regulators of virus transcription (Zhao et al., 1992; Rice and 
Lam, 1994; Knopf, 2000). ICP4 acts via the basal cellular transcription machinery and 
is essential for the transcription of early and late genes (Preston, 2000). ICP27 
operates at post-transcriptional levels to regulate splicing, termination and nuclear 
export of viral transcripts (reviewed by Phelan and Clements, 1997) and hence is also 
required for virus replication. ICP0 and ICP22 are not essential, but are required for 
efficient replication of HSV1. ICP0 stimulates the onset of virus infection, is required for 
efficient reactivation of latent virus, and is probably also involved in arresting the HSV1 
infected cell in the G1 phase (Knopf, 2000). ICP47 is believed to interfere with antigen 
presentation (York et al., 1994). 
Early (E) genes 
E (or  ) genes are not expressed in the absence of   proteins and their synthesis 
peaks 5-7 h p.i., immediately prior to viral DNA synthesis. Most viral genes involved in 
viral nucleic acid metabolism appear to be   genes (Spear, 1985). The   genes have 
been divided into 2 subclasses:  1 genes, encoding proteins such as the large 
component of ribonucleotide reductase and the major DNA binding protein (ICP8),   14 
appear early after infection;  2 genes that encode proteins such as viral thymidine 
kinase (TK) and viral DNA polymerase.   
Late (L) genes 
L (or  ) genes are also separated into 2 groups:  1 genes that encode the major capsid 
proteins, which are important as mediators of virus entry into the host cell and cell-to-
cell spread of virus (Spear, 1985), are expressed early in infection and are minimally 
affected by inhibitors of DNA synthesis;  2 genes that are expressed later in infection 
and are not expressed in the presence of inhibitors of viral DNA synthesis (Spear, 
1985).  
The EHV1 genome contains at least 76 unique genes likely to encode proteins (Crabb 
and Studdert, 1995). EHV1 homologues have been identified from DNA sequence 
analyses for 10 of 11 recognised HSV1 glycoproteins (Table 2.2). The remaining 
glycoprotein, gJ, of HSV1 has a positional counterpart in the US region of EHV1 (gene 
71) although these 2 genes do not show significant homology (Telford et al., 1992). 
EHV1 possesses 3 other glycoproteins, designated gp2 and gp21/22a, which have no 
HSV homologue, and gp10, which is homologous to the HSV1 tegument protein 
VP13/14. The EHV1 glycoproteins gp2, gp10, gC, gB, gD and gp21/22a have been 
definitively identified by SDS-PAGE, as have EHV4 glycoproteins gp2, gp10, gC, gB, 
gD and gG (reviewed in Crabb and Studdert, 1995). EHV1 glycoprotein gp14, the 
homologue of HSV1 gB, may be important for the induction of neutralizing antibodies 
(Osterrieder et al., 1994ab).  
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Table 2.2. Herpes simplex virus glycoproteins and their homologues in EHV1 and EHV4 (from 
Crabb and Studdert, 1995). 
 
HSV glycoprotein  Identified function  E or N  Homolog  Amino acid 
identity (%) 
Designation  Gene
a      EHV1  EHV4 
gB  UL27  Penetration, fusion  E  gp14  Gp14  88 
gC  UL44  Adsorption, C3b 
receptor 
N  gp13  Gp13  79 
gD  US6  Penetration, fusion  E  gp18  Gp18  83 
gE  US8  Fc receptor (with gI)  N  gE  gE  - 
gG  US4  Unknown  N  gG  gG  58 
gH  UL22  Penetration, fusion, 
complexes with gG 
E  gH  gH  85 
gI  US7  Fc receptor (with gE)  N  gI  -  - 
gJ  US5  Unknown  N  US5  US5  - 
gK  UL53  Fusion  N  gK  -  - 
gL  UL1  Penetration, fusion, 
complexes with gH 
E  gI  -  - 
gM  UL10  Unknown  N  gM  -  - 
 
a HSV1 gene assignments are according to Hutchinson et al. (1992a, b), Baines and Roizman (1993) and 
McGeoch and Davison (1999).  
 
 
2.3.6 Herpesvirus latency 
Latency in the gammaherpesviruses and alphaherpesviruses will be reviewed below.  
2.3.6.1 Gammaherpesviruses  
Latency in gammaherpesviruses appears to be different to that of alphaherpesviruses. 
The discovery of the Murine gammaherpesvirus 68 (MHV68) has provided an animal 
model for more detailed investigation of latency in a gammaherpesvirus. Infection with 
MHV68 is associated with a progressive shutdown of gene expression in infected cells   16 
(reviewed by Nash et al., 2001). Several cell types including B lymphocytes, dendritic 
cells, macrophages and pulmonary epithelial cells are implicated in maintaining latency. 
A number of unique genes, including genes M1 to M6 and a number of virus-encoded 
transfer RNA-like structures (vt-RNAs), are located at the 5‟ end of the MHV68 
genome. In other
 gammaherpesviruses, genes in this region are expressed either in 
latently
 infected cell lines or in tumours (Bowden et al., 1997; Virgin et al., 1997; 1999). 
During MHV68 infection, M2 gene expression in the lymph node and spleen seems to 
be transient, lasting for about 2 weeks. M3 is expressed for up to 10 months in the 
spleen and it is also highly expressed during productive infection (Virgin et al., 1999). 
Viral tRNAs are expressed during latency, but can also be detected abundantly during 
lytic infection (Bowden et al., 1997). Other latency-associated genes expressed by 
MHV68 include gene 73 (homologous to the latent nuclear antigen of KSHV), ORF74 
(G-protein-coupled receptor) and M11 (Bcl-2 homologue) (Virgin et al., 1999). These 3 
genes are expressed in lung epithelial cells for well over 100 days following infection, 
which strongly suggests that the respiratory tract is a major site of persistence for this 
virus. 
Gammaherpesviruses may persist in leukocytes or epithelial cells (Roizman, 1999). 
Although other sites may also harbour latent infection, the gammaherpesvirus EBV 
predominantly replicates in the epithelium of the respiratory tract and persists latently in 
B lymphocytes (Robertson et al., 1996; Favoreel et al., 2000).  
Latency of the equine gammaherpesviruses appears to occur in neurological and 
lymphoid tissue. Drummer et al. (1996) defined latency as the absence of infectious 
virus in the cells, and reported that based on the abrogation of infectious centre 
formation upon inoculation of B lymphocytes onto EKS monolayer cell cultures, EHV2 
was latent in B-lymphocytes.  Rizvi et al. (1997) used PCR to examine the distribution   17 
of EHV2 DNA within neurological and lymphoid tissues from 12 EHV2/EHV5 
seropositive Welsh mountain ponies. The lymphoid sites were almost universally PCR-
positive, thus confirming previous virus co-cultivation studies suggesting that lymph 
nodes draining the respiratory tract were the main reservoirs of EHV2/5 latency. EHV2 
DNA was also detected, albeit with lower frequency, within both the peripheral and 
central nervous systems of these animals: the trigeminal ganglion proved PCR-positive 
in 50% of the animals tested (Rivzi et al., 1997). These authors detected EHV2 DNA in 
the trigeminal ganglia and olfactory bulbs from the first day after inoculation in a murine 
(Balb/C) model of EHV2 infection. These tissues remained positive for EHV2 DNA for 
at least 30 days, by which time EHV2 DNA had been cleared from all other tissues. 
The isolation of EHV5 from a high percentage of clinically healthy horses (Dunowska 
et al., 1999; Wang, 2003) raises the question of whether the virus detected was present 
mainly in a latent or lytic state in these horses. Similarly, it is unclear whether reports of 
the isolation of EHV2 (which may have included EHV5) from PBL and/or lymph nodes 
draining the respiratory tract from more than 75% (Edington et al., 1994), 90% (Kemeny 
and Pearson, 1970) and 100% (Murray et al., 1996; Borchers et al., 1997a) of horses 
sampled represented productive virus infection of cells or the rescue of latent virus. 
Both EHV2 and EHV5 have been recovered most frequently from PBL, but PBL do not 
appear to harbour EHV2 indefinitely after infection (Borchers et al., 1997a). EHV2 (or 
EHV5) has also been identified in a variety of other tissues, including the respiratory 
tract (Kemeny and Pearson, 1970; Blakeslee et al., 1975; Palfi et al., 1978; Fu et al., 
1987). Interpretation of these earlier studies is hindered by the fact that EHV2 and 
EHV5 were not discriminated until 1987 (Browning and Studdert, 1987b) and still 
cannot be differentiated antigenically.    18 
The latency-associated genes 
Latency-associated genes in EHV2 have not yet been identified. KSHV provides the 
best model for the identification of latency-associated genes in EHV2 or other 
gammaherpesviruses because most genes with roles in the latency mechanism of 
KSHV have been identified (reviewed by Dourmishev et al., 2003). In KSHV, there are 
3 major latency loci: ORF73 (latency-associated nuclear antigen [LANA]), ORF72 
(vCyclin), and K13 (Fas-ligand IL-1
  -converting enzyme [FLICE] inhibitory protein 
(vFLIP) (Kellam et al., 1997; Sarid et al., 1999). Other genes associated with latency 
include K12 (kaposin A), K11.5 (vIRF2), K10.5 (LANA-2) and K15 (LAMP). KSHV K 
proteins generally mediate proliferation and transformation of infected cells (Muralidhar 
et al., 1998). In addition to these latency genes, a role during latency has been 
identified or postulated for a number of KSHV lytic genes, including K2 (vIL-6), ORF74 
(vGPCR), K6 (vMIP), K4 (vMIP-II), K4.1 (vMIP-III), K9 (vIRF-1), K10.5/K10.6 (vIRF-3), 
K1, ORF16 (vBcl-2), K7 (vIAP), K3 (MIR1), K5 (MIR2), and K14 (viral OX2). 
Neither ORF73 nor ORF72 is present in EHV2 (Telford et al., 1995). However, the 
KSHV K13 protein (vFLIP) has significant amino acid identity to EHV2 protein E8 (Hu et 
al., 1997). Viral FLIP proteins have also been identified in HVS (ORF71, Albrecht et al., 
1992), BHV4 (protein E1.1, Lomonte et al., 1995) and MCV (proteins 159L and 160L, 
Senkevich et al., 1996).  
Among lytic genes/proteins with roles in KSHV latency, only ORF74/GPCR (Telford et 
al., 1995) and ORF16/vBcl-2, also known as E4 (Telford et al., 1995; Marshall et al., 
1999), have significant amino acid identity to EHV2 gene products. ORF74/GPCR is 
also present in MHV68 (Virgin et al., 1997) but not in EBV (Baer et al., 1984), while 
both MHV68 and EBV contain vBcl-2, also known as protein M11, (Roy et al., 2000), 
BHRF1 (Henderson et al., 1991) and BALF1 (Marshall et al., 1999).   19 
The mechanism of viral latency has not been elucidated. The latency program has 
been associated with cellular apoptosis (Cuconati and White, 2002) as viral genes with 
an anti-apoptotic function, such as vBcl-2 and vFLIP, have been detected during latent 
infection. Apart from anti-apoptotic genes, the EHV2 gene E10 
(vCLAP/vCIPER/vCARMEN) (Koseki et al., 1999; Thome et al., 1999; Yan et al., 1999; 
Srinivasula et al., 1999; Costanzo et al., 1999; Thome et al., 2001; Poyet et al., 2001) 
can activate apoptosis via nuclear factor-κB (NF-kB) through interaction with 
components of the death receptor signalling pathway (Costanzo et al., 1999).  
Based on their putative role in the establishment or maintenance of latency associated 
with other gammaherpesviruses and the presence of possible homologue genes in the 
EHV2 genome, the effect of viral GPCR, Bcl-2, FLIP/FLICE and CLAP will be reviewed. 
vGPCR  
Cellular GPCRs (cGPCRs) are integral plasma membrane proteins containing 7 
transmembrane domains, connected by 3 intracellular and 3 extracellular “loops” 
(Figure 2.3). The N-terminus is located on the extracellular (EC) side and the C-
terminus is located on the intracellular (IC) side of the plasma membrane. The N-
terminus is typically glycosylated and the C-terminus is often palmitoylated, both of 
which can affect receptor expression and function. GPCRs bind a variety of ligands, 
which interact with the N-terminus, extracellular “loops” or transmembrane regions. 
Ligand binding causes intracellular regions (C2 and C3) and the C-terminal tail of the 
receptor to associate with and activate G proteins (guanine nucleotide binding proteins) 
located on the intracellular side of the cytoplasmic membrane. G protein activation is 
responsible for the initiation or regulation of a diverse range of intracellular signalling 
pathways.    20 
 
 
 
 
 
 
 
Figure 2.3. Structure of G-protein coupled receptors (GPCRs). Image adapted from 
http://www.polymers.unisa.it/assets/images/mps.jpg 
 
Viral GPCR have a homologous structures to cellular GPCR and engage cellular 
pathways in a phospholipase C- or phosphatidylinositol 3-kinase-dependent
 manner, 
leading
 to increased transcriptional activity of their nuclear targets,
 stimulation of cellular 
proliferation, promotion of cell survival,
 or cellular transformation (Arvanitakis et al., 
1997; Bais et al., 1998; Couty et al., 2001; Montaner et al., 2001; Munshi et al., 1999; 
Pati et al., 2001; Schwarz and Murphy, 2001; Smit et al., 2002). Although gene 
expression induced by viral GPCR may differ according to cell type, expression of 
vGPCR is typically associated with the secretion increased levels
 of autocrine and 
paracrine cytokines and growth factors (IL-1ß,
 TNF- , IL-6, IL-8, granulocyte-
macrophage colony-stimulating
 factor, VEGF, bFGF, and MCP-1) (Bais et al., 1998;  
Pati et al., 2001; Schwarz and Murphy, 2001; Shepard et al., 2001; Sodhi et al., 2000). 
In transgenic
 mice, vGPCR induces multifocal, angioproliferative, Kaposi sarcoma-like
 
lesions (Yang et al., 2000). In transient transfections, vGPCR also activate
 the 
promoters of multiple latent and lytic KSHV genes (Chiou et al., 2002).
  
Cell 
membrane   21 
vBcl-2, vFLIP/FLICE and vCLAP  
Cellular apoptosis is induced and regulated by a variety of intracellular signalling 
mechanisms. EHV2 proteins may modulate apoptosis by 3 separate mechanisms 
involving the vBcl-2, FLIP/FLICE proteins and vCLAP, each of which will be reviewed 
separately.  
Role of latency genes in the apoptosis pathway 
Apoptosis pathways 
Programmed cell death, or apoptosis, is a controlled event that is involved in many 
processes, such as tissue development, immune system management, and host 
defence. Apoptosis is characterised by several morphological changes, such as 
chromatin condensation, DNA fragmentation, membrane blebbing, cell shrinkage, and 
the formation of apoptotic bodies (for review, see Kerr et al., 1972). Apoptosis serves 
as an effective antiviral defence mechanism by which the host may eliminate virus-
infected cells. Consistent with this function, it can be triggered
 by activated cytotoxic T 
cells, pro-inflammatory cytokines such
 as tumour necrosis factor (TNF), and by viral 
disruption of cellular
 metabolism and cell cycle regulation (Shen and Shenk, 1995).  
The morphological and biochemical changes of apoptosis
 are often associated with the 
activation of a family
 of intracellular cysteine proteases known as caspases (cysteine 
aspartyl-specific proteases) (Alnemri et al., 1996). Though many pathways for 
activating caspases may exist, only
 2 have to date been elucidated in detail. One of 
these involves tumour necrosis factor (TNF) family receptors (Salvesen and Dixit, 1997; 
Wallach et al., 1999; Yuan, 1997), often referred to as the „death receptor‟ pathway; the 
other involves the release of mitochondrial caspase-activating proteins from 
mitochondria (Reed, 1997; Green, 1998). The death receptor and mitochondrial   22 
pathways
 for caspase activation are sometimes referred to as the extrinsic
 and intrinsic 
apoptosis pathways, respectively (Figure 2.4), though this is an oversimplification. 
Although commonly
 viewed as separate pathways and capable of functioning 
independently,
 interaction can occur between these pathways at multiple levels,
 
depending on the repertoire of apoptosis-modulating proteins
 expressed.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Pathways for caspase activation (from Reed, 2000). Two of the major pathways for 
caspase activation in mammalian cells are presented, the extrinsic (left) and intrinsic (right). The 
extrinsic pathway can be induced by members of the TNF family of cytokine receptors, such as 
TNFR1 and Fas. These proteins recruit adapter proteins to their cytosolic DDs, including Fadd, 
which then binds DED-containing pro-caspases, particularly pro-caspase-8. The intrinsic 
pathway can be induced by release of cytochrome c from mitochondria, induced by various 
stimuli, including elevations in the levels of pore-forming pro-apoptotic Bcl-2 family proteins such 
as Bax. In the cytosol, cytochrome c binds and activates Apaf-1, allowing it to bind and activate 
pro-caspase-9. Active caspase-9 (intrinsic) and caspase-8 (extrinsic) have been shown to 
directly cleave and activate the effector protease, caspase-3. Other caspases can also become 
involved in these pathways (not shown); thus, the schematic represents an oversimplification of 
the events that occur in vivo.    23 
The cytosolic domains of TNF family death receptors, such as Fas (Apo1/CD95), are 
linked indirectly to certain forms of caspase-8 by a network of protein interactions 
involving adaptor proteins such as Fadd (Mort1) (Chinnaiyan et al., 1995; Boldin et al., 
1995; Muzio et al., 1996; Boldin et al., 1996; Muzio et al., 1998). By contrast, the 
intrinsic pathway involves the release of mitochondrial cytochrome C, which binds to 
the caspase activating protein Apaf-1 (Zou et al., 1997). By a further series of reactions, 
pro-caspase-9 is activated to become the apical caspase in this pathway.  
Many DNA viruses encode proteins that interfere
 with key regulatory steps in apoptotic 
signalling pathways to counter the host response. Anti-apoptotic
 proteins encoded by 
viruses include Bcl-2 homologues that function by an unknown mechanism to prevent 
activation
 of apoptotic caspases, as well as inhibitors of the caspases
 themselves 
(reviewed by Bertin et al., 1997). Infection
 of cells with deletion mutants lacking these 
genes often results
 in premature apoptotic death and reduced viral yield,
 suggesting 
that anti-apoptotic proteins promote efficient
 virus replication (Pilder et al., 1984; 
Hershberger et al., 1992; Brooks et al., 1995). In addition, suppression of apoptotic
 cell 
death is important for viral persistence (Levine et al., 1993) and may be
 required for the 
establishment of certain latent infections (Gregory et al., 1991).
 Thus, understanding 
viral mechanisms of inhibiting
 apoptosis should provide further insight into viral 
replication and persistence. 
Protein domains associated with apoptosis regulation  
A number of different protein domains have been associated with apoptosis: 
i.  caspase domains (as reviewed above),  
ii.  death domains (DDs),  
iii.  death effector domains (DEDs),  
iv.  caspase-associated recruitment domains (CARDs),    24 
v.  Baculovirus IAP (inhibitor of apoptosis protein) repeat (BIR) domains, and 
vi.  Bcl-2 Homology (BH) domains.  
In gammaherpesviruses, viral genes that are well-recognised as homologues to 
apoptosis protein domains are Bcl-2 (BH), DEDs and CARDs. Bcl-2-like motifs are 
present in EHV2 protein E4, KSHV and HVS protein ORF16, EBV protein BHRF1 and 
BALF1, and MHV68 protein M11 (Roy et al., 2000). The vFLIP proteins (EHV2 protein 
E8, KSHV protein K13, HVS protein ORF71, BHV4 protein E1.1 and MCV proteins 
MCV159L and MCVL160L) represent DED-like motifs. CARDs-like motifs are present in 
the EHV2 protein E10 (vCLAP/vCIPER/vCARMEN) (Koseki et al., 1999; Thome et al., 
1999; Yan et al., 1999; Srinivasula et al., 1999; Costanzo et al., 1999; Thome et al., 
2001;Poyet et al., 2001). Bcl-2 (BH), DEDs and CARDs will be further reviewed 
because genes encoding these domains may be associated with latency in 
gammaherpesviruses.   
Bcl-2 family proteins 
Bcl-2 family proteins
 regulate the mitochondrial-dependent (or „intrinsic‟) apoptosis 
pathway, by regulating the release of cytochrome C from mitochondria. Pro-apoptotic 
Bcl-2 family proteins, such as Bax, Bak, Bok (Mtd), Bad, Bid, Bim,
 Bik, Hrk, Bcl-XS, APR 
(Noxa), p193, Bcl-G, Nip3, and Nix (BNIP), induce (or make it easier
 to induce) release 
of this caspase-activating protein; anti-apoptotic
 members of the family, including Bcl-2,
 
Bcl-XL, Mcl-1, Bfl-1 (A1), Bcl-W, and Boo (Diva), suppress cytochrome C release.
 Some 
Bcl-2 family genes produce 2 or more proteins
 through alternative mRNA splicing, 
sometimes exerting opposing
 effects on cell death regulation (for example, Bcl-XL vs 
Bcl-XS). Some proteins display anti-apoptotic activity in some contexts but have pro-
apoptotic functions at other times (Chen et al., 1996a, b; Middleton et al., 1996; Song et 
al., 1999; Inohara et al., 1998).    25 
Bcl-2 family proteins can be broadly divided into
 2 groups based on their predicted 3-
dimensional structure. One subset of these proteins is probably similar
 in structure to 
the pore-forming domains of bacterial toxins, such
 as the colicins and diphtheria toxin 
(Muchmore et al., 1996; Chou et al., 1999; McDonnell et al., 1999; Schendel et al., 
1998). These  -helical
 pore/channel-like proteins include both anti-apoptotic proteins
 
(Bcl-2, Bcl-XL, Mcl-1, Bfl-1, Bcl-W, and possibly Boo), as well
 as pro-apoptotic proteins 
(Bax, Bak, Bok, and Bid). Most of
 the proteins in this subcategory can be recognised by 
conserved
 regions of amino acid sequence identity, including the presence
 of Bcl-2 
homology (BH) domains BH1, BH2, BH3, and sometimes
 BH4 (Reed, 2000, Figure 
2.5).  
 
Figure 2.5.  Bcl-2 family proteins. The domain arrangements of the known members of the Bcl-2 
family are presented. The BH1, BH2, BH3, BH4, and transmembrane domains are indicated. In 
addition to human or murine proteins, included in the diagram are the chicken Nr13 protein, C. 
elegans proteins CED-9, EGL1, and CeBNIP, and the Drosophila proteins DBok (Drob1, dBorg 
1, Debcl). Homologues from viruses, xenopas, and marine sponges are not depicted. Human 
noxa (APR) has only one BH3 domain. (From Reed, 2000).   26 
Herpesviruses have many host-acquired genes (Kieff and Rickinson, 2001; Moore and 
Chang, 2001; Roizman and Pellett, 2001). The predominantly lymphotropic 
gammaherpesviruses encode vBCL-2s and in gammaherpesviruses that do encode 
vBCL-2s there is substantial evidence that they function as apoptosis inhibitors in 
response to diverse stimuli. For example, EBV BHRF1 blocks apoptosis induced by 
death receptor signalling (Kawanishi, 1997), as well as other stimuli such as growth 
factor withdrawal (Henderson et al., 1993; Foghsgaard and Jaattela 1997), granzyme B 
(Davis et al., 2000), gamma-irradiation, chemotherapeutic drugs (McCarthy et al., 1996; 
Khanim et al., 1997), deregulated c-myc (Fanidi et al., 1998), and p53 (Tarodi et al., 
1994; Theodorakis et al., 1996). A second EBV vBCL-2 homologue, BALF1, may either 
block apoptosis (Marshall et al., 1999) or antagonise BHRF1 (Bellows et al., 2002). 
KSHV vBCL-2 inhibits apoptosis induced by Bax or vCyclin over-expression or Sindbis 
virus infection (Cheng et al., 1997; Sarid et al., 1997; Ojala et al., 1999). HVS vBcl-2 
blocks FAS, dexamethasone, Sindbis virus and DNA damage-mediated apoptosis 
(Nava et al., 1997; Derfuss et al., 1998). Herpesvirus papio BHRF1 blocks apoptosis 
induced by DNA damage (Meseda et al., 2000) and MHV68 blocks apoptosis by anti-
FAS antibody and TNF-  (Wang et al., 1999). The function of gammaherpesvirus vBcl-
2s could logically be to protect the infected cell from apoptosis induction by the immune 
system or by the infected cell itself. 
Using FASTA and the amino acid sequence of Bcl-xl as a search sequence, Marshall et 
al. (1999) have determined that the E4 open reading frame (ORF) in EHV2 encodes a 
protein with 20% identity to Bcl-xl and contains 2 Bcl-2 homology (BH) domains, BH1 
and BH2. These 2 domains are believed to be essential for the dimerisation, 
heterodimerisation, and function of the anti-apoptotic protein Bcl-2 (Yin et al., 1997).    27 
Death effector domain (DED) protein 
Like the death domain (DD), the DED protein is comprised of 6 alpha helices (Eberstadt 
et al., 1998). Numerous DED-containing modulators of apoptosis have been identified
 
(Figure 2.6).  
 
 
Figure 2.6.  Death effector domain (DED) family proteins. The domain arrangements of some of 
the known members of the DED family are presented. Numbers represent amino acid residue 
positions. Included in the diagram are the Drosophila caspase, Dronc, and the viral DED 
proteins from Kaposi‟s sarcoma virus and MCV. (From Reed, 2000). 
 
   28 
The DED-containing protein FLIP (also known as Flame, CASH, Clarp,
 MRIT, Casper, 
I-Flice, Usurpin) shares extensive amino acid sequence identity with the 2 N-terminal 
DED domains of pro-caspase-8 and -10 and is capable of suppressing caspase-8
 
activation by Fas and other death receptors. 
Similar to cFLIP, KSHV protein K13 (one of the latent loci), EHV2 protein E8, HVS 
protein ORF71, and MCV protein MC159 and MC160, encode DED-containing proteins 
which suppress Fas-induced apoptosis (Belanger et al., 2001; Djerbi et al., 1999; 
Thome et al., 1997; Hu et al., 1997; Bertin et al., 1997).  Belanger et al. (2001) and 
Djerbi et al. (1999) reported that after the KSHV FLIP interacts with procaspase-8 to 
inhibit the apoptosis activation, it will further block the protease activities of caspase-3, 
caspase-8, and caspase-9. 
 
It has been reported that inhibition
 of constitutive NF- B activity in cell lines induces 
programmed
 cell death (Keller et al., 2000). KSHV FLIP inhibits apoptosis by direct 
interaction
 with the I B kinase (IKK) complex in the cell cytosol (Liu et al., 2002). This 
pathway is not present in the vFLIP encoded by EHV2 (Sun et al., 2003), but is present 
in EHV2 protein E10 (Poyet et al., 2001). 
CARD family proteins 
In addition to DD and DED domains, the third related protein-protein interaction domain 
designated as CARD (caspase-recruiting domain) has been recently reported by 
Hofman et al. (1997). The CARD is of similar structure to DDs and DEDs, containing 6 
alpha helices (Chou et al., 1998; Zhou et al., 1999; Vaughn et al., 1999; Day et al., 
1999) (Figure 2.7).    29 
 
Figure 2.7.  Caspase-associated recruitment domain (CARD) family proteins. Non-caspase 
CARD family proteins are shown. The domain arrangements of the known members of the 
CARD family are presented. Numbers represent amino acid residue positions. In addition to 
human proteins, the diagram includes the murine caspase-11 and caspase-12 proteins, C. 
elegans CED-3 and CED-4 proteins, and the Drosophila Dronc protein. Additional family 
members in lower organisms are not presented. (From Reed, 2000). 
 
The prototype CARDs are found in Apaf-1 (Zou et al., 1997), RAIDD (Duan and Dixit, 
1997), CARDIAK (RIP-2) (Thome et al., 1998; McCarthy et al., 1998), ARC (Koseki et 
al., 1998), c-IAP1 and c-IAP2 (Roy et al., 1997), all of which are involved in the
 
regulation of
 apoptosis. All the prototype CARDs will subsequently lead to apoptosis. 
For instance, Apaf-1 activates the
 recruitment of the CARD-containing caspase-9 (Li et 
al., 1997), RAIDD
 recruits caspase-2 to the TNFR1 (Duan and Dixit, 1997),
 while   30 
CARDIAK mediates both
 the recruitment and activation of caspase-1 by CD40 and the 
activation
 of JNK and NF- B (Thome et al., 1998; McCarthy et al., 1998). 
EHV2 encodes a CARD family protein, called E10 (also called vCLAP [CARD-like 
apoptotic protein], vCIPER and vCARMEN; Yan et al., 1999), which is homologous to 
cellular/human Bcl-10 (cBcl-10/huE10) (Koseki et al., 1999; Willis et al., 1999; Yan et 
al., 1999) and which associates with pro-caspase-9.
 In addition to its CARD, cBcl-10
 
contains a proline-rich domain that directly or indirectly mediates associations with pro-
caspase-9. When over-expressed, cBcl-10 activates NF- B (Srinivasula et al., 1999), 
inducing apoptosis. Mutant versions of cBcl-10, lacking
 the C-terminal domain 
implicated in pro-caspase-9 binding, have been
 reported in cancers, although the 
frequency of such gene mutations is
 debated (Lee et al., 1999; Willis et al., 1999; 
Zhang et al., 1999). These truncated forms of cBcl-10 retain
 the ability to activate NF-
B, but fail to induce apoptosis when over-expressed
 in cells (Willis et al., 1999). 
2.3.6.2 Alphaherpesviruses 
Latency 
Latency in alphaherpesviruses is associated with RNA gene products (latency-
associated transcripts, LAT), which are expressed during latency and also later in the 
replication cycle (Spivack and Fraser, 1988). These LAT were first described in HSV by 
in situ hybridization by Stroop et al. (1984) and they were subsequently also detected 
by Northern blotting (Spivack and Fraser, 1987; Stevens et al., 1987). They comprise 
multiple transcripts, including an 8.3 kb primary transcript and 2 stable introns of 2.0 
and 1.5 kb (Farrell et al., 1991; Zwaagstra et al., 1990), which are predominantly 
localised to the neuronal nucleus and are transcribed antisense to and partially 
complementary to the coding sequence for ICP0 (gene 64 homologue). The 2.0 kb LAT   31 
intron has been widely studied because it is the only abundant transcript found during 
the latent phase of an HSV-1 infection.   
HSV-1 establishes latent infection in neuronal cells associated with the sites of primary 
infection (reviewed by Roizman and Sears, 1996). Lytic infection is established in the 
skin or mucosal epithelium and HSV1 is subsequently able to enter local axonal termini 
and be transported to the neuronal cell body (Holland et al., 1999) as non-enveloped 
nucleocapsids (Cook and Stevens, 1973; Lycke et al. 1984). Once transported to the 
neurons of the sensory ganglia supplying the site of initial replication (Lachmann et al., 
1999), free virus can be detected within the ganglia for only a few days (Preston, 2000). 
The viral genome circularises within specific cells in a non-replicating state and only a 
small subset of genes is subsequently expressed in the nucleus of the latently infected 
cells (Gleeson and Coggins, 1985). The exposure of infected cells to various forms of 
stress may initiate active virus replication and the recurrence of clinical disease and 
further shedding of infectious virus (White and Fenner, 1994).  
The reason for the continued transcription of the LATs in an otherwise inactive genome 
is not known. No LAT gene or gene sequence has been confirmed as essential for the 
maintenance of latency or the reactivation of latent virus (Kent et al., 2003). However, 
because all HSV isolates encode a LAT transcript which contains a stable intron, the 
presence of the LAT indisputably indicates the existence of latent HSV in a neuron 
(Preston, 2000) and suggests that the LAT must have some importance to the virus. 
Kent et al. (2003) have suggested that the LAT may function to promote neuronal 
survival. This may occur via anti-apoptotic activity that protects HSV-infected neurons 
from detection and deletion by apoptotic signalling pathways or by down-regulation of 
viral gene expression during the establishment of latency, leading to large numbers of 
latently infected neurons. If LATs were not present, a lytic programme of viral   32 
transcription would continue in infected neurons, resulting in the destruction of neuronal 
cells.  
In the horse, latent alphaherpesvirus (EHV1 and EHV4) infection is common and sites 
of latent infection include PBL, lymphoid tissue and neural tissue. Both EHV1 and 
EHV4 have been experimentally reactivated from the latent state by high doses of 
corticosteroids and mild nasal trauma (Edington et al., 1985).  Scott et al. (1983) 
proposed that EHV1 (which at that time would not have been differentiated from EHV4) 
replicated in and could establish latency in T lymphocytes. Edington et al. (1994) 
reported that EHV1 and EHV4 were detected most commonly in the bronchial lymph 
nodes of horses examined at slaughter; they cultured these viruses from the lymph 
nodes draining the respiratory tract of 24 of 40 horses (60%) and demonstrated viral 
DNA in 87.5% of bronchial lymph nodes. The presence in PBL of a putative LAT of 
EHV1 (antisense to and overlapping the 3‟ end of homologues of the HSV1 IE gene 64) 
was demonstrated by Chesters et al. (1997). Smith et al. (1998) demonstrated that 
EHV1 was harboured predominantly in CD5
+ and CD8
+ T lymphocytes, and by co-
cultivation demonstrated that virus could be reactivated from these cells directly or 
indirectly by the mitogens phytohaemagglutinin and poke weed mitogen. Co-cultivation 
demonstrated that the reactivated virus was infectious (Smith et al., 1998). Van der 
Meulen et al. (2000) hypothesised that mitogen stimulation may initiate specific cell 
cycle events and, by inducing the formation of clusters, may facilitate transmission of 
virus between cells.  
While Edington et al. (1994) detected EHV1 most commonly in the bronchial lymph 
nodes of horses, they were also able to detect virus by PCR in the trigeminal ganglia of 
a similar proportion of horses. This result was confirmed by Slater et al. (1994) who 
were able to isolate virus from the trigeminal ganglia and detect viral DNA in the ganglia   33 
by PCR 3.5 months after EHV1 infection and 2 months after attempted reactivation of 
virus, in the absence of virus in other tissues. Baxi et al. (1995) also detected EHV1 
LATs (RNA antisense to gene 63) by in situ hybridisation in a small number of neurons 
of trigeminal ganglia. Similarly, in a mouse model of EHV1 infection, Baxi et al. (1996) 
demonstrated there was little or no transcription of virus in neural tissues during the 
'latent phase'. However, following a reactivation stimulus, EHV1 DNA was detected on 
the first round of nested PCR in olfactory bulbs, trigeminal ganglia and PBL. Marshall 
and Field (1997) also demonstrated EHV1 latency in the olfactory bulbs of mice by in 
situ PCR and in vitro protein synthesis methods.  
Interestingly, Edington et al. (1994) were able to isolate alphaherpesvirus only in the 
presence of EHV2/EHV5. Although this may be due to the high prevalence of the 
gammaherpesviruses, it has been suggested that EHV2 could play a role in the 
reactivation of latent EHV1 and EHV4 (Drummer et al., 1996;  Dunowska et al., 1999) 
and play an aetiological role in recurring respiratory disease of foals (Fu et al., 1986).  
Conflicting results have been reported regarding the site of latency of EHV4. While it 
has been shown to establish latency in lymph nodes of the respiratory tract and in PBL 
(Welch et al., 1992; Edington et al., 1994), strong evidence for the presence of latent 
EHV4 in neural tissue was provided by Borchers et al. (1999b) who detected EHV4 
DNA in trigeminal ganglia from 11 (65%) of 17 horses. EHV4-specific putative LATs, 
homologues of HSV1 gene 63 (ICP0) and 64 (ICP4), were detected in 6 of 10 
trigeminal ganglia by nested PCR. In one other case, only gene 64-specific transcripts 
were present. All of the transcripts proved to be antisense orientated when a strand-
specific RT-PCR was applied. By contrast, using type-specific primers for gene 33 
(encoding gB), transcripts expected during lytic infection were detected in only one of   34 
the 6 ganglia in which the LATs were detected (Borchers et al., 1999b). Overall, these 
studies demonstrated conclusively that EHV4 is latent in trigeminal ganglia.  
Role of alphaherpesvirus latency genes in apoptosis pathway 
As indicated above, there are 2 well-known latency genes in alphaherpesviruses: ICP0 
(homologous to gene 63) (Nsiah and Rapp, 1991; Ho, 1992) and ICP4 (homologous to 
gene 64) (Chen et al., 1997). The 3‟-end of the major and stable 2 kb LAT overlaps the 
ICP0, whilst the 3‟-end of the minor and unstable 8.5 kb LAT (mLAT) overlaps the 
ICP4.  
These genes are conserved among alphaherpesviruses but not related to any known 
cellular genes with roles in apoptosis. Mutation studies, particularly in HSV1, have 
revealed that these viral genes have apoptotic activity (reviewed by Kent et al., 2003). 
As mentioned previously, apart from the role of LATs in facilitating neuronal survival by 
inhibition of apoptosis, LATs may also facilitate neuronal survival by down-regulating 
lytic viral replication.  
More recent studies have demonstrated that HSV-1 has multiple anti-apoptotic genes, 
including ICP27, ICP22, US3, US5, ICP4 and most recently the region encoding the 
LATs (Aubert and Blaho, 2001). Many viral genes appear to contribute to the ability of 
HSV-1 to block apoptosis in lytically infected cells. The expression of LATs during 
latency suggests that their function would be important during latency, and possibly 
early reactivation. 
Programmed-cell death 
The anti-apoptotic function of HSV LATs was first alleged by Perng et al. (1999), based 
on experimental infection of rabbits with a LAT mutant HSV1. Subsequent experiments 
by these authors (Perng et al., 2000a), and others (for example, Thompson and Sawtell   35 
2000; 2001; Ahmed et al., 2002) have confirmed that modification of the genome in this 
region is associated with increased apoptosis in infected host cells. The involvement of 
the LATs in apoptosis has been further characterised using various cell lines 
transfected with fragments of the LAT region in the presence of exogenous apoptosis 
promoting agents (Perng et al., 2000a), Bax (a pro-apoptotic protein) (Inman et al., 
2001) and caspase 8 (Ahmed et al., 2002). These studies have demonstrated that 
plasmid expression of LAT was protective against apoptosis induced by any of the 
exogenous or endogenous apoptosis-inducing agents.  
It is possible, however, that LATs promote neuronal survival via mechanisms other than 
the inhibition of apoptosis. It was hypothesised by Sawtell (1997) and Thompson and 
Sawtell (1997) that LATs may down regulate viral gene expression during productive 
infections and, in this way, decrease infectivity. Garber et al. (1997) have advanced a 
similar argument.  
Down-regulation of viral gene expression 
Consistent with the findings of Thompson and Sawtell (1997), Garber et al. (1997) 
demonstrated increased cellular expression of viral IE and E genes in trigeminal 
ganglia of mice infected with a LAT mutant, and suggested that the LATs promoted cell 
survival by down-regulation of viral gene expression during productive infections to 
suppress viral replication. Similarly, Mador et al. (1998) observed that the expression of 
LATs in cell lines was associated with decreased expression of viral IE genes ICP0, 
ICP4, and ICP27, in addition to suppressed viral replication.  
Establishment of latency 
Once the virus reaches sensory ganglia, or other sites of latency, it may either 
maintain lytic infection or enter a latent state whereby most of the viral genes are   36 
silenced. Steiner et al. (1990) concluded that for HSV1 the choice of forming latent or 
lytic infection occurs soon after entry to the neuronal cell nucleus. The mechanism by 
which the virus enters a latent state has not been determined, however LATs are 
thought to play a role in promoting the efficient establishment of latency (Sawtell and 
Thompson, 1992; Thompson and Sawtell, 1997); a small deletion in the LAT promoter 
can cause a reduction in the number of latently infected cells, indicating that the 
transcription of the LATs is crucial for establishing latency (Sawtell and Thompson, 
1992). Although earlier studies had suggested that mutations in the LAT region had no 
effect on the level of latent viral DNA (Sederati et al., 1989), the results of Sawtell and 
Thompson (1992) in a mouse model of HSV1 infection were replicated by others in a 
rabbit model (Perng et al., 2000b). Roizman and Sears (1987) have suggested that the 
establishment of latency may occur as a result of decreased viral gene expression due 
to inefficient transfer of tegument proteins into the nucleus during interaction between 
the virus and the neuronal fast axonal transport mechanism (Roizman and Sears, 
1987).  
Maintenance of latency 
As is the case for the initiation of latency, how the latent state is maintained is also 
unclear. Because the 3‟-end of the 2.0 kb LAT intron, which is abundantly present 
during latency, overlaps the IE gene ICP0, Stevens et al. (1987) hypothesised that 
LATs play a role in maintaining viral latency by acting as antisense RNA to the IE gene 
and, in this way blocking viral replication. This possibility was further supported by 
Farell et al. (1991) who showed that the LAT intron inhibits the transactivating activity of 
ICP0 in a transient transfection assay.  
Although it had been thought that there was no transcription of other parts of the viral 
genome during latency, studies by several groups have revealed low but detectable   37 
levels of lytic viral gene mRNA during latency (Kramer and Coen, 1995; Chen et al., 
1997; Feldman et al. 2002). Chen et al. (1997) also showed that the transcripts of viral 
IE and E genes ICP4 and TK were increased several-fold during latent infection with a 
LAT mutant virus. Based on these results, it is believed that LAT transcripts may have a 
role in down-regulating the expression of ICP4 in a similar manner to that hypothesised 
for ICP0. Feldman et al. (2002) suggested that the expression of low levels of lytic 
genes may indicate that there are relatively small numbers of cells where the virus is 
able to reactivate with low levels of gene expression, but that reactivation does not gain 
sufficient momentum for recrudescence. 
Reactivation from latency 
In mouse and rabbit models of HSV1 infection, reactivation of latent virus may be 
triggered by a number of stressful stimuli, or it may be spontaneous. Thomas et al. 
(1999, 2002) identified a LAT protein encoded by an ORF within the 2.0 kb intron 
region, which they believed may act in a similar way to ICP0 to enhance lytic gene 
expression and interact with cellular factor involved in promoting transcription. The 
expression of this protein during the early stages of reactivation could be important for 
the initiation of lytic gene expression from the latent viral genome. Other studies 
indicated that the first 1.5 kb of the LAT region may be necessary for spontaneous 
reactivation in rabbits (Perng et al., 1996a) and the first 811 bp can partially restore this 
phenotype to an HSV-1 LAT-null mutant (Drolet et al., 1999). This region of LAT 
sequence has also been demonstrated to have an ability to convey protection from 
apoptosis inducing agents (Inman et al., 2001). In Bovine herpes virus 1, the latency 
related gene, which has also been shown to possess anti-apoptotic characteristics, can 
recover the spontaneous reactivation phenotype of a LAT-null mutant (Perng et al.,   38 
2002). Based on the results of these studies, it is likely that there is an association 
between the anti-apoptotic ability of LATs and the role of the LATs in viral reactivation.   
2.3.7 Transcription of herpesvirus genes 
As mentioned previously, the herpesviruses exhibit both latent
 and lytic replication. 
During lytic replication, 3 groups of virus-specific polypeptides, IE, E and L, are 
synthesised in a coordinated and sequential fashion (Honess and Roizman, 1974).  
Methodical mapping and characterisation of viral transcripts using a variety of 
techniques (such as Northern blotting, hybrid selection of RNA, primer extension and 
RNase protection) has resulted in the assignment of almost all transcripts to a temporal 
class (reviewed by Wagner et al., 1995). Most recently, the use of oligonucleotide-
based DNA microarrays to analyse the transcription programs of HSV1, HCMV, HSV1 
and KSHV has confirmed the general classification of transcripts and illustrated how the 
host cell used in such analyses may contribute to the expression and regulation of 
individual transcripts (Chambers et al., 1999; Stingley et al., 2000; Paulose-Murphy et 
al., 2001). Based on these studies, the transcription programs of a typical 
gammaherpesvirus (KSHV) and alphaherpesvirus (HSV) are reviewed.  
2.3.7.1 Gammaherpesvirus KSHV 
Like other members of the Herpesviridae, KSHV exhibits a strictly ordered programme 
of genetic transcription (Blackbourn et al., 2000; Ballestas and Kaye, 2001), with both 
latent
 and lytic replication cycles, each characterised by almost distinct gene expression 
programmes. This „biphasic‟ life cycle and the temporal regulation of gene expression 
are very important for pathogenic activity. Lytic infection is associated with the 
destruction of host cells, whereas latent infection is potentially linked to the ability to 
transform infected cells. Hence the classification of individual ORFs to latent or lytic   39 
cycle expression is critical for the evaluation of their potential roles in the pathogenesis 
of viral infection.  
The investigation of gene expression in latent and lytic KSHV has been facilitated by 
the ease of culturing primary effusion lymphoma (PEL)-derived cell lines, which are 
latently infected with KSHV but can be chemically reactivated to lytic gene expression 
by common laboratory chemicals, such as phorbol esters or sodium butyrate 
(Dourmishev et al., 2003). Such studies have distinguished viral gene expression 
characteristic of latent infection (transcription class I, genes which are expressed in 
untreated cell culture), or characteristic of late lytic infection (class III), where gene 
expression can be induced by treatment of the cell culture with tetradecanoylphorbol 
acetate [TPA]). In KSHV, a cluster of 3 class I genes (LANA-1, ORF72 (vCyclin), and 
K13 (vFLIP), shown in Figure 2.8), was reported by Sarid et al. (1998). The expression 
of these genes in Kaposi sarcoma specimens, which confirms their latent
 classification, 
was reported by Davis et al. (1997) and Dittmer et al. (1998). Class III genes encode 
mostly viral structural and replication genes, which are typically
 L genes in 
herpesviruses. A third „intermediate‟ group of genes, class II, which are expressed 
constitutively but which can be further induced by the addition of TPA, has also been 
characterised. This category includes typical herpesvirus regulatory and DNA 
replicative genes, as well as many unique genes, such as virus-encoded cytokines and 
signal transduction proteins cytokines, which may play a role in modifying cellular 
mechanisms to control viral infection and cellular transformation (Sarid et al., 1998).  
Other studies have also utilised genome-wide analyses of KSHV gene expression 
kinetics in PEL cells to identify additional latent genes. For example, Burysek, Yeow 
and Pitha (1999) and Rivas et al. (2001) reported K10.5/LANA-2 and K11.5 (both viral 
homologues of cellular interferon regulatory factors, IRFs), and Glenn et al. (1999)
   40 
reported a third (expressed from K15), that encodes the latency-associated membrane 
protein (LAMP). Viral IE genes have been identified by evaluating their resistance to 
cycloheximide, a protein synthesis inhibitor (for example, Sun et al., 1998; 1999; Zhu et 
al., 1999); and L genes have been recognised by their sensitivity to inhibitors of viral 
DNA replication (Unal et al., 1997, Chandran et al.1998).  
The differentiation of KSHV genes as latent or lytic, IE or L, based on RNA expression 
in PEL cultures, has been confounded by the possibility that small numbers of cells 
may be undergoing spontaneous reactivation at the time of sampling. The results of 
genome-wide studies of gene expression kinetics have been complemented by the 
evaluation of gene expression at the single cell level using in situ hybridisation. For 
example, Staskus et al. (1997) and Nealon et al. (2001) were able to demonstrate 
differences in gene expression for latent (kaposin, K12) and lytic (ORF25/MCP) genes 
in Kaposi sarcoma specimens, which typically display latent gene expression only.    41 
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Figure 2.8 (previous page).  The KSHV genome (from Dourmishev et al., 2003). A linear 
representation of the KSHV genome, showing the position of the ORFs as published by Burysek 
and Pitha, 2001; Lubyova and Pitha, 2000; Moore and Chang 2001; Rivas et al., 2001; 
Rosenkilde et al., 2000, is shown. Each ORF is represented by an arrow pointing in the direction 
in which it is expressed; ORFs are displayed linearly in 2 groups based on leftward or rightward 
direction. Approximate nucleotide positions are indicated in kilobases in the scale at top, as in 
Russo et al., 1996. The expression kinetics of each ORF in PEL models of latency and 
reactivation are indicated by the fill of each arrow, as shown in the figure: latent (Burysek et al., 
1999; Davis et al., 1997; Dittmer et al., 1998; Fakhari and Dittmer, 2002; Glenn et al., 1999; 
Rivas et al., 2001; Sarid et al., 1998; Staskus et al., 1997), IE (Rimessi et al., 2001, Saveliev et 
al., 2002; Sturzl et al., 1997; Sun et al., 1999; Zhu et al., 1999), and lytic <24 h post-induction (h 
p.i.) and >24 h post-induction (Jenner et al., 2001; Paulose-Murphy et al., 2001) are all shown. 
An asterisk above an ORF indicates that at least one transcript encoding the ORF is spliced 
(either removing part of the ORF or introducing additional exons from outside the ORF). ORFs 
with published functions are indicated by bold lettering, and their respective functions are 
shown. CBP, complement binding protein; DHFR, dihydrofolate reductase; TK, thymidine 
kinase; PF, processivity factor; UDG, uracil-DNA glycosylase; RR, ribonucleotide reductase; 
other abbreviations are defined in the text.  
 
More recently, microarray studies (for example, Jenner et al., 2001; Paulose-Murphy et 
al., 2001) have permitted the simultaneous determination of transcription kinetics of 
virtually all KSHV genes. This technology has allowed determination of first appearance 
and peak expression of the genes in PEL cells. Results from these studies have 
demonstrated that gene expression cannot necessarily be related to location within the 
genome or product function (Paulose-Murphy et al., 2001). The expression of candidate 
structural genes, such as ORF8 (gB) and ORF47 (gL), for example, occurs as early as 
12 h p.i., rather than late (24 h p.i.), as would be expected. Certain ORFs, which have 
similar functions (ORFs 25, 43, and 65 which encode capsid proteins, and ORFs 19, 
32, 38, 63, 64 and 74 which encode tegument proteins), display analogous expression 
patterns, even though they lie far apart on the viral genome. Meanwhile, some adjacent 
genes, such as ORFs 40 and 41, which encode subunits of a helicase-primase and are 
encoded by a single transcript, also show similar patterns of expression. By contrast, 
some adjacent genes also show evidence of quite distinct expression patterns. For 
example, ORF 56 (DNA replication protein), ORF 57 (immediate-early protein) and 
ORF K9 (vIRF-1) are located adjacent to one another on the genome but display quite   43 
different expression patterns, with ORF 57 showing an immediate early pattern of 
expression while the ORF 56 and K9 were expressed later (Andreoni et al., 2001).  
The gene expression kinetics of the cellular homologue genes may similarly offer 
insights into the role of these products in viral replication and pathogenesis strategies. 
Consistent with classical descriptions of herpesvirus replication, genes that are involved 
in gene regulation show increased expression earlier than genes involved in DNA 
replication, or the production of tegument or capsid proteins. Thus the expression of 
vIL6 (ORF K2) at the beginning of viral replication suggests an important role in 
optimising the host or host cell for viral replication (Paulose-Murphy et al., 2001). Other 
genes expressed early (10 h p.i.) in the induced lytic viral cycle (ORFs 11, 31, 35 and 
49), have similar expression patterns to those exhibited by early transactivators and 
cytokine homologues.  
As the virus starts to produce structural proteins, products which prepare the cell for 
viral replication or which combat the intrinsic host antiviral mechanisms are 
advantageous to survival. ORF 10, which has peak expression 12 h p.i., was predicted 
to be involved in preparing the cell for viral replication (Paulose-Murphy et al., 2001). 
Because the induction of cellular apoptosis is an important anti-viral defence, the 
simultaneous activation of multiple cellular homologues, for example vBcl2 (Cheng et 
al., 1997), which can prevent programmed-cell death of the infected host cell and 
concurrently alter cell cycle progression (Angeloni et al., 1998) may protect viral 
replication. Other genes expressed at this time include ORFs K7, 18, 23, 24, 27, 28, 30, 
33, 42, 52, 53 and 69 (Paulose-Murphy et al., 2001). 
The expression of ORFs K13 (gene 71 also known vFLIP), 73 (LANA), and 72 (vCyclin) 
increases between 36 and 48 h p.i., at 36 h p.i., and at 48 h p.i., respectively; at these 
time points, many of the virus-encoded cellular homologues have reached their peak   44 
expression level. The products produced by these genes contribute to cellular 
dysfunction, the promotion of viral infection and disease progression. vCyclin has the 
ability to disrupt cell cycle (Aoki and Tosato, 1999). LANA interferes with apoptosis by 
the inhibition of p53 and pRb activities (An et al., 2002; Baillargeon et al., 2001). vFLIP, 
as mentioned previously, has also been associated with the inhibition of apoptosis 
(Birkmann et al., 2001). Additional viral genes, including GPCR (ORF74) (Adams et al., 
1995) and kaposin A (ORF K12), are expressed at the end of the lytic cycle to stimulate 
the transformation of infected cells (Ascoli et al., 2001). 
Although microarray studies have provided a wealth of information on the kinetics of 
gene expression, this approach has some technical limitations (Paulose-Murphy et al., 
2001). As is indicated in Figure 2.8, KSHV contains numerous spliced transcripts, many 
of which are polycistronic (multiply transcribed). This is a relatively uncommon gene 
expression strategy for herpesviruses, which limits the application of this technology for 
the identification and delineation of discrete gene expression profiles of the different 
ORFs coded within the same part of the genome. For example, ORF50 is expressed as 
a polycistronic message, which encodes ORF K8, ORF K8.1 and ORF K8.2 (Belec et 
al., 1998; Blackbourn et al., 2000). ORF50 shows increased expression at 10 h p.i. and 
is regarded as an IE gene involved in the activation of lytic replication (Ariyoshi et al., 
1998; Berenson and Vescio, 1999). Although expression patterns for ORF K8.1 and 
ORF K8.2 were not significantly different to that observed for ORF50 using microarray 
technology (Paulose-Murphy et al., 2001), other studies (Blasiq et al., 1997; Aoki and 
Tosato, 1999) have demonstrated that ORF K8.1 is expressed as a late gene during 
lytic replication of BCBL-1 cells. The possible functions of gene products from ORFs 
K13 (ORF 71), 72 and 73 have been reviewed above. These ORFs have been   45 
identified as co-regulated, 39-coterminal transcripts (Aluigi et al., 1996; Biggar et al., 
2000).  
2.3.7.2 Alphaherpesvirus Human herpesvirus type 1  
The general pattern of HSV gene expression in productively infected cells was first 
described over 20 years ago (for review, see Roizman and Sears, 1996). Since that 
time, layers of complexity have been revealed, but the overall picture has remained 
remarkably the same as was first portrayed.  
Transcription of immediate early genes  
IE genes were originally defined as genes whose expression occurs in the absence of 
de novo protein synthesis, and 5 such genes were identified: the genes encoding ICP4 
(RS1), ICP0 (RL2), ICP27 (UL54), ICP22 (US1), and ICP47 (US12). Although there are 
reports of at least 2 other viral transcripts (UL39 and the transcript encoding ORF P) 
that are expressed to some degree in the presence of cycloheximide (which blocks de 
novo protein synthesis) (Lagunoff and Roizman, 1995), the 5 genes listed above are 
directly regulated by VP16 (discussed below) and are expressed during productive 
infection and are commonly considered to be the true HSV IE genes.  
The most distinctive feature of IE gene regulation is the control of IE gene expression 
by the virion trans-activator protein, VP16 (reviewed by O'Hare, 1993), which is 
encoded by the UL48 gene and forms a complex with cellular proteins. Expression of 
the IE genes is further regulated by various cis-acting regulatory elements (including 
TATA and CAAT), binding sites for the transcription factor SP1 and, in some cases, 
binding sites for ICP4 (Figure 2.9A). Mediation of IE gene activation occurs via a 
common regulatory element (often designated as TAATGARAT for the most well 
conserved portion of the extended consensus sequence involved,   46 
GYATGNTAATGARATTCYTTGNGGG) in the upstream region of each promoter 
(Figure 2.9A).  
 
 
 
 
Figure 2.9. Schematic representation of IE, E, and L HSV promoters (from Weir, 2001). The 
general arrangement and composition of cis-acting regulatory elements for generic IE, E and L 
promoters is shown. The actual number and arrangement of elements varies among promoters 
of each class. (A) In addition to the TATA element, IE promoters have TAATGARAT elements in 
the upstream region through which the viral VP16 protein mediates transcriptional activation. 
Binding sites for eukaryotic transcription factors such as SP1 are also present upstream from 
the TATA element, and in at least some IE promoters, binding sites for ICP4. (B) Early 
promoters have binding sites for eukaryotic transcription factors upstream of the TATA element 
but no identified cis-acting regulatory elements further downstream. (C) Late promoters have an 
initiator element (INR) at the start of transcription, and in at least some late promoters, a 
downstream activation site.   
  
 
The HSV IE genes are activated soon after virus infection by the formation of a multi-
protein complex containing the virion protein VP16 and 2 host cell proteins, HCF (host 
cell factor) and Oct-1. This complex then binds to the TAATGARAT elements present in 
each IE promoter. Transcriptional activation is a function of the highly acidic carboxy 
terminus of VP16 which may target a component of the cellular transcriptional   47 
machinery (for review, see Flint and Shenk, 1997). Oct-1 confers binding specificity and 
is a member of a subclass of homeodomain proteins referred to as POU proteins 
(O'Hare, 1993). HCF binds to the HSV VP16 to promote stable interaction with Oct-1 
(Hughes et al., 1999) and may act as a nuclear import factor for VP16, particularly in 
the early stage of infection (La Boissiere et al., 1999). This interaction between VP16 
and HCF probably mimics and subverts interactions between HCF and other cellular 
protein(s) (Freiman and Herr, 1997) and in this way disrupts the expression of cellular 
genes and progression through the cell cycle (Goto et al., 1997). HSV infection alters 
the distribution of HCF between cytoplasmic and nuclear compartments (La Boissiere 
and O'Hare, 2000) and this may have a role in the switch between latency and 
productive infection (Kristie et al., 1999).  
Four of the 5 IE proteins play critical roles in the regulation of HSV gene expression: 
ICP4 and ICP27 are essential regulatory proteins in all experimental systems (in vitro 
and in vivo); ICP0 and ICP22 are dispensable in some systems, but each would appear 
to play an important regulatory role in viral gene regulation. Elucidation of the 
method(s) by which each of these proteins functions in regulating the cascade of viral 
gene expression is still incomplete.  
ICP4, a protein of approximately 175 kDa, is perhaps the most extensively studied HSV 
protein (reviewed by Roizman and Sears, 1996). This protein is encoded by the RS1 
gene, which is present in 2 copies in the viral genome. Its role in the activation of both 
early and late gene expression was first established by Watson and Clements (1980). 
ICP4 was subsequently demonstrated to repress the expression of some viral genes, 
including its own gene (DeLuca and Schaffer, 1985; O‟Hare and Hayward, 1985). 
Functional domains of ICP4 have been described for transactivation, dimerisation, 
nuclear localisation, repression and DNA binding. Direct binding of ICP4 to specific   48 
DNA binding sites near the start of transcription would appear to be a requisite for ICP4 
to repress the expression of its own mRNA and that of the gene encoding ORF P 
(Michael and Roizman, 1993; Lagunoff and Roizman, 1995). This repression does not 
seem to be a simple steric block to transcription, but involves specific ICP4 interactions 
with the general transcription factors TATA-binding protein (TBP) and TFIIB (Gu et al., 
1995; Kuddus et al., 1995). As for other virus-cell interactions, the mechanism of 
repression is incompletely understood. 
Although multiple ICP4 DNA binding sites have been reported throughout the viral 
genome, their role in ICP4 transactivation is still not clear. Such sites do not appear to 
be necessary for ICP4-mediated transactivation, although the DNA binding domain of 
ICP4 is required. Transactivation may be mediated through ICP4 interaction with the 
TBP-containing general transcription factor TFIID (Gu and DeLuca, 1994) and the TBP-
associated factor (TAF) 250 (Carrozza and DeLuca, 1996). The cellular high mobility 
group factor 1 (HMG1) protein as a cofactor which, by means of its ability to bend DNA, 
may facilitate ICP4 interaction with TFIID (Carrozza and DeLuca, 1998). More recently, 
Grondin and DeLuca (2000) have suggested that ICP4 may promote transcription by 
the recruitment of TFID, which enhances the formation of pre-initiation complexes. 
These studies demonstrated that ICP4 was able to recruit TFIID in the absence of other 
proteins and suggested that the mechanism by which ICP4 activates gene expression 
occurs at the very earliest stages of transcription.  
The phosphoprotein ICP27 is another IE protein that is essential for lytic replication of 
HSV. As for ICP4, multiple functions have been attributed to this 63 kDa protein (for 
review, see Phelan and Clements, 1997). ICP27 has been implicated in the switch from 
early to late gene expression during virus replication, polyadenylation site selection and 
3′ RNA processing, inhibition of mRNA splicing, RNA binding and the transport of viral   49 
mRNA out of the nucleus. Multiple functional domains have been identified to 
correspond to these roles. The extent to which the varied functions ascribed to ICP27 
are interrelated is not yet completely clear. Some post-transcriptional functions, for 
example the inhibition of mRNA splicing (Hardy and Sandri-Goldin, 1994) have been 
clarified. Splicing inhibition would seem to confer an advantage to viral transcripts over 
most cellular transcripts because relatively few viral transcripts expressed during HSV 
infection contain introns. Three of the 4 spliced HSV transcripts are expressed from IE 
genes, before maximal inhibition of splicing takes place, and the fourth spliced viral 
transcript (that of the UL15 gene) is expressed late in infection when splicing may no 
longer be inhibited by ICP27 (or the transcript may be spliced by an alternative 
mechanism not inhibited by ICP27). Recent work has now shown that ICP27 interacts 
with several cellular proteins, including at least one that is known to inhibit splicing 
(Bryant et al., 2000), suggesting a possible mechanism for ICP27-mediated inhibition. A 
second post-transcriptional function of ICP27 is the potential role of this regulatory 
protein in RNA binding (Mears and Rice, 1996; Soliman et al., 1997) and transport 
between the nucleus and the cytoplasm (Phelan and Clements, 1997; Soliman et al., 
1997; Mears and Rice, 1998; Sandri-Goldin, 1998). Taken together, these findings 
suggest that ICP27 functions in a post-transcriptional manner to promote the 
expression of viral mRNA over cellular mRNA by inhibiting mRNA splicing, and by 
selectively increasing the amount of viral mRNAs in the cytoplasm late in infection.  
The possible role of ICP27 in regulating the switch from early to late gene expression 
has not been fully determined. Several studies have shown that ICP27 is necessary for 
normal expression levels of several, but not all, early genes (Samaniego et al., 1995; 
Uprichard and Knipe, 1996). These findings may explain the apparent requirement of 
ICP27 for normal viral DNA synthesis because some of these genes encode proteins   50 
necessary for viral DNA replication. The role of ICP27 in facilitating viral mRNA 
transport may become progressively more important during the course of infection as 
normal host cell functions, such as RNA export, become increasingly compromised.  
The function of ICP22 in viral gene regulation is even less clear than that of either the 
ICP4 or ICP27 proteins. ICP22 is not required for virus replication in many cell culture 
systems. In certain rodent cell lines and primary human cells, however, ICP22 is 
necessary for efficient virus replication and for the expression of both ICP0 and a 
subset of viral late genes (Sears et al., 1985). The carboxy terminus of ICP22 is 
encoded by a second overlapping transcript that has been designated as US1.5 (Carter 
and Roizman, 1996). Deletion of the amino terminal portion of ICP22 (i.e. domains 
unique to ICP22) results in virus that is avirulent in experimental animal systems (Ogle 
and Roizman, 1999). Other domains in the amino terminus have also been identified, 
including a putative nuclear localisation signal and a domain that interacts with cellular 
protein p78. Domains in the carboxy portion of ICP22, common to both ICP22 and 
US1.5, are necessary for optimal expression of a subset of late genes. Virus mutants 
lacking these domains are also avirulent in animal models of infection. The role of 
ICP22/US1.5 is intimately tied to that of the UL13 protein kinase (Purves et al., 1993) 
that, in conjunction with US3 kinase, phosphorylates ICP22/US1.5. HSV mutants lacking 
functional UL13 have similar phenotypes to ICP22 mutants. Other studies have shown 
that ICP22 is responsible for an altered phosphorylation of the large subunit of RNA 
polymerase II (RNA PolII) (Rice et al., 1995; Long et al., 1999), although the functional 
significance of this interaction is not clear. In addition, ICP22 has been reported to 
interact with several cellular proteins, including cell cycle regulated proteins (Bruni and 
Roizman, 1998; Bruni et al., 1999) such as cdc2 protein kinase (cdk1), the activation of 
which in HSV-infected cells is mediated by ICP22/UL13 (Advani et al., 2000a). Specific   51 
inhibition of this cellular kinase results in inhibition of expression of the same set of late 
genes inhibited by the inactivation of ICP22/UL13 (Advani et al., 2000b).  
The exact role of the IE ICP0 protein in regulating viral gene expression has also been 
difficult to establish. Although not absolutely required in tissue culture systems, deletion 
of ICP0 results in growth impairment of cultured HSV at low multiplicities of infection. It 
has also been implicated in the establishment and reactivation of the virus from latency, 
but it has been difficult to separate the role of the protein in these processes from its 
effects on virus growth. ICP0 has long been referred to as a „promiscuous‟ 
transactivator, in reference to its ability, alone or in concert with ICP4, to transactivate a 
variety of unrelated genes. Despite no evidence that ICP0 binds to DNA, either 
specifically or non-specifically, it localises to the nucleus soon after infection, where 
presumably its role in transactivation is manifested. ICP0 is also found in the cytoplasm 
of primary cells within a few hours after infection (Kawaguchi et al., 1997a), suggesting 
that the protein either has multiple roles, or that its role in transactivation is more 
complex than originally thought. Although the mechanism(s) by which ICP0 might 
function within the infected cell are not fully elucidated, interactions have been 
characterised with multiple cellular proteins, including translation elongation factor EF-
1  (Kawaguchi et al., 1997a), cyclin D3 (Kawaguchi et al., 1997b), the transcription 
factor BMAL1 (Kawaguchi et al., 2001) and a cellular ubiquitin-specific protease 
(Everett et al. 1999b). ICP0 localises in the nucleus and disrupts pre-existing nuclear 
sub-structures known as Nuclear Domain 10 (ND10) early in infection, suggesting that 
the degradation of specific cellular targets is an integral component of the mechanism 
by which ICP0 activates viral gene expression during productive infection (Parkinson et 
al., 1999; Everett, 2000a; 2000b). It has been proposed that ICP0 and proteasome-
mediated proteolysis in HSV infection target a cellular repressor of the viral lytic   52 
pathway. Thus, viruses deficient in ICP0 can therefore replicate only when there are a 
large number of input viral genomes. Further, in certain cells such as neurons, in which 
ICP0 expression is deficient (Chen et al., 2000), latency would be more likely than 
productive infection (Everett, 1999a).  Based on the results of Chen et al. (2000), it has 
been suggested that the lack of ICP0 accumulation may preclude the normal cascade 
of viral gene expression necessary for lytic infection and thus favour the establishment 
of latency. Alternatively, rather than specifically repressing HSV replication, a 
combination of positive and negative factors may combine to redirect critical cellular 
functions to the incoming extrachromosomal viral genome. For example, IE viral gene 
expression may be enhanced by VP16, followed by ICP4-induced activation of viral 
genes. These positively-acting mechanisms may be complemented by ICP0-mediated 
degradation of specific cellular proteins, allowing other critical cellular components to 
be re-directed to the HSV template.  
Transcription of early genes 
The HSV early gene encoding thymidine kinase (UL23) was one of the first viral genes 
to be studied in detail. Gene expression requires a TATA element, 2 binding sites for 
the transcription factor SP1, and a CAAT element (Coen et al., 1986; Figure 2.9B). 
However, despite having all cis-acting regulatory elements required for expression, the 
gene is not expressed when present in the viral genome until HSV IE proteins are 
synthesised and gene expression is turned off within a few hours of infection while 
other viral genes (late genes) are apparently being transcribed by the same host cell 
transcriptional apparatus. It has become clear that ICP4 is necessary for expression of 
the thymidine kinase gene in the viral genome and that this transactivation is mediated 
through the TATA element of the thymidine kinase promoter (Imbalzano et al., 1991).    53 
Other early genes have only more recently undergone similar analysis. Detailed study 
of the UL37 and UL50 early promoters has revealed that individual HSV early promoters 
contain a variety of cis-acting regulatory elements commonly found in eukaryotic genes 
transcribed by RNA PolII (Pande et al., 1998). Although the composition and 
arrangement of these elements differ considerably among HSV early promoters, like 
results obtained from the thymidine kinase gene, all are found upstream from an 
essential TATA element. Further, there is no evidence to date of cis-acting regulatory 
elements that directly interact with virus-specific transcription factors.  
Transcription of late genes 
The synthesis of viral DNA heralds a major switch in the program of HSV gene 
expression (for review, see Wagner et al., 1995). Concurrently with DNA replication, 
viral late gene expression increases whilst early gene expression begins to wane. 
Inhibition of viral DNA replication also inhibits late gene expression and prolongs the 
expression of early genes, demonstrating that these processes are intimately linked. 
Integration of DNA replication and late gene expression increases the efficiency of viral 
replication because the majority of late genes encode structural proteins. 
Detailed analyses of the composition of late promoters have been undertaken to 
identify differences between HSV L genes and E genes. Like IE and E promoters, L 
promoters require a TATA element (Figure 2.9C), and there is no apparent difference 
between late promoter TATA elements and other viral or eukaryotic TATA elements to 
account for differences in temporal expression (Steffy and Weir, 1991; Imbalzano and 
DeLuca, 1992). As was the case for E genes, ICP4 is necessary for the activation of L 
gene expression, again mediated through the TATA element. Unlike IE and E 
promoters, however, true L promoters do not possess cis-acting regulatory elements 
upstream from the TATA element. Other elements downstream from the TATA element   54 
are necessary for maximal expression (Homa et al., 1986; Mavromara-Nazos and 
Roizman, 1989; Kibler et al., 1991; Steffy and Weir, 1991; Guzowski and Wagner, 
1993; Guzowski et al., 1994; Petroski and Wagner, 1998; Woerner and Weir, 1998). As 
was observed for E promoters, all of the regulatory elements identified to date as 
necessary for efficient L promoter activity are common eukaryotic regulatory elements. 
Variation in the arrangement and composition of these regulatory elements is the key 
feature distinguishing E and L promoters. Temporal control of viral gene expression 
may therefore be achieved when the transcription complex recognises the distinctive 
arrangement of L promoter elements (for review, see Wagner et al., 1995). However, 
transcription complexes are hypothetical and have neither been characterised nor their 
method(s) of action determined.  
Transcription of true HSV L ( 2) genes requires DNA replication for any appreciable 
accumulation of their mRNAs. Some late genes, however, are expressed to a degree in 
the absence of DNA replication but require DNA synthesis for maximal expression. 
These genes are often referred to as leaky-late or  1 genes. Analysis of the regulatory 
regions of these viral promoters suggests that they possess regulatory features of both 
E and L promoters. For example, such promoters typically contain various cis-acting 
regulatory sequences upstream of the TATA element similar to E promoters, as well as 
an initiator element at the start of transcription similar to that of strict L genes (Huang 
and Wagner, 1994; Lieu and Wagner, 2000a, b). It has been suggested that  1 
regulation of a particular viral gene signifies that the encoded protein is required prior to 
viral DNA replication as well as late in infection. However, at least in the cell culture 
models examined, the expression of the  1 VP5 gene as either an E or a strict L gene 
had little effect on viral replication (Lieu and Wagner, 2000ab).    55 
Although the structure of L promoters has been defined, the link between L gene 
expression and DNA replication, and the mechanism of L gene activation, have not 
been determined. The observed structural differences between E and L promoters, 
discussed above, suggest that the transcriptional machinery of the cell distinguishes E 
from L genes during the course of infection. But this does not explain how 
transcriptional activation is linked to DNA replication. Despite the inherent difficulty of 
studying transcriptional activation and DNA replication individually when the 2 
processes are intimately linked, some factors necessary for efficient L gene expression 
have been identified. As noted above, inhibition of ICP22/UL13-mediated activation of 
cellular cdc2 results in the inhibition of expression of the same set of late genes 
inhibited directly by the inactivation of ICP22/UL13 (Advani et al., 2000b), although the 
mechanism by which this regulation occurs has not been determined. It is also 
unknown how this subclass of HSV L genes differs from other L genes, such as that 
encoding gC (UL44), and why their expression should be regulated differently.  
As mentioned previously, functional ICP27 is also required for L gene expression, and 
its effects on L gene expression may be manifested in multiple ways. ICP4 is necessary 
for activation of L genes as well as for E gene transcription. However, the presence of 
ICP4 is not sufficient for L gene expression because L genes are silent before DNA 
replication, even though ICP4 is present to activate E genes. As already noted, in vitro 
studies using the L gC promoter as a template have identified specific ICP4 interactions 
with HMG1 (Carrozza and DeLuca, 1998) and the cellular transcription factor TAF250 
(Carrozza and DeLuca, 1996), but it is not yet known whether these interactions are 
specific for L gene expression.  
It has also been reported that the DNA binding protein ICP8 is required for L gene 
expression, but this has been difficult to evaluate independently of its role in DNA   56 
replication. However, certain mutants of ICP8 inhibit L gene expression to a far greater 
extent than they inhibit viral DNA replication, suggesting a more direct role in L gene 
expression (Chen and Knipe, 1996; McNamee et al., 2000), or that the rate of L gene 
expression may be dependent on the rate of viral DNA replication as opposed to the 
absolute amount of DNA that has been synthesised at any one time point. Alternatively, 
viral protein(s) may have a dual role in DNA replication and L gene activation, similar to 
the situation described in the replication of phage T4, where proteins required for DNA 
replication are also required for transcription of phage L genes (Herendeen et al., 1989, 
1992; Tinker et al., 1994). Such a model cannot be extrapolated to the HSV system 
because of the inability to isolate HSV mutants which are capable of normal DNA 
replication but which do not exhibit L gene activation.  
Upon infection, input viral DNA localises to pre-existing nuclear ND10 sub-structures 
(Maul et al., 1996). As noted previously, these structures are subsequently degraded by 
ICP0 and proteasome-mediated proteolysis. Several studies have reported the 
formation of pre-replicative sites adjacent to the original ND10 sites (Uprichard and 
Knipe, 1997; Burkham et al., 1998), and the eventual formation of replication 
compartments throughout the nucleus (de Bruyn Kops and Knipe, 1988). Other studies 
have shown that, late in infection, sites of transcription and replication overlap (Phelan 
et al., 1997) and that the viral regulatory proteins ICP4 and ICP22 co-localise with RNA 
PolII and viral DNA replication proteins (Rice et al., 1995; Leopardi et al., 1997). More 
recent studies have identified 2 types of replication compartments in cells expressing a 
dominant-negative form of ICP8 (McNamee et al., 2000). In cells in which large 
replication compartments form, both DNA replication and L viral gene expression could 
be observed. Conversely, L gene expression was not observed in cells containing only 
small replication compartments suggesting that L gene expression and DNA replication   57 
are linked and that there may be a spatial control element to the temporal regulation of 
viral gene expression. 
Transcription of latency-associated genes  
The LATs represent a group of RNA molecules transcribed from the transition area 
between the UL segment and the repetitive sequence flanking that region. The major 2 
kb LAT is oriented antisense to ICP0 transcripts and its 3‟-terminus is located near to 
the PstI restriction site (at nt 118,659) of the BamHI B fragment, overlapping the OICP0 
ORF by 800 bp (Nsiah and Rapp, 1991; Ho, 1992). It is non-polyadenylated and 
uncapped and does not function as mRNA. During splicing of this major 2 kb LAT, a 
559 bp (in case of strain F) or a 556 bp (in case of strain 17) intron is removed to obtain 
a 1.5 kb, and possibly also a 1.45 kb, LAT species, although the latter 1.45/1.4 LAT is 
probably an artefact (Spivack et al., 1991). The splicing signal at the LAT 50-terminus 
consists of a G/C (not G/U) motif.  
The 2 kb LAT is present mainly in the ganglia of mice in which latent HSV infection has 
been established (Croen et al., 1987; Rock et al., 1987; Stevens et al., 1987). In 
nonpermissive cells, the viral VP16/a-TIF, which complexes with the cellular Oct-1 
transcription factor, may be prevented from binding to IE gene promoters, such as ICP0 
and ICP4, such that a productive replication cycle is not initiated (Latchman, 1999). 
Mutants lacking the ICP4 and VP16 genes support the idea that latency is established 
in the absence of viral replication. The presence of the 2 kb LAT, along with a minor 
species of spliced LAT (1.5 kb), is the hallmark of non-productive latency.  
In addition to the 2/1.5 kb LAT species, a minor 8.5 kb LAT population (mLAT) 
accumulates during latency, which may also be polyadenylated. The mLAT spans from 
just downstream of the LAP1 promoter, over the entire length of the long repeat ending 
at a poly-A signal within the beginning of the short repeat region (Devi-Rao et al.,   58 
1991). This RNA sequence is transcribed from the same DNA strand as the 2/1.5 kb 
LAT during lytic infection and possibly also during latency, and may represent the 
primary LAT, the more readily detected 2-kb LAT being a stable intron processed from 
the larger, highly unstable poly(A)+ mRNA (Goins et al., 1994). Although the 6- to 7- kb 
spliced product of this reaction has not been observed, experimental splicing at this site 
has resulted in transient gene expression in transfection assays (Farrell et al., 1991). 
Although the 30-end of the mLAT has not been precisely defined, it was reported to 
partially overlap the opposite ICP4/RS1 sequence (Chen et al., 1997). Since ICP4 
transcripts are minimally expressed during latency (Rezuchova et al., 2003), it is 
possible that mLAT expression down regulates ICP4 expression.  
Lytic HSV replication may be associated with the production of an alternative 2 kb LAT 
species which contains a poly-A tract (Devi-Rao et al., 1991). This species extends 
from the LAT cap site to a position near the 3‟-end of ICP0 mRNA. It is not clear 
whether its contiguous 3‟-end communicates with the minor 8.5kb LAT poly-adenylation 
signal located about 7 kb via a splice, or whether the poly-adenylation occurs at a 
distinct non-canonical termination/poly-adenylation signal (Wagner and Bloom, 1997). 
Critical cis elements required for accumulation of the 2kb-LAT accumulated during 
latent infection have been mapped to a LAP1 (Chen et al., 1995), an RNA polymerase 
II promoter located approximately 700 bp upstream of the 5‟ end of the 2 kb LAT 
(Wechsler et al., 1988). LAP1 has a TATA box, a SP1 binding site, an AP2 (activatory 
protein 2) binding site, a CREB (cAMP responsive element binding) site, a LPBF (LAT 
promoter binding factor) interacting site, a motif for bring the upstream stimulatory 
factor (USF) and the major late transcription factor (MLTF). Finally, it has an Oct-1/POU 
homeodomain binding site, and regulatory sites for the early growth response (EGR) 
element and for the long term transcription element (LTE) (Zwaagstra et al., 1989;   59 
1990; Soares et al., 1996). These additional transcription-regulating co-factors may 
allow the continuous expression of LAT during latency in neurons with highly specific 
and restricted transcription.  
It has been suggested that the LAT identified during lytic infection is promoted by an 
alternative promoter (Latency Associated Promoter 2, LAP2), located between LAP1 
and the LAT 5‟-end transcription initiation site, which governs the LAT/PolyA+ 
transcription occurring during productive HSV replication (Goins et al., 1994; Chen et 
al., 1995). LAP2 has GC-rich as well as GT-rich sequences, 2 SP1 sites (nt 474 to nt 
464 and nt 336 to nt 326), an AP2 site and a site for the adenovirus E2 protein (factor) 
binding. In addition to an ICP4 binding motif, there is an ICP0 binding site which is 
involved in feedback down regulation of LAT expression at the onset of lytic replication. 
At least 3 ORFs can be identified in the LAT of HSV.  Analogous transcripts have been 
identified in other  -herpesviruses, including Pseudorabies virus and the Bovine 
herpesvirus 1. Although extensively studied, the role of LAT in induction, maintenance 
of, or reactivation from, latency has not been fully elucidated (Preston, 2000; Milhaus 
and Wigdahl, 2000; Rajcani and Durmanova, 2000; Kent et al., 2003). Spivack and 
Fraser (1988) suggested that LATs function as anti-sense regulators of ICP0 
transcription. Subsequent studies have demonstrated that stable LAT inhibit ICP0 
expression via a direct suppressive effect and not via the ICP0 promoter (Chen et al., 
1997; Garber et al., 1997). Further, the expression of LAT also reduces transcription of 
the IE genes ICP4 and ICP27 (Mador et al., 1998). Because latently infected ganglia 
may express low levels ICP4, the appearance and/or up regulation of ICP0 mRNA 
production represents the most reliable indicator for the onset of lytic replication 
(Rezuchova et al., 2003). The synthesis of small amounts of ICP4 polypeptide, in the 
absence of ICP0 production, may not permit effective transactivation of β and γ-  60 
proteins. The expression of ORF1/LAT (Thomas et al., 1999) and/or ORF2/LAT (Perng 
et al., 1996b) may also enhance the transactivation of lytic proteins.  
Thus, according to Rajčáni, et al. (2004), the transition from non-productive latency to 
lytic replication, may be influenced by:  
i.  an anti-sense transcription repressor mechanism (2 kb LAT versus ICP0 mRNA 
expression; mLAT versus ICP4 mRNA expression);  
ii.  down regulation of ICP4 expression by means of the ORF O and P products, which 
are completely repressed during productive virus infection; 
iii.  an activation mechanism which, in the absence of viral VP16, maybe the protein(s) 
encoded by the ORFs in the LAT.  
 
2.4 Pathogenesis of equine herpesvirus infections  
2.4.1 Transmission of equine herpesviruses 
Both equine alphaherpesviruses, EHV1 and EHV4, are enzootic in most domestic 
horse populations, although their relative importance as contributors to respiratory 
disease fluctuates over time and is variable amongst different groups of horses (Allen, 
2002). Gilkerson et al. (1994, 1999b) have reported that by 2 years of age most horses 
have seroconverted to EHV4, but the seroprevalence for EHV1 is less. The 
transmission of EHV is horizontal, from mare to foal and from foal to foal (Murray et al., 
1996; Gilkerson et al. 1999b). Sero-epidemiological studies and DNA isolation from 
samples collected on large Thoroughbred stud farms in the Hunter Valley of NSW have 
demonstrated serological evidence of EHV1 infection in foals as young as 30 days of 
age and DNA in nasal swabs from foals as young as 11 days (Gilkerson et al., 1998a; 
1999a; Foote et al., 2004). On the basis of these studies, this group suggested that 
foals were infected with EHV1 from their dams or from other lactating mares in the   61 
group, with subsequent foal-to-foal spread of infection prior to weaning. Their data 
indicated that the mare and foal population was a reservoir of EHV1, from which new 
cases of infection propagated through the foal population both before and after 
weaning. In most cases, transmission of EHV1 results in inapparent respiratory tract 
infection or very mild clinical signs in affected horses. In this way. a cycle of 
transmission develops in which the infection of susceptible animals and the subsequent 
establishment of latency in newly infected animals is initiated. Subsequent 
recrudescence of latent virus will then begin a new cycle of transmission. Allen (2002) 
has suggested that a similar cycle of infection has been established for EHV4, although 
the detailed epidemiological studies conducted for EHV1 have not been replicated. 
Thus infection with EHV1 and EHV4 is typically widespread, possibly ubiquitous, with 
intermittent outbreaks epizootics of disease amongst susceptible populations, typically 
associated with the admix of horses, as occurs at yearling sales and racetracks.  
Following intranasal infection of mice with EHV1, virus is detectable in nasal epithelial 
and sub-epithelial cells of the respiratory mucosa (Bartels et al., 1998). These studies 
demonstrated rapid transmission of EHV1 to the brain, both via the olfactory route and 
the trigeminal nerve, but degenerative or inflammatory changes were not evident in the 
brain. Antigen-specific immune cells were never detected in the respiratory mucosa and 
immune cells residing or invading the pulmonary parenchyma did not contain viral DNA 
or proteins. The primary immune response in the lungs was alveolar and interstitial 
inflammation, dominated by the sequential appearance of neutrophils and 
macrophages. In contrast to the non-specific response to primary infection, re-infection 
was characterised by rapid perivascular accumulation and parenchymal infiltration of 
lymphocytes (predominantly CD8+ cells).    62 
As for EHV1, transmission of EHV4 is believed to be via inhalation of aerosolised virus 
particles. The incubation period is typically 1-2 days, although may be longer (Walker et 
al., 1999), and infection can spread rapidly through a group of animals. Virus is easily 
spread by inhalation of saliva or nasal discharge, fomites or contaminated water (Allen 
and Bryans, 1986).  
Murray et al. (1996) reported that EHV2 could be isolated from PBMC and tracheal 
wash samples of all but one foal in their study population (n=69) by age 45 days. In this 
study, EHV2 was isolated from foals as young as 25 days of age, suggesting that, like 
the alphaherpesviruses, transmission from mare to foal was an important source of 
primary infection. The results of early studies on the transmission of „EVH2‟ are difficult 
to interpret because discrimination of EHV5 from EHV2 has only been possible since 
1987 (Browning and Studdert, 1987a; Telford et al., 1993). Serological differentiation of 
the 2 viruses has to date not been reported. Serological and/or virological studies on 
the incidence of EHV2 and/or EHV5 infections suggest that exposure to and persistent 
infection of horses by gamma herpesviruses approaches 100% in horse populations 
world-wide (Kemeny and Pearson, 1970; Turner and Studdert, 1970; Bagust et al., 
1972; Harden et al., 1974; McGuire et al., 1974; Rose et al., 1974; Roeder and Scott, 
1975; Schlocker et al., 1995; Dunowska et al., 1999, 2002a, 2002b; Wang, 2003; Craig 
et al., 2005), although their possible contribution to respiratory or other disease has not 
been clarified.  
2.4.2 Pathogenesis of equine gammaherpesviruses 
The prevalence of EHV2 infection is high in horse populations, and it has been 
detected in both horses with respiratory disease (Palfi et al., 1978; Murray et al., 1996; 
Borchers et al., 1997a; Dunowska et al., 2002a, b) and horses without respiratory 
disease (Kemeny and Pearson, 1970; Roeder and Scott, 1975; Borchers et al., 1997a;   63 
Dunowska et al., 2002a, b). EHV2 was isolated from more than 75% horses by 
Edington et al. (1994) and 90% of horses by Kemeny and Pearson (1970). Borchers 
et al. (1997a) have reported a high prevalence of EHV2 among horses with upper 
respiratory tract disease, abortion and severe ataxia, but this result was not compared 
with an age-matched population of normal horses.  
Although diverse clinical syndromes have been associated with EHV2, clinical signs of 
disease are typically those of low grade respiratory tract infection (Blakeslee et al., 
1975, Gleeson and Studdert, 1977; Borchers et al., 1997a; Collinson et al., 1994; 
Borchers et al., 1998). EHV2 has been temporarily or circumstantially associated with 
chronic pulmonary disease (Schlocker et al., 1995), pharyngitis with or without 
conjunctivitis (Blakeslee et al., 1975; Palfi et al., 1978; Browning and Studdert, 1987a; 
Collinson et al., 1994; Agius and Studdert, 1994; Fu et al., 1986; Borchers et al., 1998), 
immunosuppression and general malaise (Agius and Studdert, 1994), poor 
performance (Browning et al., 1988; Agius and Studdert, 1994) and inappetance, 
lymphadenopathy of the head and neck and fever (Dunowska et al., 2000). 
Experimental infection with EHV2 has failed to provide convincing evidence of 
respiratory disease (Blakeslee et al., 1975; Palfi et al., 1978; Browning and Studdert, 
1987a; Wang 2003).  
It is possible that EHV2 might have an indirect effect in producing disease. Burrell et al. 
(1996) and Nordengrahn et al. (1996) have suggested that subclinical EHV2 infection 
may predispose to secondary bacterial disease and loss of performance. Nordengrahn 
et al. (1996) demonstrated that vaccination against EHV2 infection effectively reduced 
the incidence of disease due to Rhodococcus equi. It has also been suggested that 
EHV2 could play a role in the transactivation and possibly reactivation of latent EHV1 
and EHV4 (Drummer et al., 1996; Dunowska et al., 1999). Murray et al. (1996)   64 
suggested that these effects may be mediated by EHV2-induced impairment of the 
immune function of latently infected cells. Evidence of immunosuppression after both in 
vitro and in vivo infection with EHV2 was reported by Fu et al. (1986). Dunowska et al. 
(2001) demonstrated that EHV2 infection may down-regulate monocyte chemo-
attractant protein 1 gene transcription in equine peripheral blood mononuclear cells, 
suggesting that EHV2 is able to modify the chemokine environment of infected cells. 
Genes encoding G-protein-coupled receptors (GPCR) (Camarda et al., 1999) and 
human immunosuppressive cytokine IL-10 (Rhode et al., 1993) have been identified in 
EHV2, suggesting that EHV2 may be able to modulate the immune response and 
predispose horses towards secondary viral or bacterial infections (Burrell et al., 1996; 
Drummer et al., 1996; Dunowska et al., 2000). 
However, as these viruses are frequently isolated from disease-free horses, their exact 
role in causing or predisposing to respiratory disease remains to be elucidated. Further 
investigation is needed to determine their importance as primary pathogens, co-factors 
in mixed infections or possible contribution to poor performance. 
2.4.3 Pathogenesis of equine alphaherpesvirus infections  
In contrast to the gammaherpesviruses, there is irrefutable evidence that the 2 equine 
alphaherpesviruses (EHV1 and EHV4) are pathogens associated with respiratory 
disease, abortion, perinatal mortality, and myeloencephalitis in horse populations (Allen 
and Bryans, 1986). Both viruses are endemic world-wide, with a high incidence of 
infection in susceptible populations.  
Rhinopneumonitis  
Herpesvirus rhinopneumonitis may be caused by EHV1 or EHV4, but EHV4 has been 
suggested as the more common cause of clinical disease in young horses (Allen 2002).   65 
EHV4-associated respiratory disease in younger animals is characterised initially by 
fever, anorexia and profuse serous nasal discharge which later becomes mucopurulent. 
Virus may reach the lungs and cause or contribute to the development of 
bronchopneumonia. For both viruses, the severity of clinical signs can vary from 
subclinical disease to fatal bronchopneumonia (Crabb and Studdert, 1995; del Piero et 
al., 2000). Typically, EHV1 does not appear to produce severe respiratory disease 
(Matsumura et al., 1992) and in many instances, infection may go unnoticed unless the 
horses are under close supervision (Burrell et al., 1996). The severity of disease may 
relate to the dose of infectious virus (Crabb and Studdert, 1995) or to host immune 
factors. Experimental manipulation of the genome (Matsumura et al., 1996; 1998; 
Marshall et al., 1997; Neubauer et al., 1997) and presumably natural strain variation 
(Sun et al., 1996) may also influence pathogenicity in equine and murine models of 
EHV1 infection. 
Clinical signs following natural infection are variable and have not been described with 
certainty (Walker et al., 1999). Intranasal inoculation of specific-pathogen-free 3-4 
month-old foals with EHV1 induced mild clinical disease characterised by depression, 
fever, inappetance and intermittent coughing (Chong and Duffus 1992). Clinical 
recovery in these foals was evident 7 days after the onset of clinical signs and high 
titres of virus were detected in nasal mucus for at least 10 days after inoculation. 
Gibson et al. (1992a, b) demonstrated that viral antigen persisted 3-9 days p.i., 
particularly in nasopharyngeal samples and associated with cellular debris. Infectious 
virus has been isolated from nasal epithelium, nasal turbinates, pharynx, trachea, 
bronchi, bronchioles, lung, cerebrum, thyroid, uterus, conjunctiva, submandibular and 
inguinal lymph nodes, kidney, the endothelium of the epididymis and testis, semen and 
the pregnant uterus (reviewed by Walker et al., 1999). Similar clinical signs have also   66 
been reported by Gibson et al. (1992a, b) in specific-pathogen-free foals inoculated 
intranasally with EHV1 and by Sutton et al. (1998) in EHV1-seronegative pony foals. In 
these studies, affected foals typically demonstrated a febrile response, nasal discharge, 
enlarged submandibular lymph nodes and sporadic coughing, with hyperaemia of the 
large airways evident by bronchoscopic examination (Sutton et al. 1998). Pyrexia 
typically peaks 2 days p.i., although a diphasic response has been documented with a 
second peak 6 days p.i. (Gibson et al., 1992c), which may coincide with the onset of 
viraemia (Allen and Bryans, 1986). Clinical signs usually resolve within 12 days p.i. 
(Gibson et al., 1992a, b) and are usually most pronounced 4-5 days p.i. (Allen and 
Bryans 1986; McCulloch et al., 1993). Clinical signs of respiratory disease have not 
been elicited following experimental infection with EHV4, but field outbreaks of EHV4 
were associated with clinical signs similar to those described above (Pusterla et al., 
2005). 
Abortion 
EHV1 is recognised as the most common cause of virus-induced abortion in pregnant 
mares (Allen and Bryans, 1986; Wolff et al., 1986). By contrast, EHV4 has been 
infrequently isolated from aborted foetuses (Allen and Bryans, 1986; Crabb and 
Studdert, 1995). Abortion is considered a sequel to respiratory infection, but respiratory 
infection of the mare is typically asymptomatic (Allen 2002). Abortion occurs without 
premonitory signs, most commonly in the last 4 months of pregnancy (Crabb and 
Studdert, 1995). Other than the abortion event, mares are clinically normal and there 
are usually no complications for the mare. DNA in-situ hybridisation on uterine tissue 
collected from mares at around the time of abortion has demonstrated viral DNA in 
endothelial cells of endometrial arterioles, as well as in cellular debris within 
endometrial glands and diffusing across the placenta at sites of microcotyledonary   67 
infarction (Smith and Borchers, 2001). Infectious virus can be isolated from foetal lung, 
liver, spleen, thymus and adrenals of aborted foals (Bryans et al., 1977; Dixon et al., 
1978; Whitwell and Blunden, 1992) and there is extensive histopathological evidence of 
multiple organ failure. Necrotising bronchiolitis, interstitial pneumonitis, focal hepatic 
necrosis and necrosis of the germinal centres in all lymphocytic tissues are the most 
consistent histological findings in aborted foetuses (Hartley and Dixon, 1979). Abortion 
may also occur secondary to widespread vasculitis, thrombosis, and secondary 
ischemic damage to the endometrium associated with EHV1 replication within 
endothelial cells and the associated immunological response, in which case virus 
cannot be isolated from foetal tissues (Crabb and Studdert 1995). Foetuses aborted 
close to term may survive for a variable time period before succumbing to interstitial 
pneumonia and viral damage to the liver, lymphoreticular system and adrenal glands, 
as well as complications by secondary bacterial infection (Crabb and Studdert, 1995; 
Murray et al., 1998). 
Myeloencephalitis 
Myleoencephalitis has been associated with EHV1 and, while it is usually associated 
with outbreaks of abortion and/or respiratory disease, this is not invariably the case. It 
has long been suggested that myeloencephalitis is only associated with certain strains 
of EHV1 (Crabb and Studdert, 1995). Evidence to support this theory has recently been 
provided by Nugent et al. (2006) who demonstrated that a point mutation involving a 
single amino acid of the DNA polymerase is strongly associated with neuropathogenic 
isolates. Vasculitis with secondary hypoxic degeneration in adjacent neural tissue is the 
prominent histopathological lesion in natural and experimental cases of EHV-1 myelitis 
(reviewed by Crabb and Studdert, 1995). Vascular changes are generally more   68 
prominent in the spinal cord than the brain and white matter lesions are more prominent 
than grey matter lesions (Jackson and Kendrick 1971).  
EHV1 myeloencephalopathy (EHM) is typically associated with an acute onset of hind 
limb ataxia, paresis or paralysis, but the forelimbs and cranial nerves may also be 
affected. Clinical signs are rapid in onset and the consequence of both direct EHV-1 
infection and vascular changes in central nervous tissues (Jackson et al., 1977; Allen 
and Bryans, 1986). Horses that become recumbent have a poor prognosis for survival 
(Donaldson and Sweeney, 1997). Other horses have a better prognosis, although 
recovery may be slow and incomplete (Kohn and Fenner, 1987). Equine herpesvirus 
myelitis is most common in pregnant, lactating or recently foaled mares (Thorsen and 
Little, 1975; Donaldson and Sweeney, 1997), although it may affect animals of any age 
or gender. The incubation period is typically 4-7 days but may extend up to 2 weeks.  
2.5 Immune response to equine herpesviruses 
The immune response to EHV is complex and involves cell-mediated, humoral and 
specific mucosal immunity. Antibodies are responsible for neutralising extracellular 
virus and contributing to inhibition of virus infectivity and replication (Murray et al., 
1996). Cytotoxic T-lymphocytes (CTLs) are important for protection from primary 
infection and reactivation of latent EHV-1 infection (Kydd et al., 2006; Soboll et al., 
2006). Immunity to reinfection by equine herpesviruses following natural infection of the 
respiratory tract is of short duration. Doll (1961) demonstrated that the respiratory 
mucosa may be asymptomatically reinfected within 3-4 months, despite the persistence 
of virus neutralising antibody. A similar pattern was demonstrated during in vitro studies 
in which the T cell response of lymphocytes taken from spleen of the mice induced with 
EHV1 was also of short duration (2 months) (Alber et al., 1995).    69 
In EHV1-infected specific-pathogen-free horses, an ELISA was used successfully to 
detect antibody in serum from 6 days p.i. (Chong and Duffus, 1992). In this study, EHV 
antibody, identified as belonging to the IgM class by the double sandwich ELISA, was 
detected from 6 days p.i. and peak IgM titres were observed 10 and 18 days p.i., 
declining to base levels by 42 days p.i.  Virus neutralising antibody was detectable in 
serum from 14 days p.i. and rises in titre were parallel to that of total ELISA antibody. 
Cellular immunity was also examined and was significantly decreased between 3 and 
10 days after inoculation. Neutralising antibodies may be produced against a number of 
EHV1 epitopes, including glycoprotein gp14, the homologue of gB of HSV (Osterrieder 
et al., 1994ba; Munro et al., 1999). Vaccination with modified-live EHV1 stimulated a 
cellular and antibody response that cross-reacted with EHV4 (Ellis et al., 1995).  
Alber et al. (1995) have demonstrated that mice injected with EHV1 mount a T cell 
response as early as 3 days p.i., maximal proliferation occurring when the primary 
infection was established. In an in vitro study, they demonstrated that the T cell 
response is mediated by both CD4
+ and CD8
+ cells. This cellular response was 
detected both during the acute phase of infection and after challenge with a second 
dose of EHV1 at 2 months in splenic lymphocyte populations (Fitzpatrick and Studdert, 
1984; Alber et al., 1995). Results gained from a mouse model indicate that important 
interactions occur at the level of T-cell immunity between EHV1 and EHV4 which 
warrant further investigation in the natural host (Azmi and Field, 1993). Foals of 
approximately 3 weeks of age are able to mount a cell-mediated immune response 
(Frymus 1980), detected by leucocyte migration inhibition assay, despite a poor 
antibody response to live virus associated with persistent maternally-derived 
antibodies. There is evidence to suggest that cell-mediated immune responses may be 
important in vaccine response. Vaccination of young horses induced a cytotoxic cellular   70 
immune response, despite the persistence of maternal antibodies (Ellis et al., 1997) 
and, in other studies using the same vaccine preparation, appeared to afford partial 
protection against febrile respiratory disease, virus shedding and viraemia due to EHV-
1 infection (Patel, Didlick and Bateman, 2004).  
Chemokines are likely to play a role in the regulation of immune functions in equine 
hosts during EHV infection and may affect viral replication and/or escape from immune 
responses (Camarda et al., 1999). Coombs et al. (2006) reported that protection 
against EHV-1 challenge infection was characterised by increased γ-interferon 
production and enhanced EHV-1-specific lymphoproliferative responses in previously 
exposed ponies compared to naïve animals.  
2.6 Laboratory diagnosis of equine herpesvirus infection 
2.6.1 Cell culture  
Isolation of virus using routine virus culture methods has been regarded as the “gold” 
standard to which newer diagnostic methods are compared. Although time consuming, 
they are still used to identify new types of virus and to detect latent virus infection 
(Welch et al., 1992; Edington et al., 1994; Franchini et al., 1997). 
EHV1 is capable of replicating in equine, mouse, monkey, rabbit, hamster and bovine 
cells (Allen and Bryans, 1986; Crandell et al., 1988). EHV4 has a more restricted 
cellular tropism. Although not differentiated until 1981 (Sabine et al. 1981; Studdert et 
al. 1981), the 2 viruses can be distinguished by culturing virus on primary equine cells 
and then transferring the isolated virus to RK13 cells, within which EHV-4 is unable to 
grow (Crabb and Studdert, 1995). Plaques produced in equine foetal kidney cells are 
typically larger for EHV4 (Studdert and Blackney, 1979). The alphaherpesviruses EHV1 
and EHV4 produce a cytopathic effect (CPE) characterised by rounding and clumping   71 
of cells, detachment of cells, and multinucleated syncytial cells within 24 to 48 h p.i 
(Crabb and Studdert, 1995).  
The gammaherpesviruses EHV2 and EHV5 are slow-growing and culture is restricted 
to equine cells, although some isolates can replicate in bovine, monkey and hamster 
cells (reviewed by Agius and Studdert, 1994). A CPE may not be evident until at least 
3-5 days p.i.  Primary isolates usually require 10-14 days of incubation and sometimes 
several blind passages before CPE is evident (Agius and Studdert, 1994).  
2.6.2 Immunological detection of virus antigen and antibody 
Virus neutralisation test 
The virus neutralisation test is based on the detection of neutralising antibody, antibody 
able to neutralise the infectivity of virus. The test is usually unable to clearly 
differentiate antibody to viruses with high antigenic cross reactivity, such as between 
EHV1 and EHV4 (Gibson et al., 1992ab; Kydd et al., 1994a, b) and EHV2 and EHV5 
(Borchers et al., 1999a). The technique is also not suitable for the diagnosis of recent 
infection because antibody production does not increase until 10 to 14 days p.i. Further, 
EHV1 or EHV4 infection does not always stimulate a marked and often less than 4-fold 
rise in neutralisation titres in the horse (Fitzpatrick and Studdert, 1984; Ellis et al., 1995; 
Singh et al., 1995; Burrell et al., 1996). 
Immunofluorescence techniques 
Immunofluorescence was described as a sensitive method ideally suited for rapid 
screening of virus-infected cultures (Beech, 1991; Osterrieder et al., 1995). The 
technique has been used for the detection of EHV1 in lymphocytes (Smith et al., 1998) 
and EHV2 in pulmonary alveolar macrophages (Schlocker et al., 1995). The use of   72 
type-specific monoclonal antibodies to detect viral antigen in cells infected by EHV1 
and EHV4 has also been described (Yeargan et al., 1985; Matsumura et al., 1992). 
Enzyme-linked immunosorbent assay (ELISA) 
To overcome problems of cross-reactivity between EHV1 and EHV4, type-specific 
ELISAs have been developed using recombinant proteins and monoclonal antibody for 
the detection of EHV1 and EHV4 antibodies. Envelope proteins gB, from EHV1 
(Sinclair et al. 1993), and gG, from EHV1 and EHV4 (Crabb and Studdert 1993), have 
been expressed in E. coli as fusion proteins. The gG recombinant proteins, in 
particular, have been used widely for the detection and differentiation of antibody to 
EHV1 and EHV4 (Drummer et al., 1995; Gilkerson et al. 1998a, b; Gilkerson et al., 
1999a, b; Yasunaga et al., 1998, 2000; Gilkerson et al., 2000; Ruitenberg et al., 2001). 
Baculovirus recombinant EHV1 gD and gH (Tewari et al., 1994) and EHV1 gB, gC and 
gD (Packiarajah et al., 1998) have also used to detect EHV1 antibody.  
Western immunoblotting  
Western immunoblotting is used primarily to analyse the antibody response to 
individual glycoproteins or specific antibodies. It has been used to detect type-specific 
epitope(s) on gG homologues of EHV1 and EHV4 (Pilling et al., 1994) and gB, gC and 
gD expressed in the baculovirus expression system to confirm the antibodies produced 
in response to EHV1 infection in mice (Packiarajah et al., 1998).  
Immunohistochemistry 
Immunohistochemical techniques are extremely useful for the detection of EHV 
antigens in formaldehyde-fixed tissue sections, particularly when combined with the use 
of monoclonal antibodies, and have been used to define the presence of viral antigen in 
histological sections (Kydd et al., 1994a, b).    73 
2.6.3 Genetic-based techniques for the detection of virus  
The identification of EHV1 and EHV4, and EHV2 and 5, as separate and distinct 
viruses, not minor variants (subtypes), was dependent on the adoption of molecular 
biotechnology methods. For both the equine alphaherpesviruses and 
gammaherpesviruses, initial differentiation was achieved by analysis of restriction 
endonuclease treated isolates (Sabine et al., 1981; Studdert et al., 1981; Browning and 
Studdert, 1987b). DNA sequence analysis and newer molecular biological techniques 
have been applied to the detection and identification of the EHV.  
Polymerase chain reaction (PCR) 
PCR assays have been used for viral identification and to study the pathogenesis of 
EHV infection and latency (for example, Borchers and Slater, 1993; Baxi et al., 1996; 
Borchers and Frolich, 1997; Chesters et al., 1997; Franchini et al., 1997; Borchers 
et al., 1998; Borchers et al., 1999a, b, c; Buczynski et al., 1999), as well as for the 
detection of LATs (Baxi et al., 1995; Chester et al., 1997; Borchers et al., 1999b). The 
use of the PCR for the identification of viral pathogens such as the equine 
herpesviruses has a number of advantages over traditional methods of identification. 
PCR allows rapid detection of viral DNA, often at very low concentrations. PCR assays 
have been particularly valuable for the identification and differentiation of multiple 
herpesviruses in individual samples, a common finding in horses. PCR assays have 
also aided differentiation between the alphaherpesviruses EHV1 and EHV4 (O‟keefe et 
al., 1991; Hardt et al., 1992; Sharma et al., 1992; Borchers and Slater, 1993; Kirisawa 
et al., 1993a; Rimstad and Hyllseth, 1994; Lawrence et al., 1994; Carvalho et al., 
2000b; Varrasso et al., 2001), and the gammaherpesviruses EHV2 and EHV5 (Saiki et 
al., 1985; O‟keefe et al., 1994; Galosi et al., 2001;). A number of PCR assays for 
detecting EHV1 (Ballagi-Pordany et al., 1990; Osterrieder et al., 1994ab; Welch et al.,   74 
1992), EHV4 (Borchers et al., 1997b), EHV2 (Reubel et al., 1995; Borchers et al., 
1997a , 1998; Rivzi et al., 1997) and EHV5 (Reubel et al., 1995) have also been 
described.  
Most researchers have concluded that PCR assays are slightly less sensitive than 
conventional virus isolation techniques for the detection of herpesviruses. However, the 
possibility of simultaneous detection and differentiation of multiple equine herpesvirus 
types and rapid diagnosis offer considerable advantage over traditional virus detection 
techniques in some circumstances. The possibility of utilising degenerate primers to 
detect previously unidentified equine herpesviruses, or a combination of primers in a 
multiplex PCR assay to simultaneously detect multiple herpesvirus in the same sample, 
also offers an advantage. Such multiplex PCR assays have been developed for the 
human herpesviruses (Markoulatos et al., 2001; Druce et al., 2002) and for equine 
herpesviruses (Carvalho et al., 2000b; Wang 2003). PCR assays based on the use of 
consensus (degenerate) primers have been used to detect previously unrecognised 
EHV in wild and zoo Equidae (Ehlers et al., 1999). Differentiation of lytic and latent 
herpesvirus infection by utilising conventional PCR and RT-PCR, or by detection of 
LATs, would assist diagnosis and better characterisation of the epidemiology and 
pathogenesis of EHV disease.  
Reverse transcriptase PCR (RT-PCR) 
Reverse transcriptase-PCR assays are a rapid method to study the transcriptional 
activity of viral genes. Analysis of the transcription pattern of wild/mutant equine 
herpesviruses could elucidate enigmas of equine herpesvirus pathogenesis. For 
example, a new strain of EHV1 (strain 5089) isolated by Kirisawa et al. (2005) was 
reported as spreading in cultured cells by cell-to-cell infection, which is in contrast to 
the wild-type EHV1 that spreads efficiently as a cell-free virus. Analysis of expression of   75 
the gC gene in this strain via RT-PCR revealed that the expression level of 5089 gC 
mRNA was reduced considerably compared to that of wild-type EHV1. This group 
speculated that the lack of gC in 5089 virions could be the reason of lack of gC mRNA 
expression and thus lead to different mode of transmission.    
In mutational analysis studies, RT-PCR assay has also been used to examine the 
transcription pattern of mutant viruses. For example, the transcription of a recombinant 
lacZ62/63-EHV1 was analysed via RT-PCR in order to determine that the lacZ insertion 
did not interfere with the transcription and expression of late genes (Csellner et al., 
1998). The construction of this mutant-EHV1 carrying a reporter gene identifies a site 
for insertion of foreign genes and will facilitate studies on the pathogenesis of EHV1.      
Chen et al. (1996ab) used RT-PCR assay to study the transcription initiation site of a 
unique hybrid ORF, designated as IR4/UL3 gene and located between ICP22 and 
ICP27. This unique IR4/UL3 hybrid gene has been hypothesised to play a role in latent 
infection. Camarda et al. (1999) used RT-PCR assay to confirm the transcription of 
EHV2 E1 ORF in EHV2-infected primary embryonic kidney cells, before further 
experimental approaches were proceeded to determine its role in regulation of horse 
immune functions. 
The RT-PCR assay has also been used to discriminate between active and latent 
equine herpesvirus infection. Borchers et al. (1999b) detected EHV4 gene 63 and 64 
mRNA transcripts in trigeminal ganglia of 6 out of 10 horses that were DNA positive to 
EHV4 gB, thereby demonstrating that EH4 is latent in trigeminal ganglia. Further 
analysis of the transcripts via a strand specific RT-PCR revealed that all the transcripts 
were antisense orientated.    76 
Real-time PCR (rt-PCR) 
Real-time-PCR assays are currently the most advanced PCR-based technique. They 
provide high throughput, a wide dynamic range, are highly sensitive, reproducible and 
may be utilised to obtain quantitative information on the amount of DNA present. In 
equine herpesvirus research, they have been used for the detection and quantification 
of EHV1 DNA in tissue samples from equine aborted foetuses (Elia et al., 2006) and 
also in PBL and nasal swabs from mares and very young foals inoculated with EHV1 
(Foote et al., 2006).  
Using a similar technique, the kinetic expression of EHV4 viral DNA (gB gene) and 
transcriptional activity (gB and LAT) in PBL and nasal swabs of 11 foals during a field 
outbreak of respiratory disease has also been evaluated (Pusterla et al., 2005).  
In situ hybridisation (ISH)  
In situ hybridisation is used to detect virus directly in the intact cell, thereby identifying 
the cellular or sub-cellular location of viral nucleic acid. The technique, however, is 
relatively insensitive, especially in latent infections where the number of target DNA 
and/or RNA copies per cell (copy number) is low (Nuovo, 1992). In situ hybridization 
has been used to detect equine herpesviruses in equine foetuses (Schmidt et al., 
1994), trigeminal ganglia (Baxi et al., 1995) and bronchial lymph nodes (Chesters et al., 
1997). 
Restriction fragment length polymorphism (RFLP) 
RFLP analysis is based on the enzymatic digestion of DNA to produce fragments of 
differing length which can be separated and isolated by electrophoresis. In this way, 
differences between viruses at the genomic and strain level that usually cannot be 
detected by antigenic assays may be recognised. Restriction enzymes recognise   77 
specific nucleotide sequences and cut the genome at that location. Restriction 
fragments are then amplified and detected on denaturing polyacrylamide gels. RFLP 
analysis is rapid and less expensive, but also less sensitive than sequence analysis 
(Vos et al., 1995).  
RFLP methods have been used to distinguish different equine herpesviruses (Ballagi-
Pordany et al., 1990; Kirisawa et al., 1993b; Mc Cann et al., 1995; Carvalho et al., 
2000a) and to differentiate EHV1 and EHV4 (Sabine et al., 1981; Studdert et al., 1981; 
Studdert 1983). The technique was also used to identify minor variations in the mobility 
of Bam HI fragments of EHV1 strains before and after vaccination of horses (Kirisawa 
et al., 1993b) and differences between EHV5 isolates from different horses (Dunowska 
et al., 2000). 
Southern blot, Northern blot and dot blot 
These 3 techniques have potential application for the detection of EHV in tissues. 
Comparison with PCR and RT-PCR for the detection of and determination of the 
genomic heterogeneity of EHV (Browning and Studdert, 1987b; Browning and Studdert, 
1989; Kirisawa et al., 1993b; Collinson et al., 1994). Morris and Field (1988) 
demonstrated the possibility of southern blot and dot blot for detecting virus DNA and to 
distinguish between subtypes of the EHV; the dot blot method was considered to have 
potential for the rapid detection of EHV1.   78 
Chapter 3 
An epidemiological study of lytic equine herpesvirus infections 
in young horses  
 
3.1 Summary  
Detection of DNA and mRNA of EHV2, EHV5, EHV1 and EHV4 in peripheral blood 
leukocyte (PBL) and nasal swabs (NS) was attempted from 13 mares and 46 foals in 4 
stables as part of a concurrent longitudinal study of EHV infections in young foals and 
the effect of stressors such as weaning on the prevalence of virus infection.  
A variety of techniques, which included a multiplex PCR for the detection of virus DNA 
and a single-nested RT-PCR for the detection of RNA transcripts of the structural 
genes were used to detect virus and differentiate lytic and latent virus infections.  
Nested PCR assays for individual viruses were able to detect 0.9 fg EHV2 and 9 ag 
EHV5 plasmid DNA, equivalent to 100 genome copies and 1 genome copy, 
respectively.  The multiplex nested PCR was optimised to a detection limit of 9 fg for 
both EHV2 and EHV5 plasmid DNA, equivalent to 1000 genome copies of either virus.  
Nested RT-PCR assays for the detection of EHV2 and EHV5 gB RNA transcripts were 
able to detect 9 ag RNA, equivalent to 1 genome copy of the transcripts.  
EHV2 and EHV5 infections were detected commonly in the study population but 
infections with the alphaherpesviruses EHV1 and EHV4 were not detected although it is 
possible that sub-clinical or latent infections by the alphaherpesviruses may have been 
missed due to the frequency of sampling.  The prevalence of EHV2 was higher in 
young foals than in older foals and adult animals, and the prevalence of EHV5 was   79 
higher in older foals and adults than in younger foals.  The prevalence of EHV2 and 
EHV5 infection increased in association with weaning, presumably in association with 
stressors associated with weaning, but was not clearly associated with disease in the 
weaned animals.  
EHV5 produced a transient lytic infection in PBL of young foals but tended to produce a 
persistent lytic infection of PBL in older foals and adults.  Persistent lytic EHV5 
infections of ≥37 weeks duration were detected in 2 of 13 adult mares and this has not 
been reported previously.  The persistent lytic infection of PBL was not associated with 
the detection of virus in NS and the mares with persistent lytic infection of PBL with 
EHV5 did not transfer the infection to their foals.   
 
3.2 Introduction 
Equine herpesviruses are commonly detected in the respiratory tract of horses, 
sometimes but not always associated with respiratory disease. The 2 
alphaherpesviruses EHV1 and EHV4 are a major cause of acute respiratory disease in 
young horses throughout the world, causing significant economic losses to the equine 
industry due to lost training time and secondary pneumonia. EHV1 can be also 
associated with abortion and, on occasions with neurological disease, while EHV4 is 
associated with respiratory disease only. The role of EHV2 and EHV5 as pathogens is 
less clear as these 2 EHV types have been identified from healthy horses, as well as 
from horses with respiratory disease (reviewed by Browning and Agius, 1996). They 
have been associated with pharyngitis and conjunctivitis (Blakeslee et al., 1975; 
McAllister and Blakeslee, 1977; Thein, 1978; Collinson et al., 1994), upper and lower 
respiratory tract disease (Palfi et al., 1978; Jolly et al., 1986; Borchers et al., 1997a,   80 
1998; Murray et al., 1996), poor performance (Rose et al., 1974; Jensen-Waern et al., 
1998), chronic pulmonary disease (Schlocker et al., 1995) and severe pneumonia (Fu 
et al., 1986; Lakritz et al., 1993) but their role in any of these conditions is uncertain.  
The prevalence of EHV2 and EHV5 in horse populations, detected using PCR, appears 
to be high (Wang et al., 2007) in both PBL and nasal swabs (Wang et al., 2007) that 
persist for prolonged periods (Wang et al., 2007). Whether these infections represent 
lytic virus replication or latent virus infection has not been determined.  If they 
represented latent infections in PBL, reactivation of the latent infection and further lytic 
infections could create the opportunity for transmission of these viruses to other horses 
and this may be important in the epidemiology of infections by these viruses.  
The ability to be able to differentiate latent and active infection is an important step in 
understanding what is happening in a virus infected horse.  Most diagnostic tools (virus 
culture, serology, conventional PCR) do not allow differentiation between active and 
latent infection. Latency-associated transcripts have not been defined for the equine 
gammaherpesviruses and differentiation between active and latent infection of these 
viruses would be enabled by the detection of viral RNA transcripts that would be 
expected only during active replication.  
The major aim of this study was to develop PCR and RT-PCR techniques for the 
detection of virus DNA and RNA transcripts. These techniques were then applied to an 
epidemiological study of EHV infection in foals from birth to weaning in 4 cohorts 
(stables) of mares and foals.  The aim of this study was to identify the age when foals 
were first infected, to determine if the infection persisted as a latent or lytic infection, 
and if stressors such as weaning were associated with an increased virus load or 
reactivation of latent virus. The gammaherpesviruses EHV2 and EHV5 were of 
particular interest as these viruses have been poorly studied relative to the more widely   81 
investigated EHV1 and EHV4, and they were found to be common infections in horses 
in Western Australia (Wang, 2003; Wang et al., 2007). 
To facilitate this study, optimisation of methods of detection of virus DNA and virus 
mRNA transcripts was attempted.  Comparative sensitivity of the single nested PCR 
with the multiplex nested PCR for EHV2 and EHV5 utilised in this laboratory previously 
by Wang (2003) and Wang et al. (2007) was determined. The sensitivity of RT-PCR 
assays developed for the detection of EHV2 and EHV5 RNA transcripts was also 
evaluated. 
 
3.3 Materials and methods 
3.3.1 Viruses and cell culture 
Reference strains of EHV2 (strain 86/67) and EHV5 (strain 2-141) were kindly provided 
by Professor Michael J Studdert, Melbourne University. Reference strains of the 
alphaherpesviruses EHV1 and EHV4 were obtained from Dr Trevor Ellis, Animal Health 
Laboratories, Agriculture Western Australia (WA).  The viruses were cultured in primary 
equine kidney (EK) cells maintained in Dulbecco‟s modified Eagle‟s medium (DMEM; 
Gibco, Australia) supplemented with 2% foetal bovine serum (Gibco) at 37ºC in a 7% 
CO2-in-air atmosphere.  
3.3.2 Horses and samples 
Peripheral blood lymphocytes (PBL) and NS samples were collected from Stable A (13 
foals and 13 mares), Stable B (12 foals), Stable C (10 foals) and Stable D (11 foals). 
Samples from foals in Stable B, C and D were collected once a month from birth until 5 
to 9 weeks after weaning (September 2002 to May/June 2003). Samples from Stable A 
were collected weekly from mares and foals from birth until approximately 2 weeks after   82 
weaning (August 2002 to June 2003). Samples from the mares were also collected for 
approximately 1 month prior to foaling. Foals from Stable A were part of a concurrent 
but unrelated study of the efficacy of a recombinant EHV1 vaccine. As part of these 
studies, mares and foals were maintained in strict isolation from all other horses and 
were further separated on 17th March 2003 into 2 separate groups, based on foal date 
of birth, to facilitate challenge infection of Group 1 foals (described below) and infection 
by contagion (arguably more typical of field outbreaks of EHV1 disease) of Group 2 
foals.  
Experimental infection of Group 1 foals involved intranasal administration of 3 mL of 
EHV1 virus (1.3 x 10
7 pfu/mL) prepared by infecting semi-confluent rabbit kidney 
(RK13) cell monolayers and collecting supernatant fluid containing extracellular virus. 
EHV1 titres of aliquots were determined by plaque assay on RK13 cells. Group 1 foals 
all demonstrated clinical signs (pyrexia, serous and/or mucoid nasal discharge and 
lymphadenopathy) and had evidence of virus shedding within 48 to 72 h of challenge-
infection. Group 2 foals were infected by indirect contagion (staff in contact with Group 
1 foals were able to transmit infection during routine sampling procedures conducted in 
late March) and demonstrated less dramatic clinical signs and a more gradual spread 
of infection through the group.  
Whole blood samples (10 mL) were collected by jugular venipuncture into vacutainer 
tubes with EDTA. Nasal swabs (NS) were placed in 2 mL transport medium (DMEM 
with 2% FBS and antibiotics). Blood and NS samples were kept on ice until processed 
further the same day. Peripheral blood lymphocytes (PBL) were separated by Ficoll-
Paque
TM Plus (Amersham Pharmacia Biotech AB, Sweden) gradient centrifugation.    83 
3.3.3 DNA and RNA extractions 
DNA and RNA were extracted from EHV-infected EK cells, PBL and cells pelleted by 
centrifugation from NS samples, using a QIAmp Blood Mini Kit (QIAGEN) and QIAGEN 
RNeasy  minikit (QIAGEN), as per the manufacturer‟s instruction. Briefly, the cell 
suspensions were mixed with lysis buffer appropriate for each DNA or RNA, to disrupt 
cells and release the cell contents including DNA or RNA. The lysate was then passed 
through a prepared silica column to extract the nucleic acids from solution. After elution 
with nuclease-free TE-buffered water, the DNA samples were stored at –20ºC, the RNA 
samples were treated with DNAse (DNA-free™, Ambion) and resuspended in RNA 
storage solution (Ambion) before storage at -80ºC. 
3.3.4 DNA and cDNA cloning and sequencing 
Cloning of PCR and RT-PCR products was performed with the Original TA Cloning Kit 
(Invitrogen) into the pCR 2.1 vector in accordance with the manufacturer‟s instructions.  
The EHV2 positive control and samples that tested positive were sequenced by 
protocols for the Prism Big Dye Terminator Cycle Sequencing Ready Reaction kit with 
an ABI 373A Automated DNA sequencer (Applied Biosystem, Australia).  
3.3.5 In vitro transcription of EHV2 and EHV5 RNA  
Transcription of EHV2 and EHV5 gB cDNA to RNA, used to test the sensitivity of the 
RT-PCR for the detection of EHV2 and EHV5 transcripts (see below) was performed as 
follows.  Briefly, plasmids containing the gB region cDNA were linearised with the 
BamH1 restriction enzyme (New England Biolabs), dialysed and an in vitro transcription 
reaction performed with T7 RNA polymerase (Promega).  The reaction mixture (50 U of 
T7 RNA polymerase, 10  l of 5X transcription buffer, 1  g of linearised DNA, 50 U of   84 
RNase inhibitor [Applied Biosystems] and 2.0 mM each ribosomal nucleoside 
triphosphate (Promega) was incubated at 37ºC for 2 h.   
3.3.6 DNA PCR 
3.3.6.1 Primers  
The primers used are shown in Table 3.1. The nested primers for EHV2 and EHV5, and 
EHV1 and EHV4, were those previously described by Wang (2003) and Wang et al. 
(2007).  
 
Table 3.1.  Nucleotide sequence of primers and products used in the first and second rounds of 
the nested PCR. 
 
   Virus  Primer  Sequence (5'-3')  Gene 
specificity 
Location  Predicted 
amplicon 
size (bp) 
First 
round 
primers 
EHV2  EHV2L1  GATGGTCTCACCTCTAGCAT  EHV2 gB  538-557  1111 
  EHV2R1  CTGGTGTAACACAGGTCTTC    1627-1646   
  EHV5  EHV5L1  CCAACACAGAAGACAAGGAG  EHV5 gB  345-364  1339 
    EHV5R1  CACGGTGATACAGTCAGAGA    1662-1681   
  EHV1/  FC2  CTTGTGAGATCTAACCGCAC  EHV1 gB  2427-2446  1118 
  EHV4      EHV4 gB  1737-1756  1175 
    RC  GGGTATAGAGCTTTCATGGG  EHV1 gB  3607-3588   
        EHV4 gB  2911-2892   
Second 
round 
primers 
EHV2  EHV2L2  GGTCTCACCTCTAGCATAAC  EHV2 gB  541-560  817 
  EHV2R2  GCCACACTCTCTTCCTTAGT    1336-1355   
EHV5  EHV5L1  CCAACACAGAAGACAAGGAG  EHV5 gB  345-364  410 
    EHV5R2  AGTTGACCGTCGTTCTAGTG    733-752   
  EHV1/  FC3  ATACGATCACATCCAATCCC  EHV1 gB  2699-2718  188 
  EHV4      EHV4 gB  2003-2022  677 
    R1  GCGTTATAGCTATCACGTCC  EHV1 gB  2886-2867   
    R4  CCTGCATAATGACAGCAGTG  EHV4 gB  2679-2660   
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3.3.6.2 Specificity of PCR assays 
The species specificity of the PCR product of all 4 equine herpesviruses was confirmed 
by sequence analysis of the products.  
3.3.6.3 Sensitivity of PCR assays 
The sensitivity of single and multiplex nested PCR assays was determined by using 
serial 10-fold dilutions of cloned EHV2 and EHV5 PCR products. The sensitivity of 
single nested PCR and multiplex nested PCR of EHV2 and EHV5 were compared. The 
sensitivity of single nested PCR and multiplex nested PCR of EHV1 and EHV4, and 
also multiplex PCR of the 4 EHV were not compared.  
3.3.6.4 Single nested PCR 
To optimise single nested PCR conditions, changes of 2 variables were emphasised: 
annealing temperatures and magnesium chloride (MgCl2) concentrations. The initial 
reaction mixture consisted of 25  L containing 1.5 mM MgCl2, 1X PCR buffer, 200  M 
each dNTP (Applied Biosystems), 0.2  M each primer (Invitrogen, Australia) and 1 U 
Taq DNA polymerase (Applied Biosystems) and 2  L of sample containing 2  g of 
plasmid DNA. Amplification conditions were as follows: 1 cycle of 94ºC for 5 min, 
followed by 35 cycles of 94ºC for 30 seconds, 60ºC for 30 seconds, 72ºC for 1 min, and 
1 cycle at 72ºC for 7 min for final extension. For the subsequent nested reactions, 2  L 
of the amplified products of the initial PCR were used as a template in the reaction. 
Amplification conditions were as for the first round PCR. PCR products were 
electrophoresed at 95V for 45 min in 1.5% agarose containing 5 mg/mL ethidium 
bromide and visualised under UV transillumination.    86 
3.3.6.5 Multiplex nested PCR for detection of EHV2 and EHV5 
Except for primer concentrations, which were optimised for multiplex EVH2 and EHV5 
(using various EHV2 primer concentrations (0.2, 0.4, 0.6 and 0.8  M) and a single 
concentration of EHV5 primer [0.2  M], PCR conditions used for the single nested PCR 
were also used for the multiplex nested PCR for the detection of  EHV2 and EHV5.  
3.3.7 RT-PCR  
3.3.7.1 Primers 
Primers used in conventional PCR assays (Table 3.1) were used in the nested RT-PCR 
assay. RNA samples were treated with DNAse (DNA-free™, Ambion) to eliminate 
genomic DNA contamination. To further ensure that the RT-PCR products were not 
amplified from genomic DNA, the RT enzyme was omitted from the reaction mix and 
samples were treated the same way as if they contained the RT enzyme. Products 
visualised after electrophoresis from the reaction without the RT enzyme would indicate 
genomic DNA contamination.  
3.3.7.2 Single nested RT-PCR 
A single tube 2-step RT-PCR was utilised. The transcription of RNA to cDNA (the first 
step) was performed according to the manufacturer‟s instructions. Briefly, 10  L 
reactions containing 5 mM MgCl2, 1 mM of each dNTP, 2.5 U/L MuLV Reverse 
Transcriptase, 2.5  M random hexamers, 1X PCR Buffer II (Applied Biosystem, 
Australia) and 0.5  g total RNA derived from in-vitro translation (samples) were mixed 
and incubated for 10 min at room temperature to allow for the extension of the 
hexameric primers by reverse transcriptase. The reactions were amplified for 1 cycle at 
42ºC for 30 min for reverse transcription, 5 min at 99ºC for denaturing and 5 min at 5ºC   87 
for cooling. For the second step, 10  L of cDNA produced in the first step was amplified 
in 50  L reactions containing 2.0 mM MgCl2, 1X PCR Buffer II, 2.5 U/L Taq Polymerase 
(Applied Biosystems) and 0.2  M each primer (Invitrogen). 
3.3.7.3 Species specificity of PCR assays 
The species specificity of each RT-PCR product for all 4 equine herpesviruses was 
confirmed by sequence analysis of the amplified product.  
3.3.7.4 Sensitivity of PCR assays 
The sensitivity of multiplex RT-PCR was not performed in this study due to time 
constraints and because results obtained from the comparison of sensitivity between 
single nested and multiplex nested conventional PCR described above suggested 
multiplex assays to be less sensitive than single assays. The sensitivity of single nested 
RT-PCR assays for EVH1 and EHV4 were also not compared. 
The sensitivity of single nested RT-PCR reactions was determined by using serial 10-
fold dilutions of specific EHV2 and EHV5 transcripts obtained from the in vitro 
transcription assay. Due to the time constraint, the sensitivity of single nested RT-PCR 
of EHV1 and EHV4 were not done. 
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3.4 Results 
1.3.4.1  Development of conventional PCR and RT-PCR to differentiate 
between lytic and latent equine herpesvirus infection in horses   
3.4.1.1  Specificity of PCR and RT-PCR for EHV2, EHV5, EHV1 and EHV4 
The species specificity of the PCR and RT-PCR products was confirmed by 
sequencing. The sequence of the EHV2 and EHV5 fragments had >98% identity to the 
sequence of EHV2 (Accession No. EHV20824) and EHV5 (Accession No. AF050671) 
in the GenBank database, respectively.  The sequence of the EHV1 and EHV4 PCR 
and RT-PCR products had >99% identity to the sequence of several strains of EHV1 
and EHV4 available in the Genbank database.  
3.4.1.2  Sensitivity of PCR and RT-PCR for EHV2 and EHV5 
The sensitivity of the single nested PCR assays was determined by amplifying 10-fold 
serial dilutions of EHV2 and EHV5 plasmid DNA. As expected, the second round PCR 
reaction resulted in a marked increase in sensitivity of the reaction compared to first 
round reactions only (data/PCR pictures are not shown). 
Sensitivity of single nested PCR of EHV2 plasmid DNA 
Figure 3.1 shows the second round PCR products prepared from the same amount of 
EHV2 plasmid DNA following various annealing temperatures ranging from 50.6ºC to 
70.1ºC. It was evident that the intensity of the product band was mildly reduced when 
the annealing temperature exceeded 58.5ºC (lane 7) and markedly reduced as the 
temperature exceeded 64.2ºC (lane 9).  
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Figure 3.1. Second round single nested PCR reaction products obtained using 2  g of EHV2 
plasmid DNA with various annealing temperatures. Lane 1, 100 bp ladder; lane 2, 50.6ºC; lane 
3, 50.6ºC; lane 4, 51.6ºC; lane 5, 53.4ºC; lane 6, 55.8ºC; lane 7, 58.5ºC; lane 8, 61.4ºC; lane 9, 
64.2ºC; lane 10, 66.7ºC; lane 11, 68.7ºC; lane 12, 69.9ºC; lane13, 70.1ºC; lane 14, dH2O 
(negative control). The concentration of EHV2 plasmid DNA incorporated was 0.2 ug. 
 
Single nested PCR products from reactions containing the same amount of EHV2 
plasmid DNA, 0.2 ng (10-fold lower than Figure 3.1), with annealing temperatures 
between 53.4ºC and 61.4ºC, and different MgCl2 concentrations are shown in Figure 
3.2. the brighter bands in Panels C and D have indicated that the sensitivity of the PCR 
assay was increased as MgCl2 concentrations were increased to 2.5 and 3.0 mM. The 
intensity of the bands in panel D, with various annealing temperatures, was similar to 
those in panel C but the brightest bands were observed in lanes 4, 5 and 6 (boxed) of 
panel D, where the annealing temperatures used were 54.8ºC, 55.5ºC and 56.0ºC, 
respectively.  
DNA products following single nested PCR for EHV2 are shown in Figure 3.3. 
Annealing temperatures between 53.4ºC to 61.4ºC were used, as above, however the 
concentration of EHV2 plasmid DNA was diluted 10
6 fold, equivalent to 0.2  g, and only 
1.5 mM and 2.5 mM MgCl2 were compared (Panel A and Panel B, respectively).  MgCl2 
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concentration of 3.0 mM was not chosen since it can cause non-specific amplification.  
As is clearly shown, reaction products were barely detectable when 1.5 mM MgCl2 was 
used to amplify the minimum amount of EHV2 plasmid DNA, compared to that evident 
when 2.5 mM MgCl2 was used.  Panel A also shows that the brightest band was 
observed at an annealing temperature of 57ºC, whereas on Panel B, there was no 
apparent difference in the intensity of the bands throughout the range of annealing 
temperatures.  
 
 
 
Figure 3.2. Single nested second round PCR reaction products obtained using 0.2 ng of EHV2 
plasmid DNA with annealing temperatures ranged from 53.4ºC to 61.4ºC. Panel A, 1.5 mM 
MgCl2; panel B, 2.0 mM MgCl2; panel C, 2.5 mM MgCl2, and panel D, 3.0 mM MgCl2.  The 
concentration of EHV2 plasmid DNA incorporated was 0.2 ng. 
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Figure 3.3. Single nested second round PCR reaction products obtained using 0.2  g of EHV2 
plasmid DNA with annealing temperatures between 53.4ºC to 61.4ºC. Panel A, 1.5 mM MgCl2; 
panel B, 2.5 mM MgCl2.  The concentration of EHV2 plasmid DNA incorporated was 0.2 pg. 
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Based on the above results, annealing temperatures between 55ºC and 57ºC were the 
most appropriate, and therefore the average annealing temperature of 56ºC, and a 
MgCl2 concentration of 2.5 mM, were chosen for amplification of EHV2 DNA by single 
nested PCR assays.  
Sensitivity of single nested PCR of EHV5 plasmid DNA 
The same approach was used to optimise the single nested PCR for EHV5 plasmid 
DNA. As was found for the EHV2 PCR assay, an annealing temperature of 56ºC and 
MgCl2 concentration of 2.5 mM provided the most appropriate PCR conditions for 
EHV5.  
Sensitivity of multiplex nested PCR of EHV2 and EHV5 plasmid DNA 
As the annealing temperature and MgCl2 concentration were optimised for single 
nested PCR for both EHV2 and EHV5, the optimisation of the multiplex nested PCR for 
these 2 viruses was focused on primer concentration.  
Figure 3.4 shows amplification of 0.2 ng EHV2 and 0.2 ng EHV5, simultaneously in 1 
PCR reaction, using various EHV2 primer concentrations (0.2, 0.4, 0.6 and 0.8  M) and 
a single concentration of EHV5 primer (0.2  M). It is apparent that EHV5 PCR products 
(410 bp) always produced brighter bands than EHV2 PCR products (817 bp), even 
though the concentration of EHV5 primer was maintained at 0.2  M. Meanwhile, EHV2 
primer concentration of 0.6  M produced the brightest band compared to other 
concentrations.  
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Figure 3.4. Multiplex nested PCR of EHV2 and EHV5 plasmid DNA at various EHV2 primer 
concentrations and 0.2  M EHV5 primer concentration. Lane 1, 100 bp ladder; lane 2, 0.2  M 
EHV2 primer concentration; lane 3, dH2O; lane 4, 0.2  M EHV2 primer concentration, lane 5, 
dH2O; lane 6, 0.4  M EHV2 primer concentration; lane 7, dH2O; lane 8, 0.6  M EHV2 primer 
concentration; lane 9, dH2O; lane 10, 0.8  M EHV2 primer concentration, lane 11, dH2O and 
lane 12, 100 bp ladder.  
 
 
Based on these results, primer concentrations of 0.6  M for EHV2 and 0.2  M for EHV5 
were used in the multiplex nested PCR assay. To validate the sensitivity of this 
multiplex single nested PCR assay, serial 10-fold dilutions of equal amounts of EHV2 
and EHV5 plasmid DNA were amplified using the optimised assay. Figure 3.5 shows 
single nested PCR of EHV2 (lanes 2, 3, 4, 5 and 6) and EHV5 (lanes 8, 9, 10, 11 and 
12), and multiplex nested PCR of both EHV2 and EHV5 (lanes 14, 15, 16, 17 and 18). 
The plasmid DNA concentrations were 0.09 pg, 0.009 pg (9 fg), 0.9 fg, 0.09 fg and 
0.009 fg (9 ag) for each PCR reaction. It is obvious that the single nested EHV5 PCR is 
100-fold more sensitive than the single nested EHV2 PCR. The single nested PCR 
EHV2 and EHV5 were 10- and 1000-fold more sensitive, respectively, than the 
multiplex nested PCR for these 2 viruses. Interestingly, as was demonstrated in Figure 
3.4, the multiplex PCR of EHV2 and EHV5 amplified EHV5 DNA more efficiently than 
EHV2 (lane 14 and lane 15), even though the same amount of plasmid DNA was 
present for each virus.  
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Figure 3.5. Single nested PCR reaction products obtained using various dilutions of EHV2 (A), 
EHV5 (B) and multiplex nested PCR reaction products (C) obtained using various dilutions of 
mixture of EHV2 and EHV5 plasmid DNA as a template, illustrating the increased sensitivity 
obtained using single nested PCR technique. Lane 1, 100 bp ladder; lane 2-6, serial 10-fold 
dilutions of EHV2 plasmid DNA template, commencing with an initial 0.09 pg in lane 2; lane 7, 
100 bp ladder; lane 8-12, serial 10-fold dilutions of EHV5 plasmid DNA template, commencing 
an initial 0.09 pg in lane 8; lane 13, 100 bp ladder; lanes 14-18, serial 10-fold dilutions of mixture 
of EHV2 and EHV5 plasmid DNA template, commencing an initial 0.09 pg in lane 14; lane 19 
and 20, dH2O (negative control). 
 
 
Sensitivity of single nested RT-PCR of EHV2 RNA transcript 
Figure 3.6 shows nested PCR products derived from amplification products of 10-fold 
dilutions of EHV2 RNA transcript, from 0.9 ng to 9 ag. Based on the results, it is 
apparent amplification of EHV2 transcripts via RT-PCR assay was more sensitive than 
conventional PCR assay because RT-PCR could detect as little as 9 аg of EHV2 RNA 
transcript, compared to 0.9 fg EHV2 DNA (Figure 3.5).  
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Figure 3.6. Single nested second round RT-PCR reaction products obtained from amplification 
of EHV2 RNA transcript with various concentrations of viral RNA. Lane 1, 100 bp ladder; lanes 2 
– 10, serial 10-fold dilutions of EHV2 RNA transcript template, commencing with an initial 0.9 ng 
in lane 2, followed by 0.09 ng in lane 3, 0.009 ng (9.0 pg) in lane 4, 0.9 pg in lane 5, 0.09 pg in 
lane 6, 0.009 pg (9 fg) in lane 7, 0.9 fg in lane 8, 0.09 fg in lane 9, and 0.009 fg (9 ag) in lane 10. 
Lane 11 is dH2O (negative control). 
 
 
Sensitivity of single nested RT-PCR of EHV5 RNA transcripts 
Serial 10-fold dilutions of EHV5 RNA transcript, between 0.9 ng and 9 ag, 
demonstrated that the nested RT-PCR for EHV5 was as sensitive as that developed for 
EHV2 (ie. RT-PCR could detect as little as 9 аg of EHV5 RNA transcript). 
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3.4.1.3 Comparison of primers  
Table 3.2 shows the location of the EHV2 gB primers used in this study compared to 
those of Reubel et al. (1995) and Dynon et al. (2001).  EHV5 gB primers used in this 
study were compared only with those of Dynon et al. (2001), because Reubel et al. 
(1995) used a different part of the EHV5 genome (gH) in their study (Table 3.3).  
 
 
Table 3.2. Comparison of nucleotide sequence of primers and products used in the first and 
second rounds of the nested PCR of EHV2 in this study with those of Dynon et al. (2001) and 
Reubel et al. (1995). 
 
   Virus  Primer  Sequence (5'-3')  Gene 
specificity 
Location  Predicted 
amplicon 
size (bp) 
First 
round 
primers 
EHV2 
Wang 
(2003)  
EHV2L1  GATGGTCTCACCTCTAGCAT  EHV2 gB  538-557  1111 
EHV2R1  CTGGTGTAACACAGGTCTTC    1627-1646   
  EHV2 
Dynon 
et al. 
(2001) 
Forward  CAGTGTCTGCCAAGTTGATA  EHV2 gB  1523-1542  444 
  Reverse  GGCGTCTCGAAAAGCGAGAG    1945-1965   
  EHV2 
Reubel 
et al. 
(1995) 
Forward  AGAAAATGGCACAGAGCCAG  EHV2 gB    257 
  Reverse  TGGCAATAAAATGGAGACTGC       
Second 
round 
primers 
EHV2 
Wang 
(2003) 
EHV2L2  GGTCTCACCTCTAGCATAAC  EHV2 gB  541-560  817 
EHV2R2  GCCACACTCTCTTCCTTAGT    1336-1355   
  EHV2 
Dynon 
et al. 
(2001) 
Forward  AGGACTACTACTATGTCAG  EHV2 gB  1802-1820  165 
  Reverse  GGCGTCTCGAAAAGCGAGAG    1945-1965   
  EHV2 
Reubel 
et al. 
(1995) 
Forward  TGCTGTCACAAAGTACGGTG  EHV2 gB  735-991  191 
  Reverse  TGGCAATAAAATGGAGACTGC       
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Figure 3.7. Schematic diagram of EHV2 gB sequence amplified by different primer pairs, A: 
EHV2 gB sequence; B: EHV2 gB sequence (817 bp) amplified by Wang (2003); C: EHV2 gB 
sequence (191 bp) amplified by Reubel et al. (1995); D EHV2 gB sequence (165 bp) amplified 
by Dynon et al. (2001).  
 
 
The EHV2 gB region amplified by primers used in this study (Wang, 2003; Wang et al., 
2007) were different to the region amplified by the primers used by Dynon et al. (2001) 
as is shown in Table 3.2 and Figure 3.7. However, the EHV2 gB region amplified by 
primers used by Reubel et al. (1995) (C) are located within the region amplified by 
primers used by Wang (2003). Comparison of the region amplified by primers used in 
this study and that of Dynon et al. (2001) clearly demonstrated that both primers 
amplified different parts of the EHV5 gB ORF.  
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Table 3.3. Comparison of nucleotide sequence of primers and products used in the first and 
second rounds of the nested PCR of EHV5 in this study and Dynon et al. (2001). 
 
   Virus  Primer  Sequence (5'-3')  Gene 
specificity 
Location  Predicted 
amplicon 
size (bp) 
First 
round 
primers 
EHV5  EHV5L1  CCAACACAGAAGACAAGGAG  EHV5 gB  345-364  1339 
Wang 
(2003) 
EHV5R1  CACGGTGATACAGTCAGAGA    1662-1681   
  EHV5 
Dynon 
et al. 
(2001) 
Forward  ATGAACCTGACAGATGTGCC  EHV5 gB  1813-1832  293 
  Reverse  CACGTTCACTATCACGTCGC    2084-2103   
Second 
round 
primers 
EHV5 
Wang 
(2003) 
EHV5L1  CCAACACAGAAGACAAGGAG  EHV5 gB  345-364  410 
EHV5R2  AGTTGACCGTCGTTCTAGTG    733-752   
 
 
3.4.1.4  RT-PCR for detection of EHV1, EHV4, EHV2 and EHV5 RNA 
transcripts 
The amplification products from single nested RT-PCR of each individual EHV (EHV1, 
EHV2, EHV4 and EHV5) are shown in Figure 3.8. 
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Figure 3.8. Single nested second round RT-PCR reaction products obtained from amplification 
of EHV1, EHV2, EHV4 and EHV5 RNA transcripts. Lane 1, 100 bp ladder; lane 2, EHV1; lane 3, 
EHV2; lane 4, EHV4 and lane 5, EHV5.  Lane 6 is dH2O (negative control). 
 
3.4.2 Detection of active replication of equine herpesvirus infection in 
equine PBL and NS  
Two types of EHV5 infection were evident in the samples obtained from the 13 mares 
in Stable A (Table 3.4).  In 2 mares, there was a persistent lytic infection of PBL by 
EHV5 (indicated by the continuous presence of gB transcripts in the cells) and virus 
was detected in PBL of these 2 horses for the entire 37 weeks of sampling. In a third 
mare there was a transient lytic EHV5 infection (indicated by the presence of gB RNA 
transcripts) for a 4 week period only, and indicating an acute infection.  While EHV5 
was detected in PBL it was not detected in NS of any of the 13 mares during the 37 
week period during which they were sampled. There was also no evidence of infection 
by the EHV2 gammaherpesvirus or the 2 alphaherpesviruses, EHV1 and EHV4 during 
the period of observation in the mares in this Stable. 
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Table 3.4.  Results of single nested RT-CR assays for EHV5 gB transcripts in PBL collected 
from 13 mares in Stable A.  EHV5 transcripts were not detected in NS and  EHV2, EHV1 and 
EHV4gB transcripts were not detected in either PBL or NS collected from the same horses. 
 
Time (weeks) 
from initial 
sampling 
Mares 
325  359  361  363  365  367  360  362  364  366  368  369  375 
1  -  -  -  V5  -  V5  -  -  -  -  -  -   
3    -  -  V5  -  V5  -  -  -  -  -  -  - 
4    -  -  V5  -  V5  -  -  -  -  -  -  - 
5  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
6  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
7  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
8  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
9  -  V5  -  V5  -  V5  -  -  -  -  -  -  - 
10  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
11  -  V5  -  V5  -  V5  -  -    -  -    - 
12  -  V5  -  V5  -  V5  -  -  -  -  -  -  - 
13  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
14  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
15  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
16  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
17  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
18  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
19  -  -    V5    V5  -  -  -  -  -  -  - 
21  -  -    V5    V5  -  -  -  -  -  -  - 
22  -  -  -  V5  -  V5  -  -  -  -  -  -   
22+         V5    V5  -  -  -  -  -  -  - 
23               -  -  -  -  -  -  - 
24  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
26  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
28  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
30  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
32  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
32+  -  -  -  V5  -  V5               
32+  -  -  -  V5  -  V5               
32+  -  -  -  V5  -  V5               
33  -  -  -  V5  -  V5               
33+  -  -  -  V5  -  V5               
33+  -  -  -  V5  -  V5               
34  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
34+  -  -  -  V5  -  V5               
35+  -  -  -  V5  -  V5               
36  -  -  -  V5  -  V5  -  -  -  -  -  -  - 
37+  -  -  -  V5  -  V5               
37+  -  -  -  V5  -  V5               
41+                -  -    -  -  -  - 
42              -  -  -  -  -  -  - 
Solid shaded areas indicate that samples were not available at these times.  
V5 indicates positive for EHV5   101 
 
Results of examination of foals of the mares examined from Stable A are shown in 
Table 3.5.  There was evidence of lytic replication of EHV2 and EHV5 in PBL for 
transient periods in foals as young as 9 days. The prevalence of lytic EHV2 and EHV5 
infection increased markedly after weaning, when both viruses were also detected in 
NS.  It was evident that the lytic EHV2 infections were transient, persisting for 2 weeks 
or less, whereas lytic EHV5 infection in PBL persisted for periods of at least 4-5 weeks 
in some foals.  The duration of the persistence of lytic EHV5 infection in PBL was not 
determined as sampling was discontinued when the foals were 35 weeks of age.  
Persistent EHV5 infection was not detected in the NS of any of the foals, and the 
duration of lytic EHV5 infection in NS appeared to be of ≤2 weeks duration. 
EHV5 infection was not detected in the foals of the 2 mares (363 and 367) with a 
persistent lytic EHV5 infection. 
EHV1 infection following experimental infection of the foals was detected but was 
transient, persisting for 1 week or less, and was not associated with an increased 
prevalence of EHV2 or EHV5 infection.   102 
Table 3.5 (continued on next page). Detection of EHV2, EHV5, EHV1 and EHV4 gB transcripts using single nested RT-PCR assays in PBL and NS from foals in Stable A. 
 
Age of 
foal 
(weeks) 
Group 1  Group 2 
PBL  NS  PBL  NS 
325A  359A  361A  363A  365A  367A  325A  359A  361A  363A*  365A  367A*  360A  362A  364A  366A  368A  369A  375A  360A  362A  364A  366A  368A  369A  375A 
  -  -  -  -  -  -  -  -  -  -  -  -    -  -  -  -  -  -    -  -  -  -  -  - 
1.5  -  -  -  -  -  -  -  -  -  -  -  -  V5  -  -  -  -  -  -  -  -  -  -  -  -  - 
2  -  -  -  -  -  -  -  -  -  -  -  -  V2  -  -  -  -  -  -  -  -  -  -  -  -  - 
3  -  -  -  V2  -  -  -  -  -  -  -  -  -  V5  -  -  -  -  -  -  -  -  -  -  -  - 
4  -  -  -  V2  -  -  -  -  -  -  -  -  -  V2  -  -  -  -  -  -  -  -  -  -  -  - 
5  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
6  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
7  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
8  -  -  -  -  -  -  -  -  -  -  -  -  V5  -  -  -  -  -  -  -  -  -  -  -  -  - 
9  -  -  V2V5  -  V2  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
10  -  -  V2  -  -  -  -  -  -  -  -  -  -  V2,V5  -  -  -  -  -  -  -  -  -  -  -  - 
11  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  V2 
12  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
13  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
14  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
15  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
16  -  -  V2V5  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
17  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
18  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
19  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
20  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
21  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
22  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
23  -  -  -  -  -  -  -  -  -  V1  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
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24  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
25  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
26  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
26.5  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
27  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
27.5  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -      -  -  -  -  - 
28  -  -  -  -  -  -  V1  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
28.5  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
29  -  -  -  -  -  -  -  -  V1  -  V1  -  -  -  -  -  -  -  -  V1  -  -  -  -  -  - 
29.5  -   -  -  -  -  -  -  -  V1  -  V1  -  -  -  -  V2  -  -  -  V1  -  V2  V2  -  -  - 
30  -  -  -  -  -  -  -  -  -  -  -  -  -  -  V5  V2  -  -  -  -  -  V2  V2  -  -  - 
30.5  -    -   -  -  -  -    -  -  -  -  -  -  V5  -  V2  -  -  -  -  -  V2  V2  -  - 
31   -    -  -  -  -  -    -  -  -  -  -  -  -  V2  V2  -  -  -  -  -  -  V2  -  - 
31.5  -     -    -    -    -    -    V5  V5   -  V5  V5  -  -  V2V5  V2  -  -  -  -  - 
32      -    -        -    -    V5  V2V5  V5  V5  -  V5  V2  V2  V2  V2  -  -  V2  V2 
32.5                          V5  V2,V5  V5  V5   -  V5  -  V2  V2  -  -  -  V2  V2 
33                          V5  V2,V5  V2V5  V5  V5  V5  -  -  -  -  -  -  -  - 
33.2                          V5   -      V5  V5   -  V5  -    -  -  -  - 
33.5                          V5  -        V5  -  -  -        -  - 
34                          V5  V5      V2,V5  V5  -  V5  V5    -  -  -  - 
34.5                          V5  V5        V5  -  -  -        -  - 
35                          V5  V2V5        V2V5  V2  -  -        -  - 
 
V2 indicates positive for EHV2; V5 indicates positive for EHV5; V1 indicates positive for EHV1. 
Solid shading indicates samples were not available. 
Foals in Group 1 were weaned when 29 – 31 weeks of age and foals in Group 2 were weaned when 31-33 weeks of age. 
Foals in Group 1 were experimentally infected with EHV1 at the time of weaning whereas the EHV1 infection in the foal in Group 2 was the result of natural infection, possibly  
as a result of transfer of infection from Group 1 by handlers (although many efforts were taken to prevent this).   
*The dams of these mares were persistently viraemic (see Table 3.4).   104 
 
PBL and NS samples were similarly collected at monthly intervals between 
September 2002 and May/June 2003 from foals at 3 other commercial stables 
(Stables B, C and D). Tables 3.6, 3.7 and 3.8 show the results of single nested RT-
PCR assays, indicating active replication of EHV in these samples via detection of 
gB transcript of individual EHV. 
The epidemiological results above demonstrated active replication of EHV2 and 
EHV5 in foals on Stables B, C and D. There was no evidence of active replication of 
EHV1 or EHV4. In contrast to results observed at Stable A, where active replication 
of EHV2 was detected in PBL as early as 2 weeks of age and EHV5 was detected 
in a foal at 9 days of age, active replication of EHV2 and/or EHV5 was not observed 
in any of the foals until they were 3 to 4 months of age, coincident with clinical signs 
of mild respiratory disease in the foals in Stable C. In Stable C, affected foals had 
nasal discharge at the time of sampling or within the preceding week. The number 
of samples obtained from the Stables B, C and D was less than in Stable A, as 
these were commercial stables and permission to obtain samples was often difficult 
to obtain.  In Stables B and C, there was evidence that there was prolonged active 
replication in PBL of EHV2 and EHV5 after weaning, virus being detected in PBL of 
some foals on 2 occasions at 5 week intervals, although the frequency of sampling 
made it difficult to determine if this was continued replication or intermittent 
replication. 
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Table 3.6. Detection of EHV gB transcript using single nested RT-CR assays on RNA extracted from PBL and NS samples collected from foals in Stable B. 
 
Age of 
foal 
(weeks) 
PBL  NS 
F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F12  F13  F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F12  F13 
1  -  -  -  -  -  -  -  -  -  -  -  -    -  -  -  -  -  -  -  -  -  -  -  -  - 
5  -  -  -  -  -  -  -  -  -  -  -  -    -  -  -  -  -  -  -  -  -  -  -  -  - 
9  -  -  -  -  -  -  -  -  -  -  -  -    -  -  -  -  -  -  -  -  -  -  -  -  - 
13  -  -  -  -  -  -  -  -  V2  -  -  -    -  -  -  -  -  -  -  -  V2  -  -  -  - 
20  -  V2  -  V5  -  -  -  -  -  -  V2  -  -  -  -  -  V2V5  V2  -  -  -  -  -  -  -   
24  -  -  -  -  -  -  -  -  V2V5  -  -      -  -  -  -  -  -  -  -  V2V5  -  -     
30  V2V5  V2V5  -  V2V5  V2V5  -  -  -  -  -        V5  -  -  V2V5  -  -  -  -  -  -       
35  V5  V5  -  -  V2  -                -  -  -  -  -  -               
 
Foals were weaned at 25 – 29 weeks of age. Solid shading indicates samples were not available. 
V2 indicates positive for EHV2; V5 indicates positive for EHV5. 
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Table 3.7. Detection of EHV gB transcript using single nested RT-CR assays on blood and nasal swab samples collected from foals in Stable C.  
 
Age  of 
foal 
(weeks) 
PBL 
F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F12  F13  F14  F15  F16  F17  F18  F19  F20  F21  F22  F23  F24  F25  F26  F27  F28 
1  -  -  -  -  -  -      -  -  -                                   
4    -    -      -  -  -                                       
9      -          -    -  -  -  -  -  -  -  -                       
13                      -  -            -  -  -  -  -             
19                V2          -                    -  -  -  V2V5  -  V2V5 
23                -      -  -  -                          -  -  - 
28                -      -  -  -                          -  -  - 
31  -  -  -  V2,V5  -    V2V5  V2V5  -  V2V5  -                                   
33  -  -  -  V2  -    -  V2V5                                         
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Age  of 
foal 
(weeks) 
NS 
F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F12  F13  F14  F15  F16  F17  F18  F19  F20  F21  F22  F23  F24  F25  F26  F27  F28 
1  -  -  -  -  -  -                                             
4    -    -      -  -  -                                       
9      -          -    -  -  -  -  -  -  -  -                       
13                      -  -            -  -  -  -  -             
19                -          -                    -  -  -  V2V5  -  - 
23                -      -  -  -                          -  -  - 
28                -      -  -  -                          -  -  - 
31  -  -  -  -  -    -  -  -  -  -                                   
33  -  -  -  -  -    -  -  -  -  -                                   
 
V2 indicates positive for EHV2; V5 indicates positive for EHV5. 
Foals were weaned when 23 - 24 weeks of age. Solid shading indicates samples were not available.  108 
Table 3.8.  Detection of EHV gB transcripts using single nested RT-CR assays on RNA extracted from PBL and NS collected from foals in Stable D. 
 
Age  of 
foal 
(weeks) 
PBL  NS 
F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11 
1  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
5+  -  -  -  -  -  -  -  -        -  -  -  -  -  -  -  -       
10  -  -                    -  -                   
14                  -  -  -                  -  -  - 
18      -  -  -  -  -  -            -  -  -  -  -  -       
22  -  -                    -  -                   
26                  -  V5  V5                  -  -  - 
30      -  -  V2  -  V5  V2            -  -  -  -  -  -       
34  -  -                    -  -                   
 
V2 indicates positive for EHV2; V5 indicates positive for EHV5. 
Foals were weaned 22 – 26 weeks of age. 
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3.3  Discussion 
There is minimal information of the distribution and prevalence of EHV2 and EHV5 in 
the horse population, principally because they have only relatively recently been 
recognised as 2 distinct species (Browning and Studdert, 1987b; Agius et al., 1992).  
Previous studies reported that EHV2 was extremely wide-spread, with infection rates 
based on isolation of virus from PBL and/or NS approaching or exceeding 80% in 
normal horses (Kemeny and Pearson, 1970) and horses with respiratory symptoms 
(Turner and Studdert, 1970; Studdert, 1971; Roeder and Scott, 1975; Blakeslee et al., 
1975; Palfi et al., 1978; Fu et al., 1986).  Recent prevalence studies, where the viruses 
have been clearly typed, demonstrated a high prevalence of EHV2 detected by PCR 
assay in horses with clinical signs of respiratory disease (Dunowska et al., 2002a, b; 
Nordengrahn et al., 2002), compared to previous results from healthy horses (Reubel et 
al., 1995); in these reports, the prevalence of EHV2 was consistently higher than that of 
EHV5.  In contrast, Wang (2003) and Wang et al. (2007) used multiplex PCR to 
simultaneously detect EHV2, EHV5, EHV1 and EHV4 in PBL and NS samples from 
foals and adult horses in Western Australia and reported that the prevalence of EHV2 
was significantly lower than that of EHV5 in both PBL and NS of clinically normal 
animals, although the prevalence of EHV2 was higher in some cohorts of foals with 
clinical signs of respiratory disease.  These observations that EHV5 was more common 
than EHV2 in the horses examined in Western Australia are clearly different to the 
prevalence of EHV2 and EHV5 reported elsewhere in the world, including the Eastern 
part of Australia (Reubel et al., 1995), New Zealand (Dunowska et al., 2002a, b), 
Sweden, Hungary and United Kingdom (Nordengrahn et al., 2002) as shown in Table 
3.9.   
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Table 3.9. The prevalence of EHV2 and EHV5 detected in PBL and/or NS samples from normal 
and diseased horses. 
 
Reference  Country  Health 
Status 
EHV2 (% prevalence)  EHV5 (% prevalence) 
Adult  Foal  Adult  Foal 
PBL  NS  PBL  NS  PBL  NS  PBL  NS 
Reubel et al. 
(1995) 
Australia 
 
Healthy   31  -  -  -  16  -  -  - 
Dunowska et 
al.  
(2002a, b) 
New 
Zealand 
 
After 
outbreak of 
respiratory 
disease 
76  -  -  -  3  -  -  - 
Nordengrahn 
et al. (2002) 
Sweden 
 
Annual 
occurrence 
of 
respiratory 
disease 
68  -  100  93  -  -  15  - 
Hungary 
 
Annual 
occurrence 
of 
respiratory 
disease 
-  -  100  93  -  -  -  - 
UK  -  71  -  100  93  24  -  -  - 
Wang (2003)   Australia 
Healthy 
>  2  years 
of age 
<  2  years 
of age 
>  2  years 
of age 
<  2  years 
of age 
PBL or NS  PBL or NS  PBL or NS  PBL or NS 
0  6.1  40  83.2 
    Respiratory 
disease 
- 
 
74.2  - 
 
83 
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It seems likely that the selection of the most appropriate technique for the detection of 
the equine gammaherpesviruses is critical, and one possibility for the high prevalence 
of EHV5 detected in Western Australia by Wang (2003) and Wang et al. (2007) relative 
to that detected elsewhere could be the multiplex PCR technique used by Wang 
(2003).  Reubel et al. (1995) demonstrated that the multiplex nested PCR assay was 
less sensitive than single-nested PCR, especially if the concentration of 2 different 
viruses in the reaction mixture was significantly different.  Virus with a higher 
concentration were amplified faster and/or more efficiently compared to virus with a 
lower concentration.  The virus present in higher concentration virus will be rapidly 
amplified and will use PCR reagents more effectively compared to the virus present in 
lower concentration leading, in effect, to preferential amplification of the virus present in 
greater concentration.  Reubel et al. (1995) reported that the limit of detection for EHV2 
plasmid DNA was reduced 10,000-fold using multiplex PCR assay for EHV2 and EHV5.  
They reported detection limits of a single PCR assay for EHV2 and EHV5 plasmid DNA 
of 0.6 fg and 2.3 fg, respectively, compared to detection limits for the multiplex PCR of 
6 pg for EHV2 and 2.3 fg for EHV5 (Wang, 2003). 
In the current study, similar to the observations of Reubel et al. (1995), when similar 
concentrations of EHV2 and EHV5 plasmid DNA were present, the PCR products of 
both EHV2 and EHV5 could be visualised following first and second round PCR 
reactions (Figure 3.5C).  The intensity of the observed EHV5 band was much brighter 
than that of the EHV2 band, indicating that, in the multiplex assay, amplification of 
EHV5 template was more efficient than EHV2.  When the same concentrations of 
EHV2 and EHV5 plasmid DNA were mixed together, the detection limit of the multiplex 
nested PCR for EHV2 and EHV5 was reduced 10-fold for EHV2 (9 fg) and 1000-fold for 
EHV5 (9 fg), compared to single-nested PCR for EHV2 (0.9 fg) and EHV5 (9 ag or   112 
0.009 fg) (Figure 3.5), respectively.  EHV5 amplification was more efficient than that of 
EHV2 in both the current study and in that of Reubel et al. (1995), even though a 
different part of the EHV5 genome was targeted for amplification: EHV5gB and 
EHV5TK, respectively.  Reubel et al. (1995) suggested that the EHV5 primers used by 
them had a stronger affinity for their templates than the EHV2 primers, leading to a 
more efficient amplification of EHV5 and ultimately resulting in a reduced production of 
EHV2 product due to reagent competition.  Based on these findings, it is likely that the 
chances of detecting EHV5 using the multiplex nested PCR are much higher than they 
are for EHV2, particularly if the concentration of EHV2 is lower than that of EHV5.  
The multiplex nested PCR of all EHV reported by Wang (2003) and Wang et al. (2007) 
detected as little as 0.1 fg of EHV1 and 1 fg of EHV2, EHV4, and EHV5, similar to the 
results reported by Reubel et al. (1995).  However, this sensitivity was obtained when a 
single type of EHV DNA was used in the multiplex PCR reaction and the limit of 
detection was not explored when multiple DNA templates were included in a single 
reaction, or when different concentrations of viral DNA were included.  It is probable 
that, as has been reported for other multiplex assays, sensitivity is decreased when 
multiple viruses are present and that EHV5 may have been preferentially identified, 
relative to small concentrations of EHV2.  Further vigorous optimisation of multiplex 
nested PCR assays should be conducted in future studies using various combinations 
of different primer concentrations. 
Another reason for the lower than expected prevalence of EHV2 in the Western 
Australian horse population may have been the primers used.  Direct comparison of the 
results of others is difficult as the primers used by Wang (2003) and Wang et al. (2007) 
and in the current study amplified regions of the gB gene and while the primers used by 
Reubel et al. (1995) for EHV2 also amplified a region of the gB gene but their primers   113 
for EHV5 amplified the TK gene.  Different regions of the EHV2 gB gene have been 
amplified: a product (810 bp) was amplified by Wang (2003) compared to a 113 bp 
product amplified by Reubel et al. (1995).  It is possible that the smaller sized PCR 
product may be amplified more efficiently than the larger PCR product, making the 
assay of Reubel et al. (1995) more sensitive.  
It is also possible that genomic heterogeneity of EHV2 may be involved.  Browning and 
Studdert (1987b) reported genomic heterogeneity of EHV2 isolates.  It is possible that 
some EHV2 strains may not be detected by the primer pairs used, and the use of 
conservative genes such as the TK gene would give greater sensitivity.  A study 
conducted in New Zealand (Dunowska et al., 2002a, b) with the same primer pairs as 
Reubel et al. (1995) reported that they were unable to amplify 6 herpesviruses isolates 
which were most likely to be EHV2.  A third set of EHV2 gB primers, designed by 
Dynon et al. (2001), amplified a completely different region of the EHV2 gB gene 
compared to the primers used by Wang (2003) and Reubel et al. (1995).  Comparison 
of the gB gene sequence of the prototype EHV2.86/67 with that of different EHV2 
isolates demonstrated at least 3 divergent EHV2 strains (Holloway et al., 1999) which 
would not be amplified by the primers designed by Reubel et al. (1995) or Wang 
(2003).  It is therefore possible that such strains are present in horses in Western 
Australia and contributed to the low prevalence reported (Wang, 2003; Wang et al., 
2007) but this limitation would apply equally to the results reported by Reubel et al. 
(1995) and it seems an unlikely explanation for the apparent discrepancy between the 2 
study populations on each side of Australia.  
Another possible explanation for the apparent discrepancy between the reports of 
Wang (2003) and Reubel et al. (1995) is that amplification of EHV5 gB seemed to occur   114 
more efficiently than amplification of EHV2 gB, using single or multiplex nested PCR 
(discussed above). 
The detection of EHV2 and EHV5 by PCR does not necessarily differentiate between 
lytic and latent virus infection, and it was therefore a possibility that the high prevalence 
of EHV5 detected in Western Australia might be due to the detection of latent virus in 
PBL rather than lytic virus replication.  As the multiplex nested PCR in this study and 
shown previously by Reubel et al. (1995) to be less sensitive than the single nested 
PCR, a single nested RT-PCR assay for the detection of RNA transcripts of the (gB) 
structural proteins of EHV2, EHV5, EHV1 and EHV4 was selected as a method to 
detect lytic replication of these viruses and differentiate this from latent infections.  It is 
well known that different combinations of RT-PCR methodology have significant impact 
on assay outcomes and there are 3 formats for RT-PCR assays: 1 tube-1 step, 1 tube-
2 step, and 2 tube-2 step protocols.  The 1-tube-1 step protocol provides convenience, 
sensitivity, and improved contamination control. However, it is difficult to optimise both 
RT and PCR conditions because all reagents are mixed before starting the reaction.  
The 1 tube-2 step protocol requires performing RT first, then adding PCR mix to the 
entire RT reaction. This protocol allows us to optimise both RT and PCR conditions 
separately, and thus potentially maximise sensitivity. In this study, the 1 tube 2-step 
RT-PCR (nested) assay was 100-fold more sensitive than the conventional single 
nested PCR for EHV2, and could detect as little as 9 ag EHV2 transcript compared to 
0.9 fg EHV2 plasmid DNA.  The sensitivity of the single nested RT-PCR assay for 
EHV5 was no different to that of the single nested PCR, as both assays detected as 
little as 9 ag EHV5 transcript and plasmid DNA, respectively.  However, the EHV5 
single nested RT-PCR assay was able to detect 9 ag of the EHV5 transcript more   115 
efficiently and consistently than the EHV5 single nested PCR assay was able to detect 
9 ag of EHV5 plasmid DNA (data not shown).  
The current study supports that there was a high prevalence of EHV5 in normal healthy 
horses in Western Australia, as previously reported by Wang (2003) and Wang et al. 
(2007).  The results also indicate that lytic replication of EHV5 occurs in PBL, which 
may be the main reservoir of infection.  However, the clinical significance of the high 
prevalence of EHV5 in equine populations in Western Australia requires further 
evaluation. Active replication of EHV2 and EHV5 in PBL in young foals, some as young 
as 2 weeks and 9 days of age, respectively, was detected sporadically and transiently, 
and it was detected overwhelmingly in PBL rather than in NS.  The prevalence of EHV2 
and EHV5 increased post-weaning, presumably in association with stress, suggesting 
that the weaned foals may have been infected latently prior to weaning, and at this 
period these viruses were also present as a lytic virus replication in NS.  While 
simultaneous active replication of EHV2 and EHV5 was, on occasion, associated with 
clinical signs of respiratory disease (Stables B and C), the detection of EHV5 alone by 
nested RT-PCR was at no time associated with clinical abnormalities of any kind.  
The detection of both EHV2 and EHV5 in young foals is similar to results reported 
previously by Bell et al. (2006) in California.  They reported that foals were usually 
infected later in life with EHV5 than with EHV2 but this difference was not apparent 
during the current study. They were further able to genetically characterise individual 
isolates and determine that the strains of EHV2 shed in the NS of 1-month old foals 
were identical to those infecting their dams, whereas older foals often shed virus that 
were different from those of their dams.  
Further phylogenetic relationships of strain of EHV2 and EHV5 detected in this study 
should be performed to further substantiate whether active replication of EHV2 and   116 
EHV5 was derived from reactivation of latent virus or re-infection with new strains of 
virus.  If the genotypes detected intermittently in young foals were the same as those 
detected post-weaning, this would provide further evidence of latency. 
The number of adult animals examined was only 13, as this current study was primarily 
a study of the development of infection in young animals and to determine if stressors 
associated with weaning were responsible for an increase in the prevalence of equine 
herpesvirus infection, but the results in the adult horses indicated that the prevalence of 
EHV5 detected was greater than that of EHV2, and further indicated that the viruses 
were undergoing lytic virus infection and were not associated with latent virus infection 
only.  Whether additional animals were infected latently was not determined (and 
attempts to determine this were the subject of a study reported in Chapter 5).  
Not only was the overall prevalence of EHV5 infection greater than that of EHV2, the 
prevalence of EHV2 infection was greater in young animals than in older animals.  
Similarly, Wang (2003) detected a higher prevalence of EHV2 in younger horses.  The 
detection of lytic EHV2 replication in PBL of young foals, as early as 2 weeks, is 
comparable to the findings reported by Dunowska et al. (2002b) and Nordengrahn et al. 
(2002), who detected EHV2 DNA in PBL of foals as young as 2 weeks and 4 to 6 
months of age, respectively.   
The prevalence of EHV5 detected was also greater in older animals, similar to previous 
observations by Wang (2003) and others.  Nordengrahn et al. (2002) reported that 
EHV5 was not evident in foals until 5 to 10 months of age, but suggested that this could 
be associated with the sensitivity of their EHV5 PCR which, in contrast to the technique 
described in this study, was ten-times less sensitive than the EHV2 PCR.  Bell et al. 
(2006), using a non-nested PCR assay (a less sensitive PCR method), also detected a 
greater prevalence of EHV5 infection in animals more than 6 months of age.   117 
Another observation regarding EHV5 infection was that EHV5 produced a transient lytic 
infection in PBL of young foals but tended to produce a persistent lytic infection of PBL 
in older foals and adults (Tables 3.4 and 3.5).  Infection of PBL by EHV5 especially in 
adult mares was sometimes, but not always, associated with a persistent lytic infection 
(Table 3.4) for ≥37 weeks duration and this has not been reported previously.  The 
persistent lytic infection of PBL was not associated with the detection of virus in NS.  It 
was noted also that the mares with persistent lytic infection of PBL with EHV5 did not 
transfer the infection to their foals (Tables 3.4 and 3.5).   
EHV1 and EHV4 was not detected in the mares and foals examined although it is 
possible that that sub-clinical or latent infections may not have been detected.  The 
frequency of sampling (every 4 weeks for Stables B, C and D) may also have been 
inadequate as in Group 1 in Stable A, which were infected with EHV1, the infections 
was detected only transiently and never for more than a 2-week period.  Concurrent 
use of serological tests may have been useful to exclude the possibility of unrecognised 
EHV1 or EHV4 disease.  Future studies should concentrate on the development and 
application of quantitative PCR and/or quantitative RT-PCR techniques to provide a 
more sensitive diagnostic tool for characterisation of EHV1 and EHV4 infections.  The 
establishment of quantitative RT-PCR for EHV1 and EHV4 LAT genes (gene 63 and 
64) would also provide a useful means of further characterising the epidemiology of 
disease caused by EHV1 and EHV4.    118 
Chapter 4 
Detection of latent Equine herpesvirus 1 and Equine 
herpesvirus 4 infections in tissues of naturally infected horses  
 
4.1 Summary  
An examination for (RNA) transcripts of genes 63 and 64 of EHV1 and EHV4, putative 
latency-associated transcripts (LAT) of EHV, was undertaken in horses. Tissues 
examined included PBL of 13 clinically normal horses (5 mares and 8 foals) in which 
EHV1 and EHV4 gB DNA and gB RNA transcripts could not be detected. They also 
included the trigeminal ganglia, retropharyngeal, submandibular, bronchiolar and 
mandibular lymph nodes of 5 horses killed for reasons not associated with the 
occurrence of respiratory disease. 
EHV1 infection was detected in PBL and bronchiolar lymph nodes.  In the PBL, EHV1 
gene 64 RNA transcripts were detected in 3 (all foals) of the 13 horses examined but 
RNA transcripts of EHV1 gene 63 were not detected. EHV1 gB DNA was detected in 
the bronchiolar lymph node of 2 of 5 horses examined, and in these same lymph nodes 
EHV1 gene 64 (but not gene 63) RNA transcripts were also detected, indicating latent 
virus infection.  
EHV4 infection was detected in the trigeminal ganglia only and there was no evidence 
of EHV4 infection in the lymph nodes of the 5 horses examined.  In PBL, neither EHV4 
gene 64 nor gene 63 RNA transcripts were detected in the 13 horses. In the trigeminal 
ganglion, EHV4 gB DNA and gene 63 RNA transcripts were detected in 2 of 5 horses, 
but EHV4 gB RNA transcripts were not detected.  Consistent with published studies,   119 
the EHV4 gene 63 transcript was antisense orientated when a strand-specific RT-PCR 
was applied. 
The detection of RNA transcripts of genes 64 and 63 of EHV1 and EHV4, respectively, 
in tissue in the absence of transcripts of the structural gB supports previous studies 
indicating that transcripts of genes 63 and 64 may represent LAT. The presence of 
RNA transcripts of EHV1 gene 64 in PBL and lymph node in the absence of any 
evidence of the replication of structural proteins suggests PBL and lymph node are 
sites of EHV1 latent infections. The presence of EHV4 gene 63 transcripts in trigeminal 
ganglia in the absence of any evidence of replication of structural proteins suggests the 
trigeminal ganglion is the major site of latency of EHV4.  
 
4.2 Introduction 
Most herpesviruses, including Marek's disease virus (MDV), Bovine
 herpesvirus type 1 
(BHV1), Pseudorabies virus (PRV), Feline
 herpesvirus type 1 (FHV1) and Human 
herpes simplex virus
 types 1 and 2 (HSV1, HSV2) establish latency in neural tissues, 
mainly in the
 trigeminal ganglion (Gaskell et al., 1985; Rock et al., 1986 and 1987; 
Cheung, 1989; Mitchell et al., 1990; Ohmura et al.,
 1993; Slater et al., 1994), although 
MDV
 is T-cell tropic (Cantello et al., 1994; Li et al., 1994) and 
 EHV1 and PRV seem to 
be both neurotropic and lymphotropic (Ohlinger
 et al., 1987; Welch et al., 1992; Slater 
et al., 1994; Edington
 et al., 1994; Chesters et al., 1997; Smith et al., 1998).
  
The detection and differentiation of latent virus infection and active virus replication is 
important in studies of the pathogenesis of these diseases.  The detection of viral DNA 
by PCR, a common diagnostic method, does not offer any indication of whether the 
virus detected is active or latent infection.  The detection of LATs potentially offers a   120 
method of determining latent infection, as these are the only detectable viral RNA in 
latently infected cells, and in the absence of transcripts encoding the structural virus 
proteins they would enable identification of infection as latent. The identification of LATs 
of many herpesviruses has been documented and the majority of the alphaherpesvirus 
LATs studied
 to date are transcribed from IE genes. LATs have been reported for latent 
MDV-infection of T-lymphocytes (Shek et al., 1983) and for latently HSV1-infected
 
neurons (Stroop et al. 1984). Spivack et al. (1991) and Wagner and Bloom (1997) have 
characterised HSV1 LATs as a major 2 kb LAT and a smaller 1·5 kb transcript. The 2 
kb LAT is a stable intron derived from the processing of an 8·3 kb
 primary transcript 
(mLAT) (Farrell et al., 1994) and is complementary
 to the HSV1 IE gene ICP0, partially 
overlapping
 the 3' end of the corresponding transcript (Rock et al., 1987; Dobson et al., 
1989). RNA antisense to gene ICP0 has also been detected for HSV2 and BHV1 
(Kutish et al., 1990; Tenser
 et al., 1991; reviewed in Jones, 1998), while PRV, MDV and
 
FHV1 express transcripts derived from gene ICP4, another IE
 gene (Cheung, 1989, 
1991; Li et al., 1994; Cantello et al.,
 1994; Kawaguchi et al., 1994).  
The equine herpesvirus LATs are less defined although some information is available. 
In the case of EHV1, gene 64- (homologous to HSV1 gene ICP4) specific putative
 LATs 
were detected in PBL and bronchiolar lymph nodes (Chesters
 et al., 1997). EHV1 gene 
63 (HSV1 ICP0 gene homologue)
 putative LATs were detected in trigeminal ganglia 
(Baxi et al., 1995; Borchers et al., 1999c).  Latent EHV4 infections, defined as the 
presence of EHV4 gB DNA derived from co-cultured samples, were reported in PBL 
and lymph nodes of the respiratory tract by Welch et al. (1992) and Edington et al. 
(1994). The presence of EHV4 DNA in the absence of transcription of EHV4 gB was 
used to define EHV4 latency by Borchers et al. (1997b).  Borchers et al. (1999b) 
subsequently identified the presence of both EHV4 DNA and transcripts of both gene   121 
64 and 63 (putative LATs for EHV4) in the trigeminal ganglia of horses naturally 
infected with EHV4. They suggested that EHV4 is likely to be latent in the trigeminal 
ganglia, and possibly also lymphatic tissue of the respiratory tract and circulating 
lymphocytes. No information is available regarding latency of the equine 
gammaherpesviruses. 
The aim of the current study was to determine if transcripts of gene 63 and 64 of EHV1 
and EHV4 could be detected in tissues of horses and to confirm that the detection of 
these transcripts appeared to identify latent virus infection and the location of such 
latent virus infection.  
 
4.3 Materials and methods 
4.3.1 Virus and cell culture 
The reference strains of EHV1 and EHV4, previously described in Chapter 3, were 
used in this Chapter. 
4.3.2 Horses and samples 
RNA extracted from PBL samples (Table 4.1) from 13 horses (5 mares and 8 foals) 
collected during the epidemiological studies reported in Chapter 3, were used for the 
detection of virus transcripts and RNA samples extracted post-mortem from 5 horses 
(Table 4.2) euthanased for conditions unrelated to the respiratory tract were also used. 
Samples from these horses were collected by excision biopsy of the trigeminal ganglion 
(TG), mandibular, submandibular, retropharyngeal and bronchiolar lymph nodes. The 
tissue samples were washed with cold PBS, snap frozen in liquid nitrogen and kept at -
80ºC.     122 
RNA and DNA were extracted as previously described in Chapter 3. 
 
 
Table 4.1. PBL and NS derived from clinically healthy horses, some of which had been 
experimentally infected with EHV1 prior to sampling.  These were the same mares and foals 
examined from Stable A in Chapter 3. 
 
Animal    Age 
Mare 1  360  Adult 
Foal 1  360A  2 mo 
Foal 2  362A  2 mo 
Mare 6  369  Adult 
Foal 6  369A  4 mo 
Foal 12*  365A  3mo 
Mare 5  368A  Adult 
Foal 10*  361A  5 mo 
Foal 11*  363A  6 mo 
Mare 7  375  Adult 
Foal 7  375A  8 mo 
Foal 4  366A  7 mo 
Mare 4  366  Adult 
 
* denotes foals that were experimentally infected with EHV1 prior to sampling. 
** denotes a foal that was naturally infected prior to sampling. 
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Table 4.2. Necropsy samples collected from horses euthanased for problems not related to 
disease of the respiratory tract. 
 
Horse  Tissue  Clinical signs 
1  TG  Ataxia 
  BLN   
  SMLN   
  MLN   
  RPLN   
2  TG  Colic 
  BLN   
  SMLN   
  MLN   
  RPLN   
3  TG  Ataxia 
  BLN   
  SMLN   
  MLN   
  RPLN   
4  TG  Normal 
  BLN   
  SMLN   
  MLN   
  RPLN   
5  TG  Normal 
  BLN   
  SMLN   
  MLN   
  RPLN   
 
TG, trigeminal ganglia; BLN, bronchiolar lymph node; SMLN, submandibular lymph node; MLN, 
mediastinal lymph node; RPLN, retropharyngeal lymph node.  
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4.3.3 DNA and cDNA cloning and sequencing 
Methods of cloning and sequencing described in Chapter 3 were applied to EHV1 and 
EHV4 positive controls, as well as to PBL and necropsy samples that tested positive to 
EHV1 and EHV4 LATs.  
4.3.4 Conventional PCR 
4.3.4.1 Primers  
Nested primers for detection of EHV1 and EHV4 gB DNA were as previously described 
in Chapter 3. The primers used are shown in Table 4.3.  
 
 
Table 4.3. Nucleotide sequence of primers and products used in the first and second rounds of 
the nPCR for EHV1 and EHV4 gB.  
 
  Primer  Sequence (5'-3')  Gene 
specificity 
Location  Predicted amplicon 
size (bp) 
First 
round 
primers 
EHV1 FC2  CTTGTGAGATCTAACCGCAC  EHV1 gB  62427  1181 
EHV1 RC  GGGTATAGAGCTTTCATGGG    63607   
EHV4 FC2  CTTGTGAGATCTAACCGCAC  EHV4 gB  61737  1175 
EHV4 RC  GGGTATAGAGCTTTCATGGG    62911   
Second 
round 
primers 
EHV1 FC3  ATACGATCACATCCAATCCC  EHV1 gB  62699  188 
EHV1 R1  GCGTTATAGCTATCACGTCC    62886   
EHV4 FC3  ATACGATCACATCCAATCCC  EHV4 gB  62003  677 
EHV4 R4  CCTGCATAATGACAGCAGTG    62679   
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4.3.4.2 PCR conditions 
PCR conditions described in Chapter 3 were used in this Chapter to detect EHV1 and 
EHV4 DNA in necropsy samples. DNA samples from PBL were analysed by a 
colleague (Pizzirani, unpublished).  
4.3.5 RT-PCR 
4.3.5.1 Primers 
Primers used in the conventional nested PCR assay (Chapter 3) were used in a nested 
RT-PCR assay for the detection of EHV1 and EHV4 gB transcripts. The nested primers 
for genes 63 and 64 of EHV4 were those described previously by Borchers et al. 
(1999b). Primers for EHV1 were based on specific regions of EHV1 gene 63 (Baxi et 
al., (1995) and gene 64 (Chesters et al., 1997) which were reported to be transcribed 
during latent infection. Primer Design and Amplify 2.1 programs (Bio-Rad Australia) 
were used to design primers, utilising sequence data available in the Genbank 
database. Primers used are shown in Table 4.4. The  -actin primer used in Chapter 3 
was used to normalise all RT-PCR results.  
The genomic localisation and location of different primer pairs of the predicted EHV1 
transcripts by nPCR and nRT-PCR is shown in Table 4.1. The 150 kbp EHV1 DNA 
consists of 2 unique regions (UL and US) flanked by 2 repeats (IRS and TRS). Gene 33 
(gB) is located within the US region, while the 2 EHV1 LATs are located within IRS 
region. The gB primers were predicted to amplify the region located between nt 62427 
and 63607 for the first, and 62699 and 62886 for the second round PCR. Gene 63 and 
64 primers were predicted to amplify the region located between nt 109711 and 
110937, and 113920 and 114383, for the first round PCR, and 110091 and 110772, 
and 113920 and 114231, for the second round PCR, respectively. The first round   126 
product for gB was predicted to be 1181 bp and the second round product 188 bp. First 
and second round products for gene 63 and 64 were predicted to be 1227 bp and 464 
bp, and 682 bp and 312 bp, respectively.  
The genomic localisation of the predicted EHV4 transcripts by nPCR and nRT-PCR is 
shown in Figure 4.2. Similar to EHV1, the 150 kbp EHV4 DNA consists of unique 
regions (UL and US) flanked by 2 repeats (IRS and TRS). Gene 33 (gB) is located within 
the US region, while the 2 EHV4 LATs are located within the IRS region. The gB primers 
were predicted to amplify a region located between nt 61737 and 62911 for the first, 
and between 62003 and 62679 for the second round PCR. Gene 63 and 64 primers 
amplified regions located between nt 110479 and 111010, and 113955 and 115062, for 
the first round PCR, and 110504 and 110756, and 114059 and 114558, for the second 
round PCR, respectively. The first round product for gB was predicted to be 1175 bp 
and the second round product 677 bp. First and second round products for gene 63 
and 64 were predicted to be 532 bp and 253 bp, and 1108 bp and 500 bp, respectively.  
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Table 4.4. Nucleotide sequence of primers and products used in the first and second rounds of 
the nRT-PCR for LATs of EHV1 and EHV4. 
 
  Primer  Sequence (5'-3')  Gene 
specificity 
Location  Predicted 
amplicon size 
(bp) 
First 
round 
primers 
EHV1 63F1  GCTTGGTATTGGTGGTGATG  EHV1 gene 63  109711  1227 
EHV1 63R1  TACAAGCTCAAACTCTGCAA    110937   
EHV1 64F1  GGCAGACATGTGAGCAATAA  EHV1 gene 64  113920  464 
EHV1 64R1  GGGTTCGGCTCTCGCTCCAC    114383   
EHV4 63F1  GGGGCAAGGGCTCTAAACCT  EHV4 gene 63  110479  532 
EHV4 63R1  CAGGAGACACCAGCAACGAC    111010   
EHV4 64F1  GGAGACCGCGTCCAGCACTA  EHV4 gene 64  113655  1108 
EHV4 64R1  CTCCGAGGGAAGCCAGACCT    115062   
Second 
round 
primers 
EHV1 63F2  CTGCAGGTGCAGTGGTTCCC  EHV1 gene 63  110091  682 
EHV1 63R2  GGCACCGCGAGACAGCTCCA    110772   
EHV1 64F1  GGCAGACATGTGAGCAATAA  EHV1 gene 64  113920  312 
EHV1 64R2  CGCCGCGCTCCCATCAAGAT    114231   
EHV4 63F2  CAAACTCCCGCAGGTTGTATC  EHV4 gene 63  110504  253 
EHV4 63R2  ACTTTGGACAGCGAGGGTGAA    110756   
EHV4 64F2  GGACCCCCTGGGCGTTGAGG  EHV4 gene 64  114059  500 
EHV4 64R2  CCGCGGAGACTGCCACACTC    114558   
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Figure 4.1. EHV1 genomic structure and location of different primer pairs. EHV1 DNA is 150 kbp 
in size and consists of 2 covalently linked molecules, the unique long (UL) and unique short (US) 
regions. US is flanked by large repeats (IRS and TRS). The location and size of the amplification 
products of EHV1 gene 33-specific nPCR are given in relation to ORF33 (a). Two LAT 
fragments by nRT-PCR are shown in relation to ORF63 and ORF64 (b). The orientation of the 
nPCR primers and the mRNA of ORF33, ORF63 and ORF64 are indicated by arrows. 
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Figure 4.2. EHV4 genomic structure and the location within the genome of different primer pairs. 
EHV4 DNA is 150 kbp in size and consists of 2 covalently linked molecules, the unique long (UL) 
and unique short (US) regions. US is flanked by large repeats (IRS and TRS). The location and 
size of the amplification products of EHV4 gene 33-specific nPCR are given in relation to ORF33 
(a). Two LAT fragments by nRT-PCR are shown in relation to ORF63 and ORF64 (b). The 
orientation of the nPCR primers and the mRNA of ORF33, ORF63 and ORF64 are indicated by 
arrows. (Modified from Borchers et al., 1999b).  
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4.3.5.2 RT-PCR conditions 
Synthesis of cDNA and nested PCR (nPCR) reactions were performed as described in 
Chapter 3. The cycling conditions following cDNA synthesis for EHV1 gB, gene 63 and 
64, and EHV4 gB and gene 63 were the same. Briefly, following an initial denaturing 
step (3 minutes at 94ºC), 35 amplification cycles were performed consisting of 
denaturing at 94ºC at 30 seconds, annealing at 58ºC at 30 seconds and extension at 
72ºC for 1 minute. Cycling conditions for EHV4 gene 64, were as described by 
Borchers et al. (1999b) and consisted of an initial denaturing step (3 minutes at 96ºC), 
and then 35 amplification cycles of denaturing at 96ºC for 30 seconds, annealing at 
64ºC for the first round primer (60ºC for the second round primer) for 30 seconds and 
extension at 72ºC for 1 minute.  
4.3.5.3 RT-PCR for determination of the orientation of viral transcripts  
To define the orientation of EHV1 and EHV4 LAT transcripts, virus DNA-free RNA 
prepared from EHV1 and EHV4 positive samples subsequent to the corresponding 
nPCR was converted to cDNA using individual reverse transcription reactions with 
either sense or antisense primers (Figures 4.1 and 4.3) for gene 63 and gene 64. The 
reverse transcription procedure was performed as described in Chapter 3. 
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4.4 Results 
4.4.1  Detection of EHV1 putative LAT transcripts (of EHV4 gene 63 and 
gene 64) in virus-infected cell cultures 
EHV1 gB, gene 63 and gene 64 transcripts, were successfully amplified by nRT-PCR 
from RNA extracted from EHV1 infected cell cultures (Figure 4.3). EHV4 gB, and gene 
63 transcripts were also amplified by nRT-PCR from RNA extracted from EHV4 
infected cell cultures (Figure 4.4). EHV4 gene 64 transcripts were not amplified from 
RNA extracted from EHV4 infected cell cultures when the same PCR cycling conditions 
were used to amplify the product as were used to amplify the EHV1 gene 64 transcript.  
However, EHV4 gene 64-specific transcripts were detected (Figure 4.5) in RNA 
preparations from infected cell cultures obtained by nested RT-PCR when cycling 
conditions were optimised for this reaction; the first round RT-PCR product was difficult 
to discern, but the nested RT-PCR clearly yielded product of the predicted size. 
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Figure 4.3. Nested RT-PCR reaction products from RNA extracted from EHV1-infected cell 
cultures. A, first round products; B, second round reaction products. Lane 1A, 1 kb ladder; lane 
1B, 100 bp ladder; lane 2, EHV1 gB +RT; lane 3 EHV1 gB -RT; lane 4, EHV1 gene 63 +RT; lane 
5, EHV1 gene 63 -RT; lane 6, EHV1 gene 64 +RT; lane 7, EHV1 gene 64 -RT; lane 8A, 100 bp 
ladder; lane 8B, 1 kb ladder.  
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Figure 4.4. Nested RT-PCR reaction products from RNA extracted from EHV4-infected cell 
cultures. A, first round products; B, second round reaction products. Lane 1A, 1 kb ladder; lane 
1B, 100 bp ladder; lane 2, EHV4 gB +RT; lane 3, EHV4 gB -RT; lane 4, EHV4 gene 63 +RT; 
lane 5, EHV4 gene 63 -RT; lane 6, shows no RT-PCR product of EHV4 gene 64 when the same 
PCR condition used for gB and gene 63 was used; lane 8A, 100 bp ladder.  
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Figure 4.5. Nested RT-PCR reaction products from RNA extracted from EHV4-infected cell 
cultures using conditions optimised for the amplification of EHV4 gene 64 RNA transcripts. Lane 
1,100 bp ladder; lane 2, EHV4 gene 64 first round product; lane 3, EHV4 gene 64 control 
(without RT) reaction; lane 4, EHV4 gene 64 second round product; lane 5, EHV4 gene 64 
control (without RT) second round product; lane 6, dH2O.  
 
 
4.4.2 Detection of EHV1 RNA transcripts in tissues of horses 
PBL samples from 13 mares and foals that were negative for EHV1 gB DNA (Pizzirani, 
unpublished) and gB RNA transcripts were examined for EHV1 gene 63 and gene 64 
transcripts.  EHV1 gene 64 transcripts were detected in PBL of 3 foals. None of the 
PBL samples were positive for gene 63 transcripts (Table 4.5). Figure 5.6 shows the 
EHV1 gene 64 transcript amplified from the PBL of foal 6 (lane 9) and from EHV1-
infected cell cultures (lane 2). The specificity of the gene 64 transcript was confirmed by 
sequence analysis, which demonstrated greater than 98% identity with the published 
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sequence of EHV1 strain V592. In addition to the EHV1 gene 64 transcript product of 
312 bp there were also amplified products of approximately 350 bp, 290 bp and 150 bp 
in some PBL samples (Figure 4.7) but sequence analyses suggested that these were 
ribosomal RNA (with 70% identity to ribosomal RNA). As a control, RT enzyme was 
omitted from the reaction mix to ensure that the band amplified was not derived from 
genomic DNA contamination (lanes 3 and 5, Figure 4.7).  
 
Table 4.5.  Nested PCR and nested RT-PCR results for the detection of EHV1 gene products in 
PBL derived from 13 clinically normal horses. 
 
Animal    Age  nPCR 
EHV1 
gB 
nRT-PCR 
      EHV1 
gene 63 
EHV1 
gene 64 
EHV1 
gB 
-actin 
Mare 1  360  Adult  -  -  -  -  + 
Foal 1  360A  2 mo  -  -  -  -  + 
Foal 2  362A  2 mo  -  -  -  -  + 
Mare 6  369  Adult  -  -  -  -  + 
Foal 6  369A  4 mo  -  -  +  -  + 
Foal 12  365A  3mo  -  -  -  -  + 
Mare 5  368A  Adult  -  -  -  -  + 
Foal 10  361A  5 mo  -  -  -  -  + 
Foal 11  363A  6 mo  -  -  +  -  + 
Mare 7  375  Adult  -  -  -  -  + 
Foal 7  375A  8 mo  -  -  -  -  + 
Foal 4  366A  7 mo  -  -  +  -  + 
Mare 4  366  Adult  -  -  -  -  + 
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Figure 4.7. Nested RT-PCR reaction products amplified from foal PBL samples using EHV1 
gene 64 primers. Lane 1, 100 bp ladder; lane 2, EHV1 positive control; lane 3, foal 3; lane 4, foal 
4; lane 5, foal 5; lane 6, foal 7; lane 7, foal 8; lane 8, foal 10; lane 9, dH2O. Bands of 
approximately 350 bp, 290 bp and 150 bp, evident in lanes 3 to 7, were determined by 
sequence analysis to be ribosomal RNA. 
 
4.4.3  Detection of EHV1 RNA transcripts in lymph nodes and trigeminal 
ganglia of necropsied horses 
Results of examination for EHV1 gB, gene 63 and gene 64 RNA transcripts and gB 
DNA in the tissues of the 5 horses that were necropsied are shown in Table 4.6. The 
predicted EHV1 gB DNA product of 312 bp was detected in the bronchiolar lymph 
nodes from 2 of 5 horses (horses 1 and 3) as shown in Figure 4.8.  Both of these 
horses had clinical signs of ataxia associated with cervical vertebral malformations. All 
samples were further analysed for the presence of the gB and gene 63 and 64 EHV1 
transcripts, irrespective of whether gB DNA could be detected. Gene 64 transcripts of 
the predicted size of 312 bp but no other transcripts were also detected in the 
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bronchiolar lymph nodes of the same 2 horses in which gB DNA was detected. 
Sequence analysis confirmed specificity of the band and revealed that it had more than 
98% identity with the published sequence of EHV1 strain V592. RT-PCR products of 
250 bp and 150 bp were also observed in the trigeminal ganglion (lane 2) and 
submandibular lymph node (lane 3), and retropharyngeal lymph node (lane 4), 
respectively (Figure 4.8) but sequence analyses demonstrated that these products had 
70% identity to rRNA.   138 
Table 4.6. Nested PCR and nested RT-PCR results for the detection of gB DNA and gB 
transcripts, and nested RT-PCR for the detection of RNA transcripts of genes 63 and 64 from 
tissues of 5 horses which were euthanased for reasons unrelated to respiratory problems. 
 
Animal  Tissue  Clinical 
signs 
nPCR  nRT-PCR 
      gB  Gene 63  Gene 64  gB  -actin 
Horse 1  TG  Ataxia  -  -  -  -  + 
  BLN    +  -  +  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
Horse 2  TG  Colic  -  -  -  -  + 
  BLN    -  -  -  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
Horse 3  TG  Ataxia  -  -  -  -  + 
  BLN    +  -  +  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
Horse 4  TG  Normal  -  -  -  -  + 
  BLN    -  -  -  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
Horse 5  TG  Normal  -  -  -  -  + 
  BLN    -  -  -  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
 
TG, trigeminal ganglia; BLN, bronchiolar lymph node; SMLN, submandibular lymph node; MLN, 
mediastinal lymph node; RPLN, retropharyngeal lymph node.    139 
 
 
 
 
Figure 4.8. Nested RT-PCR reaction products using EHV1 gene 64 primers amplified from 
necropsy samples of Horse 1. Lane 1, 100 bp ladder; lane 2, trigeminal ganglion; lane 3, 
submandibular lymph node; lane 4, retropharyngeal lymph node; lane 5, bronchiolar lymph 
node; lane 6, mandibular lymph node; lane 7, EHV1 positive control; lane 8, dH2O. Lanes 5 and 
7 are EHV1 gene 64 transcript. Lanes 2, 3 and 4 are rRNA. 
 
Retrospective attempts to determine the orientation of the EHV1 gene 64 transcript 
were made after storage of the samples (Figure 4.9) but the transcripts were difficult to 
re-amplify. Re-amplification of the EHV1 gene 64 transcript from a bronchiolar lymph 
node using EHV1 gene 64 sense primers for cDNA synthesis, was unsuccessful (lane 
2) but synthesis of EHV1 gene 64 cDNA using an antisense primer resulted in a 350 bp 
PCR  product  (lane  3).  In  contrast,  EHV1-infected  cell  cultures  demonstrated 
transcription of EHV1 gene 64 in both sense and antisense orientations (lanes 5 and 6). 
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Figure 4.9. Orientation of viral EHV1 gene 64 transcript. Primer 1 (EHV1 gene 64 F1) or 2 
(EHV1 gene 64 R1) from the nPCR specific for EHV1 gene 64 was used in individual reactions 
for reverse transcription of total RNA preparations from equine bronchiolar lymph node (BLN) 
and acutely infected cell culture. Lane 1, 100 bp ladder; lane 2, cDNA synthesised from BLN 
with primer 1; lane 3, cDNA synthesised from BLN with primer 2; lane 4, dH2O; lane 5, cDNA 
synthesised from EHV1-infected EKS with primer 1; lane 6, cDNA synthesised from EHV1-
infected EKS with primer 2; lane 7; dH2O. 
 
 
4.4.3 Detection of EHV4 transcripts in tissues of horses  
None of the PBL samples collected from a total of 13 mares or foals was positive for 
either EHV4 gB DNA (from Pizzirani, unpublished) or EHV4 gB, gene 63 or gene 64 
RNA transcripts (Table 4.7). EHV4 infection was, however, detected in some of the 
tissue samples from the 5 necropsied horses (Table 4.8). Two of 5 trigeminal ganglia 
(from horses 1 and 2) were positive for EHV4 DNA: one of these horses (horse 1) was 
euthanased for clinical signs of ataxia and the other (horse 2) was euthanased because 
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of colic. The trigeminal ganglia that were positive for EHV4 DNA were also positive for 
EHV4 gene 63 transcripts resulting in an amplification product of the predicted 532 bp 
size (Figure 4.10) but other transcripts of gB or gene 64 were not detected in any of the 
tissues. Sequence analyses confirmed the identity of the predicted 532 bp product 
which had greater than 98% identity with the published EHV4 strain NS80567 gene 63 
sequence.   
 
Table 4.7. Nested PCR and nested RT-PCR results from PBL samples from clinically normal 
healthy horses.  No evidence of EHV1 infection was detected in any sample. 
 
Animal  Age  nPCR  nRT-PCR 
    EHV4 
gB 
DNA 
EHV4 
gene  63 
transcript 
EHV4 
gene  64 
transcript 
EHV4 
gB 
transcript 
-actin 
transcript 
Mare 1  Adult  -  -  -  -  + 
Foal 1  2 mo  -  -  -  -  + 
Foal 2  2 mo  -  -  -  -  + 
Mare 6  Adult  -  -  -  -  + 
Foal 6  4 mo  -  -  -  -  + 
Foal 12  3 mo  -  -  -  -  + 
Mare 5  Adult  -  -  -  -  + 
Foal 10  5 mo  -  -  -  -  + 
Foal 11  6 mo  -  -  -  -  + 
Mare 7  Adult  -  -  -  -  + 
Foal 7  8 mo   -  -  -  -  + 
Foal 4  7 mo  -  -  -  -  + 
Mare 4  Adult  -  -  -  -  + 
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Table 4.8.  nPCR and nRT-PCR results from 5 naturally EHV4-infected horses with different 
clinical signs. 
 
Animal  Tissue  Clinical 
signs  nPCR  nRT-PCR 
      gB 
DNA 
Gene  63 
transcript 
Gene  64 
transcript 
gB 
transcript 
-actin 
Horse 1  TG  Ataxia  +  +  -  -  + 
  BLN    -  -  -  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
Horse 2  TG  Colic  +  +  -  -  + 
  BLN    -  -  -  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
Horse 3  TG  Ataxia  -  -  -  -  + 
  BLN    -  -  -  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
Horse 4  TG  Normal  -  -  -  -  + 
  BLN    -  -  -  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
Horse 5  TG  Normal  -  -  -  -  + 
  BLN    -  -  -  -  + 
  SMLN    -  -  -  -  + 
  MLN    -  -  -  -  + 
  RPLN    -  -  -  -  + 
 
TG, trigeminal ganglia; BLN, bronchiolar lymph node; SMLN, submandibular lymph node; MLN, 
mediastinal lymph node; RPLN, retropharyngeal lymph node.    143 
 
 
 
 
Figure 4.10.  Nested RT-PCR reaction products of EHV4 gene 63 transcript from necropsy 
samples of Horse 1. A, first round products; B, second round reaction products. Lane 1, 100 bp 
ladder; lane 2, trigeminal ganglion; lane 3, submandibular lymph node; lane 4, retropharyngeal 
lymph node; lane 5, bronchiolar lymph node; lane 6, mandibular lymph node; lane 6, EHV4 
positive control; lane 8, dH2O. The trigeminal ganglion contained EHV4 gene 63 transcripts 
(lane 2): Panel A (lane 2) shows the first round RT-PCR product, 532 bp, which was barely 
detectable compared to the positive control (lane 7);Panel B (lane 2) shows the second round 
253 bp product which was clearly evident, similar to the positive control (Panel B lane 7). 
Sequence analyses confirmed the specificity of the band, which demonstrated greater than 98% 
identity with the published EHV4 strain NS80567 gene 63 sequence.   
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Demonstration of the orientation of the EHV4 gene 63 transcripts which were amplified 
from EHV4-positive trigeminal ganglion and infected EHV4-cell cultures is shown in 
Figure 4.11.  The EHV4 gene 63 transcript product (Lane 2) was not observed when 
total RNA from the trigeminal ganglion was transcribed using the sense primer (primer 
1/EHV4 gene 63 F1). However, the band was demonstrable when the antisense primer 
(primer2/EHV4 gene 63 R1) was used for cDNA synthesis (lane 3), indicating that the 
gene 63 transcript from the ganglion was exclusively in an antisense orientation. This 
was in contrast to the EHV4-infected cell cultures, where an amplification product was 
observed after reverse transcription with both sense and antisense primers (lanes 4 
and 5), indicating the presence of both sense and antisense transcripts, and the 
transcript was amplified to a significantly greater extent in a sense orientation (lane 4).  
 
4.5 Discussion 
Latent virus infection is a feature of herpesvirus infection and the ability to differentiate 
between active and latent infection is important for the study of any virus infection in the 
natural host.  Studies of the prevalence of virus within tissues, which normally aim to 
detect  actively  replicating  virus  perhaps  in  association  with  disease,  could  perhaps 
provide  very  misleading  results  if  active  and  latent  virus  infection  were  not 
distinguished.  Although this may not be a problem if the site of latency is ganglia, as 
these would not normally be sampled during disease investigations, if the site of latency 
was perhaps PBL then conventional techniques may not differentiate the 2 types of 
infection.  
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Figure 4.11. Orientation of EHV4 gene 63 transcript. Primer 1 (EHV4 gene 63 F1) and 2 (EHV4 
gene 63 R1) from the nPCR specific for EHV4 gene 63 was used in individual reactions for 
reverse transcription of total RNA preparations from equine trigeminal ganglion and infected cell 
cultures. Lane 1, 100 bp ladder; lane 2, cDNA synthesised from TG with primer 1; lane 3, cDNA 
synthesised from TG with primer 2; lane 4, cDNA synthesised from EHV4-infected EKS with 
primer 1; lane 5, cDNA synthesised from EHV4-infected EKS with primer 2. 
 
 
In Chapter 3 it was hypothesised that horses previously infected with EHV1 in which 
EHV1 gB DNA could not be detected in PBL could still have latent EHV1 infection. Most 
horses are infected with EHV1 very early in life (Foote et al., 2004; Gilkerson et al., 
1998a; 1999a) and following initial lytic inflection, latent infection of EHV1 has been 
reported in PBL and bronchiolar lymph nodes (Chesters et al., 1997) and trigeminal 
ganglia (Baxi et al., 1995; Borchers et al., 1999c).   
Two methods are available for differentiating latent and active virus replication.  First, 
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RNA transcripts of the genes encoding structural proteins would not be expected to be 
present during latent virus infection, and their detection would indicate active virus 
replication.  Second, during latent virus infection, LATs are present (Chesters et al., 
1997; Borchers et al., 1999b; Virgin et al., 1999) and may be detected.  However, LATs 
are most commonly transcripts of the IE genes which may also be transcribed during 
active virus replication (Virgin et al., 1999), although perhaps not to the same degree as 
during latency (Virgin et al., 1999). In this study, latency was defined as the absence of 
transcripts of the genes encoding the structural gB glycoprotein and the simultaneous 
presence of LATs.  Putative LATs have been identified in both EHV1 and EHV4 (Baxi 
et al., 1995; Chesters et al., 1997; Borchers et al., 1999b, c). In this current study, 
specific primers for the detection of EHV1 and EHV4 gene 63 and 64, based on studies 
conducted by Chesters et al. (1997), Baxi et al. (1995) and Borchers et al. (1999b, c), 
respectively, were used as markers for detection of LATs. 
In this current study, evidence of EHV1 infection in PBL and bronchiolar lymph nodes of 
horses was obtained, but not in trigeminal ganglia or other lymph nodes of horses.  
There was also evidence that the EHV1 detected was present as a latent and not as an 
active (lytic) infection as EHV1 gene 64 transcripts and not EHV1 gB transcripts were 
detected.  Chesters et al. (1997) also reported the detection of EHV1 gene 64 
transcripts in PBL and bronchiolar lymph nodes, and Borchers et al. (1999c) were also 
unable to detect EHV1 in trigeminal ganglia. The percentage of horses in which EHV1 
gene 64 transcripts were detected in PBL in this study was much lower than that 
reported previously by Chesters et al. (1997) but this could be due to the difference 
between naturally EHV1-infected horses used in this study compared with 
experimentally EHV1-infected horses examined by Chesters et al. (1997). Another 
possible reason for the low prevalence of horses with EHV1 gene 64 transcripts in PBL   147 
and other tissues in this current study might the extraction technique used in this study: 
EHV1 gene 64 transcripts were amplified directly from the total RNA extracted from 
PBL and necropsy samples using a 2-step 1-tube RT-PCR, without further treatment of 
the first round product with a restriction enzyme as suggested by Chesters et al. (1997). 
They reported that treatment of the first round amplification product of EHV1 gene 64 
transcript with restriction endonuclease BpmI facilitated detection of the gene 64 
transcript. In the current study, further treatment with this enzyme was not pursued 
because it was considered likely to increase the risk of contamination, and deemed 
impractical for the screening of a large number of epidemiological samples. Further 
studies on the prevalence of latent infection would require optimisation of RT-PCR 
conditions, the development of quantitative RT-PCR, and possibly the use of mRNA 
instead of total RNA in the technique.  
EHV1 gene 63 transcripts were not detected in PBL or other tissue samples, in contrast 
to the ability to detect EHV1 gene 64 transcripts in these tissues. This contradicts 
results obtained by Baxi et al. (1995) and Borchers et al. (1999c), who were able to 
amplify gene 63 transcripts from the trigeminal ganglion of experimentally and naturally 
EHV1-infected horses. As the results obtained by Baxi et al. (1995) and Borchers et al. 
(1999c) indicate it is therefore likely that gene 63 transcripts are present in at least 
some cases, and as the detection of gene 64 transcripts indicates that latency was 
present in at least some horses examined in the current study, the failure of detection 
of gene 63 transcripts in the trigeminal ganglia in this current study might be because 
transcripts of gene 63 are present in lesser quantity than that of gene 64 ; perhaps 
there is selective expression of EHV1 LAT genes in neural and lymphoid cells, or it 
might be due to the sensitivity of RT-PCR used for the detection of gene 63 transcripts. 
The optimisation of RT-PCR and the development of quantitative real-time RT-PCR   148 
procedures would provide the opportunity for more sensitive detection of gene 
products. 
Evidence of EHV4 infection in the trigeminal ganglia but not PBL or lymphoid tissue of 
horses was also obtained in the current study. Using EHV4 gene 63 and 64-specific 
nested primers, EHV4 gene 63 transcripts (but not gene 64 transcripts) were detected 
in 2 of 5 trigeminal ganglia. These findings are consistent with those of Borchers et al. 
(1997b) who detected latent EHV4 infection in the trigeminal ganglia of naturally 
infected-horses, but not in PBL or lymph nodes of respiratory tract of these horses, and 
Borchers et al. (1999b) who detected both EHV4 gene 63 and 64 transcripts in the 
trigeminal ganglia of some but not all infected horses. The failure to detect EHV4 gene 
63 but not 64 transcripts in the 2 positive samples in the present study may have been 
due to low amounts of EHV4 gene 64 transcription in the trigeminal ganglia, when 
compared to transcription of gene 63. It may also reflect small numbers of latently 
infected neuronal cells and insensitivity of the nested PCR assay used.  
It is not unexpected that EHV4 infection could not be detected in PBL of the healthy 
horses examined.  Previous reports suggest that even in outbreaks of EHV4 infection, 
active replication (defined in this study by transcription of gB) of EHV4 in PBL could not 
be detected in foals that were positive to EHV4 DNA and where there were clinical 
signs of respiratory disease, even using real-time RT-PCR assays (Pusterla et al., 
2006). Similarly, the inability to detect EHV4 DNA in PBL was consistent with previous 
findings in Western Australia (Wang, 2003), and by Matsumura et al. (1992) and 
Pusterla et al. (2006) where EHV4 DNA was detected in PBL from a small percentage 
of horses but only in association with disease. Perhaps viraemia may not occur with all 
EHV4 infections (Matsumura et al., 1992) or when it does occur, EHV4 DNA load in 
PBL is low and of short duration after the onset of clinical signs (Pusterla et al., 2005).   149 
While active replication in PBL has not been detected except in association with clinical 
disease, latent EHV4 infection of PBL has been reported following experimental 
infection  of horses (demonstrated in a co-culture study by Welch et al., 1992). Allen 
and Bryan (1986) and Edington et al. (1994) have also reported reactivation of latent 
EHV4 by co-cultivation of both lymphoid and neural tissues with normal cells.  
Borchers et al. (1999b) have suggested that the presence of latent EHV4 in trigeminal 
ganglia may be significant, as it would provide a reservoir from which latent EHV4 could 
be reactivated and spread to the nasal mucosa, where transmission to susceptible 
hosts via the respiratory tract would be facilitated. EHV4 is most likely to enter the 
trigeminal ganglion via the nasal epithelium, as has been demonstrated for EHV1 (Baxi 
et al., 1995; Bartels et al., 1998) and PRV (Kritas et al., 1994 and 1995). Anterogade 
axonal distribution, without viraemia, is in accordance with the finding that EHV4 has 
seldom been found in the peripheral blood (Matsumura et al., 1992), as observed in the 
current study. 
In this study, the orientation of the EHV4 gene 63 transcript was determined to be 
antisense, consistent with results reported for EHV4 by Borchers et al. (1999b) and for 
other LATs in alphaherpesviruses (Ohmura et al., 1993; Chesters et al., 1997; Rock, 
1994; Enquist, 1994). This orientation was also exhibited by the LAT transcripts of the 
alphaherpesvirus MDV (Fukuchi et al., 1985; Roizman et al., 1992; Buckmaster, 1988). 
The antisense polarity of EHV4 gene 63 transcripts strongly suggests that they are 
LATs because the orientation of latent genes during lytic infection is both sense and 
antisense (Borchers et al., 1999b). The results of the current study also demonstrated 
that it was much more abundant in an antisense orientation. Further studies are 
necessary to define the full size of the transcript and its functional role in natural 
infection.   150 
Chapter 5 
 
Investigation of vGPCR (ORF74), vBcl-2 (gene E4), vFLIP (gene 
E8) and vCLAP (gene E10) transcripts as putative latency-
associated transcripts in Equine herpesvirus 2 infections 
 
5.1 Summary  
EHV2 genes ORF74, E4, E8 and E10 were selected as having possible roles during 
EHV2 latency based on sequence analysis and comparison with other gene products 
identified or postulated as having roles in latency in other gammaherpesviruses.  As 
there is currently no in vitro model of latent EHV2-infection, kinetic transcription of these 
genes was evaluated in an in vitro time course study using a non neuronal cell line 
(equine kidney [EK] cells) for 96 h post-infection (p.i.). 
The in vitro study demonstrated that the 4 selected putative EHV2 transcripts (LATs) 
were minimally transcribed during lytic infection in EK cells, a result analogous to 
results obtained for the expression of LATs in other gammaherpesviruses, particularly 
MHV68 (Virgin et al., 1999). In contrast, genes encoding the gB and gH structural 
glycoproteins were abundantly transcribed in vitro: the gB gene was abundantly 
transcribed commencing 2 h p.i. and gradually increasing until 100% CPE was 
observed 96 h p.i.; the gH gene was transcribed commencing 6 h p.i. and persisted 
until 96 h p.i. Transcription of gene E8, ORF 74 and gene E10 was first detected 2 h p.i. 
and peaked 12 h, 24 h and 24 h (p.i.), respectively, prior to the development of maximal 
CPE.  Gene E4 demonstrated similar kinetic expression to gB, initially detected 2 h p.i.   151 
and gradually increasing until 96 h p.i., however the apparent level of transcription of 
this gene, determined by the density of the PCR product, was only half the amount of 
the gB transcript.  
Transcription products from these genes were not detected in PBL or other tissues of 
presumed latently infected with EHV2 (in which gB transcripts had been detected 
previously), actively infected with EHV2 (in which gB transcripts had been detected at 
the time of sampling) and horses in which there was no evidence of EHV2 infection.  
 
5.2 Introduction 
In Chapter 3, the gammaherpesviruses EHV2 and EHV5 were commonly detected in 
clinically normal horses, EHV2 especially in foals and EHV5 in both foals and adult 
horses.  Infection with EHV5 appeared in some cases to be associated with a 
persistent lytic infection especially in PBL whereas EHV2 infection appeared to be 
transient.  In this Chapter, the possible presence of latent EHV2 infection was 
investigated, using transcription of a series of IE and E genes present in EHV2 and 
related to genes in other gammaherpesviruses suspected to be involved in latency. 
The gammaherpesviruses are characterised by the ability to establish latent infection in 
lymphoid cells and some of the primate gammaherpesviruses, such as EBV and KSHV, 
are closely associated with abnormal cell proliferation and cancer (reviewed in 
Damania et al., 2001). While the precise role of EHV2 as a pathogen remains largely 
uncharacterised, there are reports that it can induce respiratory disease, including 
chronic pharyngitis associated with lymphoid proliferation in infected horses (Blakeslee 
et al., 1975).  It was suggested that the persistence of the virus in PBL indicated that it   152 
might have developed strategies to prevent apoptosis and to neutralize growth-
arresting processes in the infected host cells (Thome et al., 2001). 
During the herpesvirus lytic replicative
 cycle, there is a cascade of gene expression 
(reviewed in Chapter 2).  The IE genes expressed in the initial stages
 of lytic replication, 
products
 of which activate the cascade of E gene expression
 essential for viral DNA 
replication and the regulation of
 late gene expression.  However, the cascade of this 
gene expression does not always follow the sequence of expression from IE, E and 
then late (L) genes.  This is because the expression of  -1 late genes, such as gB, is 
not dependent on products produced by the early genes.  Therefore, gene transcription 
can occur before DNA replication. On the other hand, the expression of  -2 late genes, 
including  gH,  is  dependent  on  activation  by  the  cascade  of  early  genes.    Thus, 
expression of  -2 late genes occurs only after DNA replication (in gammaherpesviruses, 
DNA replication typically starts 6 to 8 h p.i.).  
Latency has been defined by Virgin et al. (1999) as the presence of the viral genome in 
a reactivable form in the absence of ongoing production of preformed infectious virus 
using a very highly sensitive assay that can confirm the absence of preformed virus, 
lytic transcripts and linear genome.  The detection of latency would be dependent on 
the  sensitivity  of  available  assays  to  detect  a  negative  result.    Virgin  et  al.  (1999) 
identified 3 important aspects of latency: (1) the absence of preformed infectious virus, 
which  could  be  determined  by  the  limiting-dilution  assay  (the  most  sensitive  assay 
currently available for detecting infectious virus in tissues); (2) the absence of lytic gene 
transcription from multiple regions of the viral genome, which  could be detected using 
sensitive nested RT-PCR assays; (3) the identification of genome regions preferentially 
expressed in latently infected tissues as opposed to lytically infected cells.    153 
EHV2 contains 79 ORF that encode 77 distinct molecules, several of which show 
significant similarity to cellular genes (Telford et al., 1995). In this Chapter, based on 
sequence and functional structural homology to latency–associated genes of other 
gammaherpesviruses, 4 possible latency-associated genes were identified in EHV2: 
ORF74, E4, E8 and E10 (Table 5.1).  
 
 
Table 5.1.  EHV2 genes investigated for potential roles as markers of latent infection.  
 
EHV2 gene  Product  Suspected function 
ORF74
1  G-protein coupled receptor  Structure homologous to IL-8 receptor 
E4
2  Bcl-2  Anti-apoptotic protein associated with 
inhibition of mitochondrial-dependent 
cellular apoptosis 
E8
3  vFLIP 
(viral FLICE inhibitory protein) 
Inhibition of Fas-induced apoptosis 
E10
4  vCLAP 
(viral CARD-like apoptotic protein) 
Pro-apoptotic protein associated with 
promotion of CARD-mediated cell death 
 
References: 
1  Telford et al. (1995); 
2 Marshall et al. (1999); 
3 Thome et al. (1997); 
4 Costanzo 
et al. (1999), Srinivasula et al. (1999) and Thome et al. (1999, 2001). 
 
 
The EHV2 ORF74 encodes a G-protein coupled receptor (GPCR; Telford et al., 1995).  
GPCR are signal-transducing molecules that serve as receptors for many extracellular 
regulatory molecules,
 including hormones, growth factors, and neurotransmitters. In 
other gammaherpesviruses, homologous genes encoding a GPCR/IL-8 are thought to 
be involved in latency and/or tumorigenesis. These virus GPCR are conserved in all 
gamma-2-herpesviruses that have been sequenced to date, suggesting that they play 
an important role in viral growth and/or immune evasion    154 
The EHV2 gene E4 is thought to encode the viral Bcl-2 (proto-oncogene) homologue 
BALF1 as described in EBV (Marshall et al., 1999) that functions in preventing the 
apoptotic death of virus-infected cells. The Bcl-2 family of genes governs the production 
of proteins that regulate mitochondrial dependent cellular apoptosis. Other well known 
viral Bcl-2 homologues include the BHRF1 of EBV (Cleary et al., 1986; Marchini et al., 
1991; Henderson et al., 1993), the ORF16 of KSHV (Russo et al., 1996; Nicholas et al., 
1997) and HVS (Nava et al., 1997; Derfuss et al., 1998), and M11 of MHV68 (Virgin et 
al., 1997).  
The EHV2 E8 gene is homologous to ORF71 of KSHV and HVS, the 159L and 160L of 
MCV, and the E1.1 of BHV that encode a putative FLICE (Fas-associating protein with 
death domain-like interleukin-1-converting
 enzyme) inhibitory proteins (FLIP; Thome et 
al., 1997) that inhibit cellular apoptosis mediated through death receptors. The proteins 
encoded are homologous to the cellular death effector domain (cDED). In KSHV, vFLIP 
is one of the major latent loci (reviewed by Dourmishev et al., 2003). By preventing 
premature death of the host cell, the anti-apoptotic function of both E4 and E8 may 
impair virus production (Smith et al., 1995), enable efficient emergence from latency 
(Hoge et al., 2000; van Dyk et al., 2000; Gangappa et al., 2002), facilitate persistent 
infection (Roy et al., 2000; Austin et al., 1998; Foghsgaard and Jaattela, 1997; Sarid et 
al., 1997), and logically may contribute to the avoidance of immune surveillance by the 
host. 
The EHV2 E10 gene encodes homologues of a cellular CARD (Caspase activation and 
recruitment domain)-like apoptotic protein (CLAP; Costanzo et al., 1999; Srinivasula et 
al., 1999; Thome et al., 1999; Yan et al., 1999) also sometimes referred to as BCL-10, 
CIPER,c-E10 or CARMEN).  These proteins regulate apoptosis and NF- B activation 
(McCarthy et al., 1998; Koseki et al., 1998; Srinivasula et al., 1999) and contain N-  155 
terminal caspase-recruitment
 domains (CARDs) and novel C-terminal domains (CTDs) 
rich in serine and threonine (cCLAP) or glycine (vCLAP) residues and were therefore
 
named CLAPs (CARD-like apoptotic proteins). A diagrammatic comparison of cellular 
and viral CLAP is shown in Figure 5.1. These CLAP proteins can activate NF- B 
(Srinivasula et al., 1999; Koseki et al., 1999; Costanza et al., 1999; Poyet et al., 2001; 
Thome et al., 2001) and high levels of NF- B have been reported to inhibit lytic 
replication of gammaherpesviruses and could contribute to the establishment and 
maintenance of viral latency in lymphocytes (Brown et al., 2003).  
 
 
 
 
 
 
Figure  5.1.    Schematic  representation  of  cellular  (A)  and  viral  (B)  CARD  (caspase  recruitment 
domain)-like apoptotic proteins (CLAPs) (modified from Srinivasula et al., 1999).  
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In this chapter of the thesis, the aims were to develop methods for the detection of the 
4  putative  EHV2-putative  latency-associated genes  in  non-neuronal  (primary  equine 
kidney) cell cultures, and to then determine whether their transcription products could 
be detected within tissues of horses, similar to studies conducted previously with the 
alphaherpesviruses EHV1 and EHV4 that were reported in Chapter 4. 
 
5.3 Materials and methods 
5.3.1 Virus and cell culture 
The EHV2 strain 86/67 and primary EK cells described in Chapter 3 were used.  
5.3.2 Plaque assay 
Plaque assays were performed in EK cell monolayers. A total of 3 x 10
6 to 3.5 x 10
6 EK 
cells per well were plated in 6-well cell culture plates 1 day prior to infection with EHV2. 
Serial 10-fold dilutions of 200  L of EHV2 stock, which had been previously passaged 
10 times, were added to EK cell monolayers. The plates were rocked every 15 minutes 
for 1 h at 37 C in a 7% CO2 incubator and overlaid with 3 mL of a 1:1 mixture of 1% 
noble agar and 2X DMEM supplemented with 10% foetal calf serum and a 2X 
concentration of antibiotics (200 U/mL penicillin, 0.4 mg/mL streptomycin, 100 mg/mL 
gentamycin, 10  g/mL amphotericin B [Sigma]) and L-glutamine. An additional 2 mL of 
Noble agar-2X MEM mixture was added 3 days later and the monolayers were stained 
between 6 and 8 days p.i. by the addition of 2 mL of neutral red overlay (0.01% neutral 
red in 2X DMEM diluted 1:1 with 1% Noble agar). After an additional 18-24 h, the clear 
non-stained plaques were counted and the titre of EHV2 determined.    157 
5.3.3 Time course study 
Six-well plates with EK cells monolayers were prepared as described above. Cells were 
infected with 200  L of EHV2 at a multiplicity of infection (MOI) of 10. The plates were 
rocked every 15 minutes for 1 h at 37 C in 5% CO2 incubator, and washed with PBS 
before 3 mL of DMEM supplemented with 2% foetal bovine serum was added into each 
well. The plates then were incubated at 37 C in a 7% CO2-in-air atmosphere. Infected 
cells were harvested at 0 (prior to infection), 2, 4, 6, 8, 12, 24, 36, 60, 84, and 96 h p.i.  
DNA and total RNA were then extracted using methods described in Chapter 3 and 
used to quantify the transcription of each EHV2 gene. All assays were performed in 
triplicate.  
5.3.4 Samples  
DNA and RNA was extracted from the tissue samples described in Chapter 4 (Tables 
4.1 and 4.2).  The PBL samples were derived from foals and adult horses, in some of 
which EHV2 gB RNA had been detected previously and in which EHV2 latency was 
assumed to be possible (Table 5.2).  
5.3.5 DNA and cDNA cloning and sequencing 
The methods of cloning and sequence analysis of PCR products were as described in 
Chapter 3.   
5.3.6 Conventional PCR and RT-PCR 
5.3.6.1 Primers  
Primers for 2 EHV2 lytic genes, gB ( 1-late gene) and gH ( 2- late gene), and 4 EHV2 
putative latency-associated genes, ORF74 (vGPCR), E4 (vBcl-2), E8 (vFLIP) and E10 
(vCLAP) were produced. The nested primers for gB were those previously described by    158 
Table 5.2.  Clinically healthy adult horses and foals from which PBL samples were derived for 
detection of putative LATs.  In some of these animals, EHV2 gB transcripts had been detected 
in PBL prior to sampling and a latent infection was presumed to be possible.  In foal 375A gB 
transcripts were detected in PBL on the day of sampling and this animal was presumed to have 
a lytic EHV2 infection of these cells. The data shown is summarised from data shown in Table 
3.5 (Chapter 3). 
 
Animal  Age  Previous detection of EHV2 gB transcripts in PBL 
samples (weeks prior to sampling)  
Foal 360A  2 days  Not examined previously 
Mare 360  Adult  - (0) 
Foal 362A  2 wks  - (0) 
Foal 366A  31 wks  + (3 and 4 wks) 
Mare 366  Adult  - (0) 
Mare 368A  Adult  - (0) 
Mare 369  Adult  - (0) 
Foal 369A  11 wks  - (0) 
Mare 375  Adult  - (0) 
Foal 375A  34 wks  + (0 and 4 wks) 
Foal 361A  34 wks  + (24 and 25 wks) 
Foal 363A  27 wks  + (23 and 24 wks) 
Foal 365A  20 wks  + (11 wks) 
 
 
Wang (2003). Semi-nested EHV2 gH primers were previously described by 
Nordengrahn et al. (2002). Primers for EHV2 ORF74, E4, E8 and E10 were designed 
with Primer Design and Amplify 2.1 programs (Bio-Rad), using sequence data of a 
conserved region of the particular genes derived from sequence data available in the 
Genbank database. For EVH2 protein E10, primers were designed for both the original 
sequence (referred to as E10a) that encodes a 211 amino acid (Telford et al., 1995; 
GenBank accession number U20824), and a longer sequence, E10b (Thome et al., 
1999; GenBank accession numbers AJ006410, AF100340 or AF134394), which 
encodes a 311 amino acid protein. All primers are shown in Table 5.3. Equus caballus   159 
-actin primer was also used as a „house keeper‟ gene to normalize all PCR and RT-
PCR results (Giguere and Prescott , 1999).  
 
 
Table 5.3.  Nucleotide sequence of primers and products used in the first and second rounds of 
the nested PCR.  
 
 
Primer  Sequence (5'-3')  Gene 
specificity  Location 
Predicted 
amplicon size 
(bp) 
First 
round 
primers 
EHV2L1  GATGGTCTCACCTCTAGCAT  EHV2 gB  538  1109 
EHV2R1  CTGGTGTAACACAGGTCTTC    1646   
  gHEF   ATGCTCTCTGACAAGAATCACTAC  EHV2 gH  46  424 
  gHEB  TGTTGTAGACAATGGGAATCTG    448   
  EHV274F  GAGTCTGGAAGTGGTAGTGG  EHV2 ORF74  4  898 
  EHV274R  ATAAGCCAAGCAGTGGGAGC    901   
  EHV2E4F  GTGCCGTCGCGAGAGTTCTT  EHV2 E4  4  404 
  EHV2E4R  GCTCGGATGCAAATACGCTC    407   
  EHV2E8F  GAGTCACTACAGTATGATTG  EHV2 E8  154419  516 
  EHV2E8R  ACCAGGTCGGCCCGTCCGAT    154934   
  EHV2E10aF  ATGGCGGAGAAATACCCTCT  EHV2 E10a  162824  633 
  EHV2E10aR  TCAGCAGGCTACCGCCTCGC    163456   
  EHV2E10bF  ATGGCGGAGAAATACCCTCT  EHV2 E10b  1  867 
  EHV2E10bR  CTGAACAGACAGGCTAGGGT    867   
Second 
round 
primers 
EHV2L2  GGTCTCACCTCTAGCATAAC  EHV2 gB  541  815 
EHV2R2  GCCACACTCTCTTCCTTAGT    1355   
gHEB2   CGAGACAAACATCTTTTTCTCT  EHV2 gH  378  354 
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5.3.6.2 PCR and RT- PCR conditions 
Conditions for conventional PCR and RT-PCR for gB were optimised as described in 
Chapter 3. PCR and RT-PCR for gH and the 4 putative EHV2 latency-associated genes 
were performed using conditions optimised for gB.  
Samples were treated with DNAse (DNA-free™, Ambion) in order to eliminate any 
genomic DNA contamination. RNA was converted to cDNA with reverse transcriptase. 
Products visualised after electrophoresis from this reaction were considered indicative 
of genomic DNA contamination.  
5.3.7 Computer analysis 
Protein sequence comparisons were aligned using CLUSTAL W 1.82, which can be 
accessed through http://www.ebi.ac.uk/clustalw/ (Chenna et al., 2003). The resulting 
multiple alignments were presented using BOXSHADE 3.2.1, which can be accessed 
through http://www.ch.embnet.org/software/BOX_form.html, and predicted 
transmembrane helices were analysed using the TMpred program, which can be 
accessed through http://www.ch.embnet.org/software/TMPRED_forn.html (Hofman and 
Stoffel, 1993). Phosphorylation sites were predicted using NetPhos 2.0 program, which 
can be accessed through http://www.cbs.dtu.dk/services/NetPhos/ (Blom et al., 1999). 
P and potential N-linked glycosylation sites in the N-terminal domain were analysed 
using the NetNGlyc 1.0 program, which can be accessed through 
http://www.cbs.dtu.dk/services/NetNGlyc/ (Gupta et al., 2004).  
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5.4 Results 
5.4.1 Sequence alignment comparison of EHV2 with cellular and other 
gammaherpesvirus GPCR, Bcl-2, FLIP and CLAP  
EHV2 ORF74 encoding a putative GPCR  
Alignment of the amino acid sequences demonstrated that the EHV2 ORF74 product 
had 19% identity with the GPCR of mammalian CXCR2, 18% with that of KSHV and 
14% with MHV68. Further analyses of the EHV2 GPCR sequence, via identification of 
conserved sequence motifs that are characteristic of GPCRs, revealed that its products 
are likely to be a functional GPCR (Figures 5.2 and 5.3). 
Analysis of potential transmembrane helices using the TMPRED program revealed the 
presence of 7 transmembrane spanning domains (TM1-7, Figure 5.3), a defining 
characteristic of GPCRs. The predicted orientation of the molecule was such that the 
hydrophilic N-terminal domain is extracellular (EC1) (Figure 5.3, ECI) and the C-
terminal domain intracellular (ICIV) (Figure 5.3). There are 3 predicted IC loops (ICI - 
III) and 3 EC loops (ECII - ECIV) (Figure 5.3). Potential N-linked glycosylation sites in 
the N-terminal domain were identified using the NetNGlyc 1.0 program (Figure 5.2 and 
5.3). Three cysteine residues, located in the first, second and third EC loop, were 
demonstrated in the EHV2 ORF74 gene product (Figure 5.2 and 5.3). These residues 
are highly conserved in GPCRs. Conserved modules GFLLPLL and FLLTWGPY were 
located in the TM5 and TM6, respectively. Mutation of the aspartate-arginine-tyrosine 
(DRY) motif (Figure 5.2 and 5.3) to aspartate-threonine-tryptophan (DTW) was 
observed in the EHV2 ORF74 product. This sequence was located at the start of the 
second IC domain and was highly conserved in other GPCRs. Using the NetPhos 2.0 
program, potential targets for phosphorylation at the C-terminal domain, which are   162 
present in the other gammaherpesvirus GPCRs, were absent in EHV2 OF74 (Figure 
5.2).  
 
 
 
Figure 5.2. Sequence comparison of the structural motifs present in the cellular and 
gammaherpesvirus ORF74 gene product. Regions with identical amino acids are shown in black 
and conserved regions are shown in grey. The N-linked glycosylation sites (NXS and NXT) are 
red boxed, highly conserved cysteines are blue boxed, highly conserved „DRY‟ motifs are black 
boxed, the conserved module GFLLPLL and FLLTWGPY are purple boxed, and targets for 
phosphorylation are pink boxed.  GenBank accession numbers for the protein sequences used 
are listed below in parentheses: CXCR2 (BC084427), KSHV ORF 74 (AF079845), MHV 68 (NP-
044912)., and EHV2 ORF 74 (U20824). Format is based on that used by Wakeling et al. (2001) 
but which excluded EHV2. 
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Figure 5.3. Diagrammatic representation of the structural motifs present in the EHV2 ORF74 
gene product. The transmembrane helices are green shaded, N-linked glycosylation sites are 
red boxed, the N-terminal extracellular domain is yellow shaded, the C-terminal intracellular 
domain is blue shaded, intracellular loops are red underlined, extracellular loops are blue 
underlined, highly conserved cysteine residues are blue boxed, and mutation of highly 
conserved „DRY‟ motifs to „DTW‟ are black boxed . Format is based on that used by Wakeling et 
al. (2001).  
 
 
EHV2 E4 encoding a putative Bcl-2 
EHV2 protein E4 encoded 4 Bcl-2 homology (BH) domains and a predicted 
transmembrane (TM) domain at the C-terminal region, similar to cellular Bcl-2s and 
some other viral Bcl-2s (Figure 5.4). Protein sequence comparison and alignment of 
cBcl-2 and gammaherpesvirus Bcl-2 homologues (Figure 5.4) demonstrated that EHV2 
protein E4 BH3 was conserved at least at the level of sequence identity among cBcl-2s 
and other gammaherpesvirus Bcl-2.  In contrast to the other vBcl-2 BH4 domains 
(except EBV BALF1), EHV2 E4 protein BH4 domain was conserved in comparison to   164 
human cBcl-2 and Bcl-x, all sharing a KLS (Figure 5.4). The BH1 and BH2 of EHV2 
protein E4 were significantly conserved relative to the cBcl-2s and vBcl-2 of other 
gammaherpesviruses (except BH2 in MHV68).  
Sequence alignment comparison of BH1 demonstrated significant identity between the 
EHV2  E4  BH1  product  and  human  Bcl-2  (31%),  EBV  BHRF1  (20%),  EBV  BALF1 
(20%), HVS ORF16 (25%) and MHV68 (15%) (Table 5.5). Sequence identity was low, 
however,  at  the  amino  acid  level.  Conversely,  EHV2  E4  BH2  demonstrated  much 
greater identity with BH2 of other gammaherpesviruses, particularly to the EBV BALF1 
(45%) (Table 5.4). The relationship between EHV2 E4 BH2 and EBV BALF1 BH2 is 
also  shown  diagrammatically  in  Figure  5.5.  The  identity  of  this  domain  to  the  EBV 
BHRF1, HVS ORF16, and MHV68, was 36%, 27% and 18%, respectively (Table 5.5).  
 
 
Table 5.4. The amino acid identity of BH1 and BH2 of EHV2 protein E4 to cellular and other 
gammaherpesvirus Bcl-2 proteins. 
 
EHV2 E4 
Amino acid identity (%) 
BH1  BH2 
Human Bcl-2  31  27 
EBV BHRF1  20  36 
EBV BALF1  20  45 
HVS ORF16  25  27 
MHV68 M11  15  18 
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Figure 5.4. Protein sequence alignment of cellular Bcl-2 and gammaherpesvirus Bcl-2 
homologues. Regions with identical amino acids are shown in black and conserved regions are 
shown in grey. The locations of the BCL-2 homology (BH) and transmembrane (TM) regions are 
boxed. GenBank accession numbers for the protein sequences used are listed below in 
parentheses. Human Bcl-x (Q07817); Human Bcl-2 (P10415); Epstein-Barr virus (EBV) BHRF1 
vBCL-2 (P03182); Herpesvirus saimiri (HVS) orf16 vBCL-2 (NP-040218); Epstein-Barr virus 
(EBV) BALF1 vBCL-2 (QQBE49); EHV2 E4 (U20824); Murine herpesvirus (MHV) 68 M11 vBCL-
2 (NP-044912). Format is based on that utilised by Marshall et al. (1999) and Roy et al. (2000).  
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EHV2 E8 encoding a putative vFLIP (viral FLICE inhibitory protein) 
EHV2 encoded 2 complete DED motifs within protein E8 (171 amino acids). Table 5.5 
shows the identity (%) of cDEDs and vDEDs to EHV2 E8 DED1 and DED2 proteins. 
The average sequence identity was 20%. The highest identity was observed between 
EHV2 E8 DED1 protein and the N-terminal part of Fadd (32%). Figure 5.5 illustrates the 
amino acid sequence alignment of cDEDs and vDED-containing molecules. Most of the 
DEDs were conserved at the N-terminal part of the FLICE/FLIP, which is boxed, with 
the highly conserved module RXDL/I(L), where „X‟ is any amino acid.  In EHV2 E8 
DED, this highly conserved module is denoted as RLDLI (DED1) and RADLV (DED2).  
. 
 
 
Table 5.5. The identity (%) of cDED and vDED proteins to EHV2 E8 DED1 and DED2 proteins. 
 
  Identity (%) to EHV2 E8 DED1 
protein 
Identity  (%)  to  EHV2  E8  DED2 
protein 
FADD_Bos taurus  19  27 
FADD_DED  32  22 
Homo sapiens_DED  18  17 
PEA-15_DED  16  19 
Mhc4_DED1  16  23 
Mhc4_DED2  15  22 
MCV_159L_DED1  23  20 
MCV_159L_DED2  15  23 
MCV_160L_DED1  23  18 
MCV_160L_DED2   16  19 
KSHV_K13_DED1  23  18 
HVS_ORF71_DED2  16  19 
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Figure 5.5.  Sequence alignment of cellular and viral-DED molecules. The DED motifs contained 
within the adaptor molecule FADD and the initiating caspase FLICE were aligned to DED-like 
motifs present in the EHV2 protein E8, the KSHV protein K13, the HVS protein ORF71 and the 
Molluscum contagiosum virus proteins MCV159L and MCVL160L. The conserved module 
RXDLL is boxed. GenBank accession numbers for the protein sequences used are listed below 
in parentheses. The FADD Bos taurus DED2 (AY725483), FADD (CASP8) DED1 (NM003879), 
PEA-15 DED (X86809), Mhc4 DED1 and DED2 (U60519), MCV 159 and 160 DED1 and DED2 
(U60315), HVS DED2 (X64346), KSHV DED1 (U90534), and EHV2 DED1 and DED2 (U20824). 
Modified from Thome et al. (1997), Hu et al. (1997) and Bertin et al. (1997).  
 
 
EHV2 E10 encoding a putative vCLAP 
The alignment of human and mouse CLAP (CIPER) is shown in Figure 5.6. Human and 
mouse CLAPs, which are both 233 amino acids, showed 91% identity. The CARD motif 
(boxed) and the CTD showed 98% and 87% identity, respectively.  
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Figure 5.6.  Sequence alignment between human and mouse CLAPs showing the CARD motif 
(boxed). GenBank accession numbers for the protein sequences used are: human CLAP 
(AF057700) and mouse CLAP (AF057701).  Modified from Koseki et al. (1999),Yan et al. (1999) 
and Srinivasula et al. (1999).  
 
 
The alignment of EHV2 protein E10a (the original sequence, reported by Telford et al., 
1995) and E10b (a longer sequence subsequently identified by Thome et al., 1999) is 
shown in Figure 5.7.  Both EHV2 CLAPs, proteins of 211 and 311 amino acids 
respectively, showed 71% identity with one another. The CARD motifs (boxed) were 
identical (100% identity), while the CTD showed only 38% identity. The human and 
mouse CLAP/CIPER/CARMEN sequence alignment to the EHV2 protein E10, is shown 
in Figure 5.8. The N-terminal region, which contained the CARD motif, was conserved 
between cellular and viral CLAPs (approximately 26-29% identity), but differed in its 
CTD extension, which demonstrated approximately 12-14% identity.  Neither of the 
EHV2 CTD extensions had significant identity to protein sequences currently found in 
public data bases.  
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Figure 5.7. Sequence alignment between EHV2 protein E10a, which encodes a 211-amino acid 
(GenBank accession number U20824) and EHV2 protein E10b (GenBank accession number; 
AJ006410, AF100340 or AF134394), which encodes a 311-amino acid. The 2 CLAPs contain a 
100% identical CARD motif (closed box) at the N-terminal domain. The C-terminal domain of 
each EHV2 CLAP is completely different.  
 
 
Further sequence alignment of cellular and viral CARDs to the apoptosis regulating 
proteins containing CARDs, including caspase-2, caspase-9, RIADD, CED-3, CED-4, 
and Apaf-1, demonstrated that EHV2 protein E10 CARD exhibited greatest homology 
to the CARD present in human and mouse (46 and 47% sequence identity, 
respectively), but only approximately 20-25% sequence identity with other CARD-
containing proteins (Figure 5.9).  
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Figure 5.8. Structure and predicted amino acid sequence of human, mouse and EHV2 CLAP 
(CIPER). CLAPs contain a highly homologous CARD motif (closed box). GenBank accession 
numbers for the protein sequences used are: human CLAP (AF057700), mouse CLAP 
(AF057701), EHV2 CLAPs (E10a; U20824 and E10b; AJ006410, AF100340 or AF134394). 
Modified from Koseki et al. (1999), Yan et al. (1999), Srinivasula et al. (1999) and Thome et al. 
(1999).   171 
 
Figure 5.9. The CARD motif of hCLAP, mCLAP and EHV2 CLAP aligned to the CARDs of 
caspase-2, caspase-9, RAIDD, CED-3, CED-4 and Apaf1. For each block of aligned sequences, 
black boxes indicate > 50% amino acid sequence identity and gray shading indicates > 50% 
sequence identity through conservative amino acid substitutions. GenBank accession numbers 
for the protein sequences used are: human CLAP (AF057700), mouse CLAP (AF057701), 
EHV2 CLAP (U20824), caspase-2 (U13021), caspase-9 (U56390), RAIDD (U79115), CED-3 
(L29052), CED-4 (X69016), and Apaf1 (AF013263).  Modified from Koseki et al. (1999), Yan et 
al. (1999), Srinivasula et al. (1999) and Thome et al. (1999). 
 
 
5.4.2  The kinetic transcription of EHV2-putative LATs during lytic 
infection in non neuronal cell culture 
Figures 5.10 to 5.15 show the RT-PCR products of EHV2 gB, gH, ORF74, gene E4, E8 
and E10 derived from RNA preparations collected during the time course study in 
EHV2-infected EK cells. The detection of gB and gH transcripts at intervals after 
infection with EHV2 is shown in Figures 5.10 and 5.11, respectively. Even though these 
2 genes are both late genes, they clearly have different transcription patterns, including 
the onset, level and duration of transcription. EHV2 gB gene is a  1-late gene, and   172 
transcription of this gene was not influenced or induced by proteins encoded by early 
genes. The gB transcripts can be seen at 2 h p.i. and transcription of the gB gene 
increased consistently and gradually until maximum transcription occurred coincident 
with 100% CPE at 96 h p.i. In contrast, the EHV2 gH gene is a  2-late gene and 
transcription of this gene can only occur under the influence of proteins released by 
early genes. The EHV2 gH transcript was not evident until 6 h p.i., and gradually 
increased until its maximum transcription occurred at 96 h p.i. Comparison of the 
intensity of the bands of gB and gH at 36 h p.i. (lane 8) and 96 h p.i., the gB transcript 
was more abundant at both times, relative to that of gH.  
 
 
  
 
 
 
Figure 5.10. RT-PCR reaction products of EHV2 gB from cell culture-derived total RNA 
preparations of EHV2 from EHV2-infected primary EK cells.  Lanes 1 and 13, 100 bp ladder; 
lane 2, 2 h p.i.; lane 3, 4 h p.i.; lane 4, 6 h p.i.; lane 5, 8 h p.i.; lane 6, 12 h p.i.; lane 7, 24 h p.i.; 
lane 8, 36 h p.i.; lane 9, 60 h p.i.; lane 10, 84 h p.i.; lane 11, 96 h p.i. (when there was 100% 
CPE); lane 12, dH2O. RNA preparations from negative controls (cell culture cells only) and from 
0 h p.i. were negative. Results are representative of assays performed in triplicate. 
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Figure 5.11. RT-PCR reaction products of EHV2 gH from cell cultures-derived total RNA 
preparations of EHV2 from EHV2-infected primary EK cells. Lane 1, 100 bp ladder; lane 2, 2 h 
p.i.; lane 3, 4 h p.i.; lane 4, 6 h p.i.; lane 5, 8 h p.i.; lane 6, 12 h p.i.; lane 7, 24 h p.i.; lane 8, 36 h 
p.i.; lane 9, 60 h p.i.; lane 10, 84 h p.i.; lane 11, 96 h p.i. (when there was 100% CPE); lane 12, 
dH2O. Negative controls and 0 h p.i. preparations were negative. Results are representative of 
assays performed in triplicate. 
 
 
 
The ORF74 transcript demonstrated a different pattern of transcription to that observed 
for gB or gH (Figure 5.12). Like gB, the onset of ORF74 transcription was observed as 
early as 2 h p.i. Transcription then gradually increased until 24 h p.i. (lanes 2 to 7), 
gradually decreased, and then increased back to a maximum transcription at 100% 
CPE (96 h p.i., lanes 11 and 12). As was observed for gH, the level of transcription of 
ORF74 was not as abundant as the gB transcript.  
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Figure 5.12. RT-PCR reaction products of EHV2 ORF74 from cell culture-derived total RNA 
preparations of EHV2 from EHV2-infected primary EK cells. Lane 1, 100 bp ladder; lane 2, 2 h 
p.i.; lane 3, 4 h p.i.; lane 4, 6 h p.i.; lane 5, 8 h p.i.; lane 6, 12 h p.i.; lane 7, 24 h p.i.; lane 8, 36 h 
p.i.; lane 9, 60 h p.i.; lane 10, 84 h p.i.; lanes 11 and 12, 96 h p.i. (when there was 100% CPE); 
lane 13, dH2O. Results are representative of assays performed in triplicate. 
 
 
The E4 transcript had a similar kinetic transcription pattern (Figure 5.13) to that 
observed for gB transcript, whereby the level of transcription consistently increased 
from 2 h p.i. until it reached maximum expression at 100% CPE (96 h p.i., lane 11). 
Based on the intensity of the bands, it was obvious that the amount of the product 
transcribed was significantly less than that of gB throughout of the time course study.  
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Figure 5.13. RT-PCR reaction products of gene EHV2 E4 from cell cultures-derived total RNA 
preparations of EHV2 from EHV2-infected primary EK cells. Lane 1, 100 bp ladder; lane 2, 2 h 
p.i.; lane 3, 4 h p.i.; lane 4, 6 h p.i.; lane 5, 8 h p.i.; lane 6, 12 h p.i.; lane 7, 24 h p.i.; lane 8, 36 h 
p.i.; lane 9, 60 h p.i.; lane 10, 84 h p.i.; lane 11, 96 h p.i. (when there was 100% CPE); lane 12, 
dH2O. Results are representative of assays performed in triplicate. 
 
 
The detection of E8 and E10 transcripts, respectively, at intervals after infection of EK 
cells with EHV2, is shown in Figures 5.14 and 5.15. As expected, the levels of 
transcription of these products were significantly less than was observed for transcripts 
of gB, gH, ORF74 and gene E4, particularly before 100% CPE was observed.  
Transcripts of genes E8 and E10 were detected 2 h p.i. but were barely detectable until 
96 h p.i. (Figure 5.14) when 100% CPE occurred, but were still less abundant relative 
to gB, gH, ORF74 and gene E4 transcripts. 
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Figure 5.14. RT-PCR reaction products of gene EHV2 E8 from cell culture-derived total RNA 
preparations of EHV2 from EHV2-infected primary EK cells. Lanes 1 and 14, 100 bp ladder; lane 
2, 2 h p.i.; lane 3, 4 h p.i.; lane 4, 6 h pi; lane 5, 8 h p.i.; lane 6, 12 h p.i.; lane 7, 24 h p.i.; lane 8, 
36 h p.i.; lane 9, 60 h p.i.; lane 10, 84 h p.i.; lane 11 and 12, 96 h p.i. (when there was 100% 
CPE); lane 13, dH2O. Results are typical of assays performed in triplicate. 
 
 
 
Figure 5.15. RT-PCR reaction products of EHV2 E10 from cell cultures-derived total RNA 
preparations of EHV2 from EHV2-infected primary EK cells. Lane 1, 100 bp ladder; lane 2, 2 h 
p.i.; lane 3, 4 h p.i.; lane 4, 6 h p.i.; lane 5, 8 h p.i.; lane 6, 12 h p.i.; lane 7, 24 h p.i.; lane 8, 36 h 
p.i.; lane 9, 60 h p.i.; lane 10, 84 h p.i.; lane 11 and 12, 96 h p.i. (when there was 100% CPE); 
lane 13, dH2O. Results are typical of assays that were performed in triplicate. 
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5.4.3 Detection of EHV-2 putative LATs in naturally infected horses 
PBL samples from 5 mares and 8 foals (Table 5.6), and necropsy samples from 5 
horses (Table 5.7) were tested for all 4 putative latency-associated genes of EHV2. 
None of the samples was positive for any of the transcripts.   
 
 
Table 5.6. PBL samples derived from clinically healthy horses, some of which had been positive 
to EHV2 gB transcripts prior to sampling, during sampling, and also after sampling.  
 
Animal  Age  Previous detection of EHV2 
gB transcripts in PBL 
samples (weeks prior to 
sampling)  
Detection of EHV2 putative 
LATs in PBL (E4, E8, 
ORF74 and E10) 
Foal 360A  2 days  Not examined previously  - 
Mare 360  Adult  - (0)  - 
Foal 362A  2 wks  - (0)  - 
Foal 366A  31 wks  + (3 and 4 wks)  - 
Mare 366  Adult  - (0)  - 
Mare 368A  Adult  - (0)  - 
Mare 369  Adult  - (0)  - 
Foal 369A  11 wks  - (0)  - 
Mare 375  Adult  - (0)  - 
Foal 375A  34 wks  + (0 and 4 wks)  - 
Foal 361A  34 wks  + (24 and 25 wks)  - 
Foal 363A  27 wks  + (23 and 24 wks)  - 
Foal 365A  20 wks  + (11 wks)  - 
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Table 5.7. Necropsy samples collected from horses euthanased for problems not related to the 
respiratory tract. 
 
Horse  Tissue  Clinical signs  Detection of 
EHV2 gB 
DNA 
Detection of 
EHV2 gB 
RNA 
transcripts 
Detection of EHV2 
putative LATs in 
PBL (E4, E8, 
ORF74 and E10) 
1  TG  Ataxia  -  -  - 
  BLN    -  -  - 
  SMLN    -  -  - 
  MLN    -  -  - 
  RPLN    -  -  - 
2  TG  Colic  -  -  - 
  BLN    -  -  - 
  SMLN    -  -  - 
  MLN    -  -  - 
  RPLN    -  -  - 
3  TG  Ataxia  -  -  - 
  BLN    -  -  - 
  SMLN    -  -  - 
  MLN    -  -  - 
  RPLN    -  -  - 
4  TG  Normal  -  -  - 
  BLN    -  -  - 
  SMLN    -  -  - 
  MLN    -  -  - 
  RPLN    -  -  - 
5  TG  Normal  -  -  - 
  BLN    -  -  - 
  SMLN    -  -  - 
  MLN    -  -  - 
  RPLN    -  -  - 
 
TG, trigeminal ganglia; BLN, bronchiolar lymph node; SMLN, submandibular lymph node; MLN, 
mediastinal lymph node; RPLN, retropharyngeal lymph node.  
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5.5 Discussion 
The hallmark of infection by members of the Herpesviridae family
 is the establishment 
of latent infection and the maintenance
 of their genome in the host with the expression 
of a limited
 number of viral genes in latently infected cells. In this Chapter, 4 possible 
genes of EHV2 (ORF74, E4, E8 and E10) that might be involved as latency-associated 
genes were identified on the basis of sequence identity of the EHV2 genes to the 
sequence of known latency-associated genes in other gammaherpesviruses.  The 
results of this study demonstrated that these 4 putative latency-associated genes were 
transcribed early after infection and at a low level during lytic infection in non neuronal 
cell cultures.  This would be consistent with their identification as LATs. These 
transcripts could not be detected, however, in horses in which previous naturally 
occurring infection with EHV2 had been demonstrated and so their identification as 
LATs could not be confirmed.  
The EHV2 ORF74 was homologous to that of other gammaherpesviruses and likely to 
encode a GPCR.  A number of studies (reviewed in Chapter 2) have been conducted to 
examine the role in pathogenesis of the GPCR.  A recent study (Rosenkilde et al., 
2005) demonstrated that the EHV2 GPCR encoded by ORF74 is a fully functional 
receptor, exhibiting both constitutive and ligand-induced activation of G protein 
signalling, determined by biochemical analyses.  Based on analogy with the GPCR 
encoded by KSHV and MHV68 (Arvanitakis et al., 1997; Gershengorn et al., 1998; 
Moorman et al., 2003) it is likely that the protein encoded by EHV2  would be 
associated with the induction of cellular proliferation and transformation, or effects on 
viral replication and reactivation, as observed for MHV68 GPCR.  While the analysis of 
the predicted encoded protein suggested there were some differences in the sequence 
of the EHV2 GPCR to that of other viruses, these changes may not be significant as   180 
Rosenkilde et al. (2005) demonstrated that the EHV2 GPCR is totally functional, 
performing both constitutive and ligand-induced activation of G protein signalling.  
As previously reported by Rosenkilde et al. (2005) and Sharp et al. (2007) it was found 
that the „DRY‟ motif (Asp-Arg-Tyr), conserved in the GPCR of other gammaherpesvirus, 
was substituted with “DTW” in EHV2.  The conserved DRY motif in GPCR has been 
extensively studied, particularly in relation to mechanisms of receptor activation and 
interaction with G proteins (reviewed by Flanagan, 2005). Most GPCRs contain a highly 
conserved “DRY” motif at the start of the second IC loop in the cytosolic surface of 
GPCRs (Dohlman et al., 1991; Probst et al., 1992). The first 2 residues, the acidic (Asp) 
and basic (Arg), of the DRY motif are important for isomerisation of receptors between 
inactive and activated conformations (Flanagan, 2005). The Asp residue is believed to 
play an important role in receptor activation because mutations of this residue result in 
impaired constitutive GPCR activity of some GPCRs (Cohen et al., 1993; Scheer et al., 
1996;
 Morin et al., 1998; Rasmussen et al., 1999). The Arg residue is considered to be 
a key residue in signal transduction of GPCRs (Oliveira
 et al., 1994; Scheer et al., 1996; 
Ballesteros et al., 1998), since mutations result in receptors with impaired signal 
transduction (Oliveira et al., 1993; Zhu
 et al., 1994; Jones et al., 1995; Scheer et al., 
1996) and also dysfunction of the receptor (Sung et al., 1991; Rosenthal et al., 1994). 
Changes to the DRY motif can affect function of the GPCR. In KSHV, the conserved 
DRY motif of GPCR is changed to VRY, and this has been associated with increased 
constitutive GPCR signalling, which leads to transforming/proliferating activity 
(Arvanitakis et al., 1997).  
The prospective target for phosphorylation in the C-terminal domain were absent in the 
EHV2 product predicted to be encoded by ORF74. The absence of potential targets for 
phosphorylation in the C-terminal domain (located IC), which are present in cellular and   181 
other functional gammaherpesvirus GPCRs, might be part of the reason why EHV2 has 
not been associated with neoplastic transformation of host cells. Such a hypothesis 
should be evaluated by gene mutation studies. Moreover, it should be noted that EHV2 
also encodes gene E10, which does confer proliferative activity (Thome et al., 1999), so 
other host or viral factors may be important.  
Analysis of the EHV2 protein encoded by gene E4 revealed several structural features 
that define it as a Bcl-2 family member, and consistent with previous reports (Marshall 
et al., 1999) that EHV2 E4 protein encodes two Bcl-2 homology (BH) domains (BH1 
and BH2), and suggesting that transcripts of this gene might be associated with 
latency. Cellular Bcl-2-related proteins (cBcl-2s) function as a regulator of apoptosis 
(reviewed in Chapter 2) and DNA viruses are also known to encode homologues of 
cellular anti-apoptotic Bcl-2 proteins (vBcl-2s). Inhibition of apoptosis by vBcl-2s in 
infected cells can prevent premature death of the host cell, which would impair virus 
production, could enable efficient emergence from latency, could facilitate persistent 
infection, and could contribute to the avoidance of immune surveillance by the host.  
The structural features that define the Bcl-2 proteins include sequence homology in the 
functionally important BH domains BH1 to BH4 (reviewed by Kroemer, 1997). The 
results of the present study demonstrate that EHV2 protein E4 is likely to contain 4 BH 
domains, including domains that are likely to promote cell survival, and a predicted TM 
domain at the C-terminal region. Like other Bcl-2 proteins in other 
gammaherpesviruses (such as KSHV ORF16, HVS ORF16, EBV BHRF1 and EBV 
BALF1), BH1 and BH2 in EHV2 E4 are well conserved relative to cBcl-2. Based on 
defined functional structural features of BH domains in EHV2 E4 protein, it is probable 
that it would also block apoptosis. This hypothesis is supported by the similarity of 
EHV2 E4 protein to the EBV BALF1 (Marshall et al., 1999), particularly the BH2 (45%   182 
identity) (Table 5.1). The precise role most of the vBcl-2s remain to be determined. 
Other studies (reviewed in Chapter 2) have shown that specific vBcl-2s promote cell 
survival via different pathways, which might relate to the lack of certain structural 
features in the BH domains. It is therefore evident that different vBcl-2 can inhibit 
apoptosis via different mechanisms. 
The expression of Bcl-2 by MHV68, KSHV, HVS and EBV has been documented both 
in lytic cycles and during persistent infections. Roy et al. (2000) detected transcription 
of MHV68 M11 (vBcl-2) during persistent infection in vivo. Virgin et al. (1999) detected 
low level transcription of vBcl-2 in lytically infected fibroblasts and also in latent tissue. 
These findings suggest that vBcl-2 may play an important role during latency and vBcl-
2 transcripts were detected in cell lines latently infected with KSHV and in Kaposi 
sarcomas (Sarid et al., 1997). However, there is general agreement that KSHV Bcl-2 is 
also expressed during lytic infection (Cheng et al., 1997b; Sarid et al., 1997 and 1998) 
and that it may be critical to lytic replication (Virgin et al., 1999). Similarly, HVS Bcl-2 is 
expressed in lytically infected cells (Kraft et al., 1998). As for EBV, the BHRF1 gene is 
expressed as an early gene in lytically infected cells or lymphoblastoid cell lines 
induced into the lytic cycle (Henderson et al., 1993; Lee and Yates, 1992; Marchini et 
al., 1991; Pearson et al., 1987) but it is also expressed in latently infected cells and 
tumours (Austin et al., 19898; Foghsgaard and Jaattela, 1997).  Transcriptional 
analyses have shown, however, that the structure of the mRNA encoding BHRF1 
differs for lytic and latent infection (Austin et al., 1998). A logical assumption is that the 
function of gammaherpesvirus Bcl-2s is necessary to protect the infected cell from 
apoptosis induced by either the immune system or by the infected cell itself. 
Meanwhile, mutational analysis indicated that MHV68 mutants lacking vBcl-2 display no 
prominent defects in acute replication in vitro or in vivo in wild-type or   183 
immunocompromised mice (Hoge et al., 2000; van Dyk et al., 2000; Gangappa et al., 
2002). Establishment of MHV68 viral latency was also unaffected by vBcl-2 mutations 
(Hoge et al., 2000; Van Dyk et al., 2000; Gangappa et al., 2002). The EBV BHRF1 and 
KSHV Bcl-2 are also dispensable for acute virus replication and latent infection 
(Marchini et al. 1991; Lee and Yates 1992). Given that herpesviruses encode multiple 
gene products that are probably functionally redundant inhibitors of apoptosis, it is not 
surprising that the anti-apoptotic function of vBcl-2 is not required during acute 
replication and establishment of latency. Like vGPCR, however, it has been 
demonstrated that mutant vBcl-2s, MHV68 and KSHV, have significant defects in re-
emergence from latency (Hoge et al., 2000; Van Dyk et al., 2000; Gangappa et al., 
2002). Therefore, based on previous in-vitro, in-vivo, transcriptional and mutational 
studies conducted on various vBcl-2, future studies of EHV2 should further evaluate the 
role of EHV2 Bcl-2 gene (gene E4) in maintaining EHV2 latent infection in horses. 
The results of this current study confirm results from other studies (Bertin et al., 1997; 
Hu et al., 1997; Thome et al., 1997) that EHV2 E8 encodes proteins analogous to those 
in other gammaherpesviruses. E8 was predicted to encode 2 complete tandem repeats 
of a so-called DED (Bertin et al., 1997; Hu et al., 1997; Thome et al., 1997) which are 
characteristic structural feature of FLIPs.  The EHV2 encoded protein was shown to 
have a conserved RXDLL motif at the N-terminal domain that is also conserved in the 
DEDs of Fadd and other virus-encoded DED proteins. vFLIPs normally interfere with 
apoptosis signalled through the death receptor, or extrinsic pathway (Bertin et al., 1997; 
Hu et al., 1997; Nagata, 1997; Thome et al., 1997; Sun et al., 2003; reviewed in 
Chapter 2) and cells expressing vFLIPs are therefore protected against apoptosis 
induced by CD95 or by the related death receptors (Bodmer et al., 1997; Marsters et 
al., 1996; Kitson et al., 1996; Yu et al., 1996). In several FLIP-encoding viruses,   184 
protection of virus-infected cells against death receptor-induced apoptosis may lead to 
greater viral replication and also contribute to cellular persistence and oncogenicity 
(Chang et al., 1994). The protective effect of vFLIP is associated
 with its ability to 
activate the nuclear factor-  B (NF- B) pathway
 and is missing in the vFLIP encoded by 
EHV2 that
 lacks this activity (Sun et al., 2003). It remains possible, however, that these 
putative LAT genes of EHV2 are responsible for latent infection. Other possible 
(apoptosis) pathways, facilitated by EHV2 FLIP and other EHV2 putative LAT genes, 
and also their protein-protein interactions, may explain the relationship between 
productive acute, latent and re-emergent EHV2 infection in horses. 
While vGPCR and vBcl-2 have been detected both during persistent and latent 
infections, vFLIP of HVS has been detected late in the lytic viral replication cycle only, 
at the time when host cells are partially protected from CD95-ligand-mediated 
apoptosis (Thome et al., 1997). The expression of vFLIP late in the lytic replication 
cycle of HVS may protect infected cells from premature apoptosis induced by viral 
overload, similar to the role proposed for other viral inhibitors such as baculovirus p35 
and IAPs, and the adenovirus Bcl-2 homologue E1B19K (Shen and Shenk, 1995). Loss 
of function of these viral genes leads to a decrease in the productivity of infection of 
these viruses, which is due to increased apoptosis of infected cells (Smith et al., 1994).  
Numerous studies have demonstrated that EHV2 E10 encodes CLAP molecules 
(Srinivasula et al., 1999; Koseki et al., 1999; Costanza et al., 1999; Thome et al., 1999; 
Yan et al., 1999) and this was confirmed by the current analysis. Sequence analysis of 
the EHV2 protein E10a and E10b revealed that they encode proteins of 211 and 311-
amino acids, respectively, with approximately 26-29% overall identity between the viral 
and similar mouse and human cellular proteins. In the N-terminal CARD homology 
domain (cellular protein, residues 13-103; EHV2 protein E10, 21-111). In this region the   185 
2 proteins share approximately 47% identity but there was only 20-25% sequence 
identity between the EHV2 E10 CARD protein and other CARD-containing proteins 
including caspase-2, caspase-9, RAIDD, CED-3, CED-4 and Apaf1. The selective 
conservation of the CARD homology domain within the mammalian and viral proteins 
suggests that they might play a role in regulating apoptosis (Srinivasula et al., 1999).  
The transcription of vCLAP either in persistently or latently infected tissues has not 
been examined. More studies have been focussed on the function of this gene, 
especially its role in inducing apoptosis pathway, particularly the activation of the NF-
B.  
A time course study was conducted during the current studies to evaluate the kinetics 
of the transcription of the EHV2 putative latency-associated genes transcribed from 
ORF74, E4, E8 and E10 in lytically infected non-neuronal cell culture (EK) cells.  If 
associated with latency, it was hypothesised that these genes would be detected early, 
but only minimally transcribed during lytic infection.  The results obtained in this study 
clearly demonstrated that all 4 putative latency-associated genes examined were 
minimally transcribed when compared to the genes encoding the structural 
glycoproteins gB and gH. Gene E8 (encoding a vFLIP), which has a similar structure to 
one of the major LAT loci in KSHV, had the lowest amount of transcript when compared 
to the other genes and peak transcription of this gene was observed 12 h p.i., before 
any CPE was observed. Gene E10 (encoding vBcl-10) was also transcribed at low 
levels but like the transcripts of ORF74, highest transcription was observed 24 h p.i., 
but before CPE was detected. Transcription of ORF74 was significantly greater 
compared to that of E10. The E4 (encoding a vBcl-2) transcript had similar kinetic 
transcription to gB, whereby transcription gradually increased until 100% CPE was 
observed, but the amount of gB transcript was greater than the amount of E4 transcript   186 
at all times assayed. Further studies are needed to elucidate the biological significance 
of the different kinetic expression patterns and level of transcription of these genes, and 
to more precisely quantitate transcription products.  
The low level of transcription of the putative EHV2 LATs relative to the EHV2 lytic 
genes encoding gB and gH in non neuronal cell culture are comparable to results 
reported for MHV68 lytic and latent gene transcription in fibroblast cells by Virgin et al. 
(1999). These authors demonstrated that putative LATs of MHV68 were transcribed in 
latently infected tissues, but not transcribed to high levels during lytic replication.  The 
transcription of KSHV in neuronal cell cultures was however, different.  This was 
characterised
 by the concurrent transcription of latent genes and a limited number
 of 
lytic genes immediately following infection and a subsequent
 decline and/or absence of 
lytic gene transcription with the persistence
 of latent genes (Krishnan et al., 2004). In 
neuronal cells, transcription of limited lytic cycle genes
 could be a strategy evolved to 
allow it to evade
 the immune system and provide the necessary factors and time
 to 
establish and/or maintain latency during the initial phases
 of infection. The different 
kinetic transcription patterns of KSHV may be due to the neuronal cell type used and in 
which it has been possible to establish latent KSHV infection (Krishnan et al., 2004).   
Interestingly, in this current study, differing kinetic transcription patterns were observed 
for the 2 lytic genes, gB and gH. The transcription of gB was detected as early as 2 h 
p.i., comparable to the findings of Krishnan et al. (2004) who reported that the  1-late 
genes of KSHV could be detected before viral DNA replication and substantially
 higher 
levels were expressed after viral DNA replication. In contrast, the transcription of gH 
was not detected at 6 h after virus infection and this is also comparable to the onset of 
2-late gene transcription in other gammaherpesviruses. The detection of gB as early 
as 2 h p.i. would be dependant on the assay used to identify the transcript, and also the   187 
multiplicity of infection (MOI). In this study, RT-PCR was used to detect transcription 
but real-time RT-PCR is a more sensitive method and has been used by Krishnan et al. 
(2004) to examine the kinetics of KSHV latent and lytic gene expression during
 primary 
infection of primary human dermal microvascular endothelial
 (HMVEC-d) and foreskin 
fibroblast (HFF) cells. In contrast to our study and Krishnan et al. (2004), Virgin et al. 
(1999) detected MHV68 late  genes, including  -1 late  genes, transcribed in lytically 
infected fibroblasts  by  12  to  18  h  p.i.    In that study,  Northern  blot  analysis,  a  less 
sensitive  method  than  RT-PCR  or  real  time  RT-PCR,  was  used  to  detect  the 
transcription of late gene transcripts in the fibroblast cells, and the MOI was 7. In our in 
vitro time course study, a MOI of 10 was used, while Krishnan et al. (2004) have used 
MOI of 100 to infect cells with KSHV. 
To support of the hypothesis that EHV2 ORF74, gene E4, E8 and E10 are candidate 
latency genes for EHV2, several attempts were made to detect these genes in samples 
collected from horses that were naturally infected with EHV2 (Chapter 3). 
Unfortunately, transcripts were not detected in PBL or other tissue samples from 
horses, even though some of the horses sampled were known to be previously infected 
with EHV2.  It is well documented that the detection of LATs in latently infected animals 
is very difficult (Wakeling et al., 2001). This might be due to the sensitivity of the RT-
PCR used to amplify these transcripts as the sensitivity of the assays was not 
determined, even though they were certainly capable of detecting transcripts in infected 
cell cultures. Difficulty in the detection of transcription of MHV68 GPCR in 
experimentally infected mice has been overcome by using a highly sensitive nested 
RT-PCR (Wakeling et al., 2001). The negative results might be because of small 
numbers of latently infected cells in the samples collected, and examination of purified 
and concentrated subpopulations of cells might provide improved detection rates.    188 
Drummer et al. (1996) reported that EHV2 is latent in B lymphocytes and higher levels 
of gene transcription might be demonstrable in purified B lymphocytes.  It is well 
documented that gamma herpesviruses have multiple gene programs and multiple 
different cell types, each of which has a different role during latency (Virgin et al., 
1999). Future mutagenesis and transcriptional studies of the putative EHV2 latent 
genes will be required to prove the relevance of these genes to latency as compared to 
mere association of transcription of a region with latency. 
In conclusion, transcripts of the 4 putative genes transcribing EHV2 LAT examined in 
this study (ORF74, E4, E8 and E10) could be detected in non neuronal cell culture. 
Based on structural homology to LAT in other herpesviruses and low levels of 
transcription in non neuronal cell culture, it seems most likely that gene E8 and E10 are 
likely LAT candidates for EHV2. Based on the cGPCR and cBcl-2 encoded by EHV2 
ORF74 and E4, respectively, these genes may also play an important role during EHV2 
latency, particularly reactivation from latency and the induction of apoptosis, 
respectively.    189 
Chapter 6  
General discussion 
The horse industry contributes more than AUD15 billion a year to the Australian 
economy (RIRDC; Whalley and Love, 2002).  Respiratory disease is one of the most 
important causes of wastage in the industry (Bailey et al., 1997).  Equine herpesviruses 
(EHV) are an important contributor to respiratory disease, with the 2 
alphaherpesviruses EHV1 and EHV4 widely regarded as important respiratory 
pathogens whereas the role of the 2 gammaherpesviruses, EHV2 and EHV5, is poorly 
understood but probably minimal.  The situation with the equine herpesviruses is further 
confounded by the ability of herpesviruses to cause latent infections.  The potential for 
reactivation of latent EHV infection as a contributor to respiratory disease and the 
potential problems in not being able to differentiate lytic and latent infections during 
diagnosis requires elucidation.  In order to understand the role of latent equine 
herpesvirus infection, techniques that can differentiate between active and latent 
equine herpesvirus infection are required and for this purpose a single nested RT-PCR 
was successfully developed to detect active infection based on the detection of RNA 
transcripts of a gene encoding the gB structural protein of the 4 EHV. 
Although EHV1 and EHV4 are regarded as important pathogens causing respiratory 
disease in horses, none of the samples collected from the horses sampled for the 
studies reported in this thesis were naturally infected with either EHV1 or EHV4 
(Pizzirani, unpublished; Raidal and Foote, personal communication), although a group 
of foals in Stable A were experimentally infected with EHV1 as a component of another 
study.  These findings do not necessarily indicate that natural infection by EHV1 or 
EHV4 did not take place, only that it was not possible to detect it by the PCR   190 
techniques used in the study.  The absence of EHV1 in particular is in contrast to 
studies of foals in large stables in large breeding centres on the east coast of Australia, 
where serological studies (Gilkerson et al., 1998a; 1999a, b; Foote et al., 2003; 2006) 
and DNA isolation (Foote et al., 2004) suggested subclinical infection of foals within the 
first weeks of life was common.  The reason for the inability to detect infection using 
PCR may well have been that sampling was too infrequent to detect the transient 
infection in the respiratory tract. 
The studies confirmed previous results which demonstrated a high prevalence of EHV2 
and EHV5 infections in foals in Western Australia (Wang, 2003).  The prevalence of 
EHV5 in Western Australia reported by Wang (2003), via multiplex nested PCR, was 
significantly higher than EHV2. For reasons that are unknown, this result was in 
contrast to previous studies using single nested PCR (Reubel et al., 1995; Dunowska et 
al., 2002a, b; Nordengrahn et al., 2002), which have reported a higher prevalence of 
EHV2 than EHV5.  It was thought the differences in prevalence rates might be due to 
the sensitivity of multiplex versus single nested PCR techniques but this was shown not 
to be so as the principle technique used in this study was a RT-PCR for RNA 
transcripts and this was shown to be extremely sensitive, equally as sensitive as 
techniques used elsewhere.  It was thought that it might be due to strain variation in 
EHV2 present in the 2 locations although this would seem unlikely due to the 
considerable movement of horses throughout Australia.  
The RT-PCR technique provided a method to differentiate between active and latent 
infections of EHV2 and/or EHV5.  The single nested RT-PCR had the added advantage 
that it was also more sensitive than single nested PCR.  Its use enabled the detection 
of active replication of EHV2 and EHV5 in PBL of the foals as early as 2 weeks and 9 
days of age, respectively.  It was not detected prior to this time, suggesting that   191 
maternally-acquired immunity was able to suppress infection by these viruses in the 
immediate post-partum period.  Active replication of these gammaherpesviruses was 
also detected in PBL and NS of the foals pre- (3 to 4 months of age) and post-weaning 
(7 to 9 months of age), and an increase in prevalence after weaning.  The prevalence 
of lytic EHV2 and EHV5 infection was high in foals at all stables examined and the 
increase in the prevalence of lytic EHV2 and EHV5 infection after weaning was 
observed at all stables.  This increase may have been linked with the stress of weaning 
although it raises an interesting question about the source of the EHV2 and EHV5 
infection in the foals at this time. A low prevalence of lytic virus infection was detected 
in foals prior to weaning and it is presumed that the high prevalence of active infection 
after weaning was due to reactivation of latent virus in some foals due to stress but may 
well have been also due to consequent foal-to-foal transmission of the lytically 
replicating virus.  Interestingly, in one cohort of foals (Stable D), no active viral 
replication was detected prior to weaning but there was a high prevalence detected 
after weaning; it is presumed the active replication of the virus was present but 
undetected in these foals, possibly due to inadequate sampling frequency from foals at 
this stable.  
While there was an increase in prevalence of the gammaherpesviruses after weaning, 
there was no increase in prevalence of the gammaherpesviruses in association with 
experimental EHV1 infection, which was thought likely to act as a stressor.  Samples 
from the foals infected with EHV1 were unfortunately not available post-weaning to 
further evaluate stress-associated reactivation of EHV1. 
Differences between lytic infection with EHV2 and EHV5 were noted.  Firstly, 
detectable active infection with EHV5 persisted for longer periods in foals, and was 
much more common in PBL than in NS.  In contrast, infection of PBL with EHV2 was   192 
always transient and was associated with a simultaneous transient subclinical infection 
of the respiratory tract.  Lytic EHV2 was detected infrequently before weaning and there 
was a marked increase in the frequency of the detection of lytic EHV2 after weaning, 
especially in one stable (Stable A).  This raises an interesting issue regarding previous 
associations between the presence of EHV2 and respiratory disease (Palfi et al., 1978; 
Jolly et al., 1986; Borchers et al., 1997a, 1998; Murray et al. 1996; Wang et al., 2003).  
While the RT-PCR was a sensitive method for the detection of RNA transcripts of late 
genes encoding structural proteins and enabled the detection of lytic virus replication, 
sensitive methods for the sensitive detection of latent virus infection are also needed, 
and the detection of genes switched on during latency (latency-associated genes) are 
required.  In human herpesvirus research, many techniques have been used to identify 
candidate LAT genes.  Gene mapping via microarray assay is the latest technique used 
to understand and differentiate kinetic expression of viral genes (Paulose-Murphy et al., 
2001).  This technique permits the simultaneous identification and analysis of all 
candidate viral genes that are transcribed during active and latent infection in a single 
experiment. However, it requires rigorous optimisation and is therefore expensive to 
develop.  RT-PCR was used in this study to examine the kinetic expression of selected 
EHV2 genes, which were identified as putative LAT genes, as described in Chapter 5.  
This Chapter focussed on identification of LAT genes in EHV2, as the LAT genes of 
EHV1 and EHV4 have been well documented (Baxi et al., 1995; Chesters et al., 1997; 
Borchers et al., 1999b, c) and the complete sequence of EHV5 has not been published.  
Furthermore, epidemiological studies reported in this thesis did not support a role for 
EHV5 as a significant equine pathogen. Further evaluation of the potential of these 
genes as candidate LAT genes for EHV2 were analysed based on time-course study   193 
(in-vitro), evaluating their differential transcription levels and patterns during viral 
replication, and also through detection of the genes in samples from necropsy horses.  
An examination of latent infection of tissues of horses with the alphaherpesviruses 
EHV1 and EHV4 was undertaken in this thesis to not only confirm previous results 
describing aspects of latency of these viruses but as a preliminary study of LAT in the 
equine gammaherpesviruses.  The putative LAT genes of equine alphaherpesviruses, 
gene 64 and gene 63, have been investigated previously (Edington et al., 1985; Scott 
et al., 1983; Welch et al., 1992; Edington et al., 1994; Baxi et al., 1995, 1996; Chester 
et al., 1997; Marshall and Field 1997; Smith et al., 1998; Borcher et al., 1999b, c).  The 
detection of these LAT in horses during this current study (Chapter 4) confirmed 
previous results and also provided the tools for future studies of alphaherpesvirus 
latency in the local horse population.  
EHV1 DNA was not detected in PBLs or NS samples of any of the horses sampled 
throughout period of the epidemiological study except associated with experimental 
EHV1 infections of foals at Stable A (Pizzirani, personal communication).  However, the 
presence of gene 63 and gene 64 transcripts using RT-PCR was detected.  EHV1 gene 
64 transcript, but not EHV1 gene 63 transcript, was detected in PBL samples from 
some foals, and in the absence of detectable EHV1 DNA indicated that these foals had 
been exposed to EHV1 infection and were latently infected.  Further examination of 
these transcripts in post-mortem tissues from horses detected gene 64 transcripts but 
not gene 62 transcripts in bronchiolar lymph nodes.  This study thus demonstrated the 
presence of gene 64 transcripts in PBL and bronchiolar lymph node, also reported by 
Chester et al. (1997), and the absence of the transcript in trigeminal ganglia, also 
reported by Chester et al. (1997) and Borchers et al. (1999c).  Although Borchers et al.   194 
(1999c) and Baxi et al. (1995) demonstrated gene 63 transcript in the trigeminal 
ganglia, this was not confirmed in the current study.  
EHV4 DNA was not detected in PBL and NS samples collected during the studies 
reported in Chapter 3 (Pizzirani, personal communication).  Neither gene 63 nor gene 
64 transcripts were detected in the PBL or NS in representative samples of these 
tissues but gene 63 transcripts were detected in the trigeminal ganglia.  The detection 
of gene 64 in association with EHV1 and gene 63 in association with EHV4 maybe 
represents selective expression of gene 63 and gene 64 in latent equine 
alphaherpesvirus infections. 
The orientation of the EHV4 gene 63 transcript proved to be antisense when a strand-
specific RT-PCR was applied.  This means the transcript was only observed when the 
RNA was converted to cDNA using antisense (reverse) primers, and there was no 
transcription observed when sense (forward) primer was applied to the RNA sample. In 
contrast to the RNA extracted from EHV4-infected non-neuronal cell culture (lytic 
infection), the transcript was detected with both sense and antisense orientations.  
These findings were comparable to those reported by Borcher et al. (1997b). 
Unfortunately, the orientation of the EHV1 gene 64 transcript from the PBLs and 
bronchiole lymph node could not be determined because when this was attempted the 
RNA extracted from the samples had degraded.  
It is well documented that LAT genes are minimally transcribed during lytic replication in 
non-neuronal cell lines (Virgin et al., 1997), and maximally transcribed during latent 
infection in neuronal cell lines (Dourmishev et al., 2003).  Latent genes are also 
transcribed in a high level in tissues sampled from latently infected animals (Virgin et 
al., 1997). As there are currently no tightly latent EHV2-infected cell lines available, the 
transcription of these genes in equine kidney (EK) cells and also in PBLs and necropsy   195 
samples including trigeminal ganglion, retropharyngeal, submandibular, bronchiolar and 
mandibular lymph nodes isolated from horses presumed to have naturally acquired 
latent infections was evaluated.  Four potential EHV2 candidate LAT genes were 
identified: EHV2 gene 74 (vGPCR), E4 (vBcl-2), E8 (vFLIP) and E10 (vCLAP), based 
on specific criteria that have been used to determine LAT genes in mouse (Virgin et al., 
1997) and human (Dourmishev et al., 2003) gammaherpesviruses.  In EK cells, all 
these genes were minimally transcribed when compared to gB, especially gene E8 and 
E10.  This finding is consistent with LATs in other gammaherpesviruses (Virgin et al., 
1997). Gene E8, which has a sequence similar to one of the major LAT loci in KSHV, 
had the lowest amount of transcript compared to the other genes, and the highest 
transcription was observed 12 h p.i., well before CPE was detected.  Qualitatively, gene 
E10 was also similarly transcribed in low amounts as was observed for gene E8, but 
the transcription of this gene was similar to ORF74 and greatest transcription was 
observed 24 h p.i., before 100% CPE was reached at 96 h p.i.  However, the level of 
expression of E10 was significantly less than that of gene ORF74. Interestingly, gene 
E4 had similar kinetic expression to gB: expression gradually increased until 100% 
CPE was reached at 96 h p.i., but the amount of gB transcript was double the amount 
of gene E4 transcript.  
Of the 4 potential EHV2 LAT genes examined in Chapter 5, it is postulated that gene 
E8 (vFLIP) was the most likely potential gene associated with latency.  This conclusion 
is based on homologies of the sequence to one of the identified LAT products of KSHV 
(vFLIP) and the low level transcription of the gene in cell culture.  Gene E10 (vCLAP) is 
another probable LAT gene for EHV2, based on its low level transcription in lytically 
infected cell cultures.  Gene ORF74 and E4 might also have a role during latency, 
particularly reactivation from latency and inducing apoptosis, respectively, based on   196 
their homologous structure to the cellular GPCR and Bcl-2, respectively.  Unfortunately, 
transcription of these genes was not detected in PBL, trigeminal ganglia, 
retropharyngeal, submandibular, bronchiolar and mandibular lymph nodes of horses in 
which previous EHV2 infection had been detected.  This may have been due to a small 
sample size, perhaps to small numbers of latently infected cells in the samples, or they 
might be transcribed in other tissues, such as B-lymphocytes or macrophages.  This 
latter possibility is consistent with observations that gammaherpesviruses have multiple 
gene programs and different cell types in which latency may be established.    197 
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